The summaries are free for public use. ARTHROS will continue to add and archive summaries of articles deemed relevant to ARTHROS by our Faculty.
| 1 | |
Rheumatoid Meningitis: Clinical Characteristics, Diagnostic Evaluation, and Treatment |
Neurohospitalist. 2020 Apr;10(2):88-94.doi: 10.1177/1941874419859769. Epub 2019 Jun 30. Angela M Parsons 1, Fawad Aslam 2, Marie F Grill 1, Allen J Aksamit 3, Brent P Goodman 1 |
| 2 | |
Real-World Outcomes Associated With Triple Therapy Versus TNFi/MTX Therapy |
Arthritis Care Res (Hoboken). 2020 May 6. doi: 10.1002/acr.24253. Online ahead of print. Jeffrey R Curtis 1, J Lynn Palmer 2, George W Reed 3, Jeffrey Greenberg 4, Dimitrios A Pappas 5, Leslie R Harrold 3, Joel M Kremer 4 |
| 3 | |
Rheumatology Is Exiting the Age of "Can We" (We Certainly Can) and Now Must Entertain the Question "Should We"? |
Arthritis Care Res (Hoboken). 2020 May 6. doi: 10.1002/acr.24247. Online ahead of print. Bruce Rothschild 1 |
| 4 | |
Management of Fatigue in Rheumatoid Arthritis |
MD Open. 2020 May;6(1):e001084. doi: 10.1136/rmdopen-2019-001084. Janet E Pope 1 |
| 5 | |
Collaboration in Hand Surgery: Experiences From Silicone Arthroplasty in Rheumatoid Arthritis, Finger Replantation and Amputation Challenges in Assessing Impairment, Satisfaction, and Effectiveness, Wrist and Radius Injury Surgical Trial, and Surgery of the Ulnar Nerve |
J Am Acad Orthop Surg. 2020 Apr 27. doi: 10.5435/JAAOS-D-20-00102. Online ahead of print. Robert L Kane 1, Kevin C Chung |
| 6 | |
High Serum Interleukin-6 Is Associated With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis |
Arthritis Rheumatol. 2020 Apr 28. doi: 10.1002/art.41299. Online ahead of print. Anita Boyapati 1, Sergio Schwartzman 2, Jérôme Msihid 3, Ernest Choy 4, Mark C Genovese 5, Gerd R Burmester 6, Gordon Lam 7, Toshio Kimura 1, Jonathan Sadeh 8 9, David M Weinreich 1, George D Yancopoulos 1, Neil M H Graham 1 |
| 7 | |
The Future of Axial Spondyloathritis Treatment |
Rheum Dis Clin North Am. 2020 May;46(2):357-365. doi: 10.1016/j.rdc.2020.01.014. Sinead Maguire 1, Raj Sengupta 2, Finbar O'Shea 3 |
| 8 | |
Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study |
J Clin Med. 2020 Apr 24;9(4):E1227.doi: 10.3390/jcm9041227. Maria Antonietta Barbieri 1, Giuseppe Cicala 1, Paola Maria Cutroneo 2, Elisabetta Gerratana 1, Caterina Palleria 3, Caterina De Sarro 3, Ada Vero 3, Luigi Iannone 3, Antonia Manti 3, Emilio Russo 3, Giovambattista De Sarro 3, Fabiola Atzeni 1, Edoardo Spina 1 |
| 9 | |
Tapering of Biological Antirheumatic Drugs in Rheumatoid Arthritis Patients Is Achievable and Cost-Effective in Daily Clinical Practice: Data From the Brussels UCLouvain RA Cohort |
Arthritis Res Ther. 2020 Apr 28;22(1):96.doi: 10.1186/s13075-020-02165-4. Stéphanie Dierckx 1, Tatiana Sokolova 1, Bernard R Lauwerys 1, Aleksandra Avramovska 1, Laurent Meric de Bellefon 1, Adrien Nzeusseu Toukap 1, Maria Stoenoiu 1, Frédéric A Houssiau 1, Patrick Durez 2 |
| 10 | |
Checkpoint Inhibitor-Associated Arthritis: A Systematic Review of Case Reports and Case Series |
J Clin Rheumatol. 2020 Apr 25. doi: 10.1097/RHU.0000000000001370. Online ahead of print. Nilasha Ghosh 1 2, Michael D Tiongson 3, Carolyn Stewart 2, Karmela K Chan 1 2, Bridget Jivanelli 1, Laura Cappelli 4, Anne R Bass 1 2 |
| 11 | |
The Microbiome in Rheumatology: Where Are We and Where Should We Go? |
Rheum Dis. 2020 Apr 24;annrheumdis-2019-216631.doi: 10.1136/annrheumdis-2019-216631. Online ahead of print. Julia Manasson 1, Rebecca B Blank 1, Jose U Scher 2 |
| 12 | |
Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019 |
JAMA Netw Open. 2020 Apr 1;3(4):e203969. doi: 10.1001/jamanetworkopen.2020.3969. Alexandra Erath 1, Stacie B Dusetzina 2 |
| 13 | |
Precision Medicine With Leflunomide: Consideration of DHODH Haplotype and Plasma Teriflunomide Concentration Can Substantially Modify Outcomes in Patients With Rheumatoid Arthritis |
Arthritis Care Res (Hoboken). 2020 Apr 27. doi: 10.1002/acr.24236. Online ahead of print. Michael D Wiese 1 2, Ashley M Hopkins 3, Catherine King 1 4, Mihir D Wechalekar 3 5, Anita Lee 6 7, Llewellyn Spargo 6, Robert Metcalf 6, Leah McWilliams 6, Catherine Hill 6 7 8, Leslie G Cleland 6, Susanna M Proudman 6 7 Affiliations collapse |
| 14 | |
Pathogenesis of Axial Spondyloarthritis - Sources and Current State of Knowledge |
Joerg Ermann 1 Rheum Dis Clin North Am. 2020 May;46(2):193-206. doi: 10.1016/j.rdc.2020.01.016 |
| 15 | |
Lipocalin 2 Links Inflammation and Ankylosis in the Clinical Overlap of Inflammatory Bowel Disease (IBD) and Ankylosing Spondylitis (AS) |
Arthritis Res Ther. 2020 Mar 18;22(1):51.doi: 10.1186/s13075-020-02149-4. Aifeng Lin 1 2 3, Robert D Inman 4 5 6, Catherine J Streutker 7 8, Zhenbo Zhang 5, Kenneth P H Pritzker 9 7, Hing Wo Tsui 5, Florence W L Tsui 9 6 |
| 16 | |
A Qualitative Metasynthesis of the Experience of Fatigue Across Five Chronic Conditions |
Pain Symptom Manage. 2019 Dec 20;S0885-3924(19)31063-2. doi: 10.1016/j.jpainsymman.2019.12.358. Online ahead of print. Rosario B Jaime-Lara 1, Brittany C Koons 2, Lea Ann Matura 2, Nancy A Hodgson 2, Barbara Riegel 2 |
| 17 | |
The Impact of Exercise, Lifestyle, and Clinical Factors on Perceived Cognitive Function in Patients With Rheumatoid Arthritis: Results From a Prospective Cohort Study |
Nancy A Shadick 1, Patricia Katz 2, Christine I Iannaccone 1, Gabriela Maica 1, Jonathan Coblyn 1, Michael E Weinblatt 1, Jing Cui 1 ACR Open Rheumatol. 2019 Oct 24;1(10):620-626. doi: 10.1002/acr2.11088.eCollection 2019 Dec. |
| 18 | |
Comparison of Biologic Discontinuation in Patients With Elderly-Onset Versus Younger-Onset Rheumatoid Arthritis |
ACR Open Rheumatol. 2019 Oct 26;1(10):627-631. doi: 10.1002/acr2.11083.eCollection 2019 Dec. Michael D Richter 1, Eric L Matteson 1, John M Davis 3rd 1, Sara J Achenbach 1, Cynthia S Crowson 1 |
| 19 | |
Utility of the Brief Illness Perception Questionnaire to Monitor Patient Beliefs in Systemic Vasculitis |
Rheumatol. 2020 Apr 1;jrheum.190828. doi: 10.3899/jrheum.190828. Online ahead of print. Mollie N Schwartz 1, Casey A Rimland 1, Kaitlin A Quinn 1, Marcela Ferrada 1, K Bates Gribbons 1, Joel S Rosenblum 1, Wendy Goodspeed 1, Elaine Novakovich 1, Peter C Grayson 1 |
| 20 | |
Effectiveness and Safety Over 3 Years After the 2-year U-Act-Early Trial of the Strategies Initiating Tocilizumab and/or Methotrexate |
Rheumatology (Oxford). 2019 Dec 20;kez602. doi: 10.1093/rheumatology/kez602.Online ahead of print. Maxime M A Verhoeven 1, Janneke Tekstra 1, Paco M J Welsing 1, Attila Pethö-Schramm 2, Michelle E A Borm 3, George A W Bruyn 4, Reinhard Bos 5, Ed N Griep 6, Ruth Klaasen 7, Jacob M van Laar 1, Floris P J G Lafeber 1, Johannes W J Bijlsma 1, Marjolein J H de Hair 1, Johannes W G Jacobs 1 |
| 21 | |
Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage |
Tatangelo M1,2, Tomlinson G1,2, Paterson JM1,3, Ahluwalia V4, Kopp A3, Gomes T1,3,5, Bansback N6, Bombardier C1,2. JAMA Netw Open. 2019 Dec 2;2(12):e1917053. doi: 10.1001/jamanetworkopen.2019.17053. |
| 22 | |
The roles of post-diagnosis accumulation of morbidities and lifestyle changes on excess total and cause-specific mortality risk in rheumatoid arthritis |
Yoshida K1,2, Lin TC1, Wei M3, Malspeis S1, Chu SH1,2,4, Camargo CA2,4,5, Raby BA2,6,7, Choi HK2,8, Tedeschi SK1,2, Barbhaiya M9,10, Lu B1,2, Costenbader KH1,2, Karlson EW1,2, Sparks JA1,2. Arthritis Care Res (Hoboken). 2019 Dec 7. doi: 10.1002/acr.24120. [Epub ahead of print] |
| 23 | |
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study |
Strand V1, van der Heijde D2, Tanaka Y3, Keystone E4, Kremer J5, Zerbini CAF6, Cardiel MH7, Cohen S8, Nash P9, Song YW10, Tegzová D11, Gruben D12, Wallenstein G13, Connell CA12, Fleischmann R8; ORAL Scan investigators. Clin Exp Rheumatol. 2019 Dec 19. [Epub ahead of print] |
| 24 | |
Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication |
Mohamed MF1, Klünder B2, Othman AA3. Clin Pharmacokinet. 2019 Dec 23. doi: 10.1007/s40262-019-00855-0. [Epub ahead of print] |
| 25 | |
Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients |
Coates LC1, Orbai AM2, Morita A3, Benichou O4, Kerr L5, Adams DH5, Shuler CL5, Birt J5, Helliwell PS6. BMC Rheumatol. 2018 Aug 13;2:24. doi: 10.1186/s41927-018-0030-y. eCollection 2018. |
| 26 | |
Artificial intelligence in detecting early RA |
Stoel BC1. Semin Arthritis Rheum. 2019 Dec;49(3S):S25-S28. doi: 10.1016/j.semarthrit.2019.09.020. |
| 27 | |
Origins of rheumatoid arthritis |
Boissier MC1, Biton J2, Semerano L3, Decker P2, Bessis N2. Joint Bone Spine. 2019 Dec 5. pii: S1297-319X(19)30175-7. doi: 10.1016/j.jbspin.2019.11.009. [Epub ahead of print] |
| 28 | |
Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials |
Keystone EC1, Ahmad HA2, Yazici Y3, Bergman MJ4. Rheumatology (Oxford). 2019 Dec 9. pii: kez455. doi: 10.1093/rheumatology/kez455. [Epub ahead of print] |
| 29 | |
Disease activity flares and pain flares in an early rheumatoid arthritis inception cohort; characteristics, antecedents and sequelae |
McWilliams DF1,2,3, Rahman S1,2,3, James RJE1,4, Ferguson E1,3,4, Kiely PDW5, Young A6, Walsh DA1,2,3,7. BMC Rheumatol. 2019 Nov 18;3:49. doi: 10.1186/s41927-019-0100-9. eCollection 2019. |
| 30 | |
Update on Lupus Nephritis: Core Curriculum 2020 |
Parikh SV1, Almaani S1, Brodsky S1, Rovin BH2. Am J Kidney Dis. 2020 Mar 24. pii: S0272-6386(19)31170-9. doi: 10.1053/j.ajkd.2019.10.017. [Epub ahead of print] |
| 31 | |
Update on Lupus Nephritis: Core Curriculum 2020 |
Parikh SV1, Almaani S1, Brodsky S1, Rovin BH2. Am J Kidney Dis. 2020 Mar 24. pii: S0272-6386(19)31170-9. doi: 10.1053/j.ajkd.2019.10.017. [Epub ahead of print] |
| 32 | |
A quarter of patients time their early rheumatoid arthritis onset differently than physicians |
Ellingwood L1, Kudaeva F1, Schieir O2, Bartlett SJ3,4, Bessette L5, Boire G6, Hazlewood GS7, Hitchon C8, Keystone E9, Tin D10, Thorne C11, Bykerk VP12,13, Pope J1; CATCH Investigators. RMD Open. 2019 Nov 14;5(2):e000931. doi: 10.1136/rmdopen-2019-000931. eCollection 2019. |
| 33 | |
Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis |
Curtis JR1, Xie F2, Kay J3, Kallich JD4. Arthritis Res Ther. 2019 Dec 12;21(1):285. doi: 10.1186/s13075-019-2022-8. |
| 34 | |
Insulin Resistant Pathways are associated with Disease Activity in Rheumatoid Arthritis and are Subject to Disease Modification through Metabolic Reprogramming; A Potential Novel Therapeutic Approach |
Gallagher L1,2, Cregan S1, Biniecka M3, Cunningham C2, Veale DJ3, Kane DJ1, Fearon U2, Mullan RH1. Arthritis Rheumatol. 2019 Dec 16. doi: 10.1002/art.41190. [Epub ahead of print] |
| 35 | |
Low Muscle Density is Associated with Deteriorations in Muscle Strength and Physical Functioning in Rheumatoid Arthritis |
Baker JF1,2,3, Mostoufi-Moab S4, Long J5, Taratuta E6, Leonard MB5, Zemel B4. Arthritis Care Res (Hoboken). 2019 Dec 16. doi: 10.1002/acr.24126. [Epub ahead of print] |
| 36 | |
Impact of discordance between patient |
Michelsen B1,2,3, Ørnbjerg LM1,4, Kvien TK3, Pavelka K5, Nissen MJ6, Nordström D7, Santos MJ8, Koca SS9, Askling J10, Rotar Z11, Gudbjornsson B12, Codreanu C13, Loft AG4,14, Kristianslund EK4, Mann HF5, Ciurea A15, Eklund KK16, Vieira-Sousa E8, Yazici A17, Jacobsson L18, Tomšic M11, Löve TJ19, Ionescu R13, van der Horst-Bruinsma IE20, Iannone F21, Pombo-Suarez M22, Jones GT23, Hyldstrup LH1, Krogh NS24, Hetland ML1,25, Østergaard M1,25. Rheumatology (Oxford). 2020 Jan 20. pii: kez656. doi: 10.1093/rheumatology/kez656. [Epub ahead of print] |
| 37 | |
Obstructive lung diseases and risk of rheumatoid arthritis |
Friedlander HM1, Ford JA1,2, Zaccardelli A1, Terrio AV1, Cho MH2,3,4, Sparks JA1,2. Expert Rev Clin Immunol. 2020 Jan;16(1):37-50. doi: 10.1080/1744666X.2019.1698293. Epub 2020 Jan 6. |
| 38 | |
Rheumatoid arthritis and risk of spontaneous abortion: a Danish nationwide cohort study |
Nathan NO1,2, Mørch LS2, Wu CS3,4, Olsen J5,6, Hetland ML7,8, Li J5, Rom AL1,2. Rheumatology (Oxford). 2019 Nov 27. pii: kez565. doi: 10.1093/rheumatology/kez565. [Epub ahead of print] |
| 39 | |
Patient Perspectives on Switching from Infliximab to Infliximab-dyyb in Patients with Rheumatologic Diseases in the United States |
Chau J1, Delate T2, Ota T2, Bhardwaja B3. ACR Open Rheumatol. 2019 Mar 15;1(1):52-57. doi: 10.1002/acr2.1007. eCollection 2019 Mar. |
| 40 | |
The Self-Administered Rheumatoid Arthritis Disease Activity Index (RADAI) is Less Accurate than DAS28-CRP as a Disease Activity Measure in Pregnancy |
Smeele HTW1, Naterop J1, Röder E1, Hazes JMW1, Dolhain RJEM1. ACR Open Rheumatol. 2019 Mar 30;1(2):97-103. doi: 10.1002/acr2.1012. eCollection 2019 Apr. |
| 41 | |
Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis |
Strand V1, Elaine Husni M2, Betts KA3, Song Y4, Singh R5, Griffith J5, Beppu M5, Zhao J4, Ganguli A5. BMC Rheumatol. 2018 Feb 12;2:3. doi: 10.1186/s41927-018-0011-1. eCollection 2018. |
| 42 | |
Tumour necrosis factor inhibitor exposure and radiographic outcomes in Veterans with rheumatoid arthritis: a longitudinal cohort study |
Cannon GW1,2, Erickson AR3, Teng CC1,4, Huynh T1,4, Austin S1,5, Wade SW6, Stolshek BS7, Collier DH8, Mutebi A7, Sauer BC1,4. Rheumatol Adv Pract. 2019 May 28;3(1):rkz015. doi: 10.1093/rap/rkz015. eCollection 2019. |
| 43 | |
Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs |
Strand V1, Schiff M2, Tundia N3, Friedman A4, Meerwein S5, Pangan A4, Ganguli A4, Fuldeore M4, Song Y6, Pope J7. Arthritis Res Ther. 2019 Dec 2;21(1):263. doi: 10.1186/s13075-019-2059-8. |
| 44 | |
Variation and implications of treatment decisions in early rheumatoid arthritis: results from a nationwide cohort study |
Yates M1, MacGregor AJ2, Ledingham J3, Norton S4, Bechman K1, Dennison EM5, Galloway JB1. Rheumatology (Oxford). 2019 Dec 5. pii: kez550. doi: 10.1093/rheumatology/kez550. [Epub ahead of print] |
| 45 | |
Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT |
Strand V1, Pope J2, Tundia N3, Friedman A4, Camp HS4, Pangan A4, Ganguli A4, Fuldeore M4, Goldschmidt D5, Schiff M6. Arthritis Res Ther. 2019 Dec 9;21(1):272. doi: 10.1186/s13075-019-2037-1. |
| 46 | |
Treatment Outcomes of Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Patients Over Age 75 Years: A Meta-Analysis |
Morris AD1, Elsayed ME2, Ponnusamy A2, Rowbottom A3, Martin F4, Geetha D5, Dhaygude AP2. Am J Nephrol. 2020 Mar 11:1-9. doi: 10.1159/000506532. [Epub ahead of print] |
| 47 | |
Early response to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RA |
Hamann PDH1, Pauling JD2, McHugh N2, Hyrich K3,4, Shaddick G5. Rheumatology (Oxford). 2019 Nov 12. pii: kez518. doi: 10.1093/rheumatology/kez518. [Epub ahead of print] |
| 48 | |
Comparative United States autoimmune disease rates for 2010-2016 by sex, geographic region, and race |
Roberts MH1, Erdei E2. Autoimmun Rev. 2020 Jan;19(1):102423. doi: 10.1016/j.autrev.2019.102423. Epub 2019 Nov 14. |
| 49 | |
Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis |
Burmester GR1, Gordon KB2, Rosenbaum JT3, Arikan D4, Lau WL4, Li P4, Faccin F4, Panaccione R5. Adv Ther. 2020 Jan;37(1):364-380. doi: 10.1007/s12325-019-01145-8. Epub 2019 Nov 20. |
| 50 | |
Reasons for b/tsDMARD cessation and persistence of second line treatment in a large real world rheumatoid arthritis dataset |
Youssef P1, Marcal B1, Button P1, Truman M1, Bird P1, Dip G1, Griffiths H1, Roberts L1, Tymms K1, Littlejohn G1. J Rheumatol. 2019 Dec 1. pii: jrheum.190535. doi: 10.3899/jrheum.190535. [Epub ahead of print] |
| 51 | |
The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease |
Inoue D7, Kawano M8, Khosroshahi A9, Lanzillotta M10, Okazaki K11, Perugino CA12, Sharma A13, Saeki T14, Schleinitz N15, Takahashi N16, Umehara H17, Zen Y18, Stone JH19; Members of the ACR/EULAR IgG4-RD Classification Criteria Working Group. Ann Rheum Dis. 2020 Jan;79(1):77-87. doi: 10.1136/annrheumdis-2019-216561. Epub 2019 Dec 3. |
| 52 | |
Lupus nephritis |
Anders HJ1, Saxena R2, Zhao MH3,4, Parodis I5,6, Salmon JE7, Mohan C8. Nat Rev Dis Primers. 2020 Jan 23;6(1):7. doi: 10.1038/s41572-019-0141-9. |
| 53 | |
The Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis |
Garg S1, Unnithan R2, Hansen KE1, Costedoat-Chalumeau N3,4, Bartels CM1. Arthritis Care Res (Hoboken). 2020 Jan 31. doi: 10.1002/acr.24155. [Epub ahead of print] |
| 54 | |
Patterns of Health Care Utilization and Medication Adherence Among Youth with Systemic Lupus Erythematosus During Transfer from Pediatric to Adult Care |
Chang JC1, Knight AM1, Lawson EF1. J Rheumatol. 2020 Feb 1. pii: jrheum.191029. doi: 10.3899/jrheum.191029. [Epub ahead of print] |
| 55 | |
Treatment of Childhood-Onset Lupus Erythematosus Panniculitis With Rituximab |
Correll CK1, Miller DD2, Maguiness SM3. JAMA Dermatol. 2020 Feb 12. doi: 10.1001/jamadermatol.2019.4984. [Epub ahead of print] |
| 56 | |
Is there an association between alopecia areata and systemic lupus erythematosus? A population-based study |
Kridin K1, Shalom G2, Comaneshter D3, Cohen AD2,3. Immunol Res. 2020 Jan 22. doi: 10.1007/s12026-020-09115-x. [Epub ahead of print] |
| 57 | |
Interstitial Lung Disease in Rheumatoid Arthritis Remains a Challenge for Clinicians |
Bendstrup E1, Møller J1, Kronborg-White S1, Prior TS1, Hyldgaard C2. J Clin Med. 2019 Nov 21;8(12). pii: E2038. doi: 10.3390/jcm8122038. |
| 58 | |
Retrospective Analysis of the Impact of Adalimumab Initiation on Corticosteroid Utilization and Medical Costs Among Biologic-Naïve Patients with Rheumatoid Arthritis |
Spivey CA1, Winthrop KL2, Griffith J3, Kaplan CM4, Qiao Y1, Postlethwaite AE5, Wang J6. Rheumatol Ther. 2020 Mar;7(1):133-147. doi: 10.1007/s40744-019-00184-5. Epub 2019 Nov 18. |
| 59 | |
Interstitial Lung Disease as the Initial Manifestation of Rheumatoid Arthritis: A Case Report and Review of the Literature |
Singh K1, Al-Sadawi M1, Ortega RR1, Akter K1, Zrodlowski T1, Zmijewski C1, McFarlane IM1. Am J Med Case Rep. 2019;7(12):342-347. doi: 10.12691/ajmcr-7-12-10. Epub 2019 Oct 28. |
| 60 | |
Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis |
Schäfer M1, Meißner Y1, Kekow J2,3, Berger S4, Remstedt S5, Manger B6, Listing J1, Strangfeld A1, Zink A1,7. Rheumatology (Oxford). 2019 Nov 20. pii: kez535. doi: 10.1093/rheumatology/kez535. [Epub ahead of print] |
| 61 | |
Supplementing Claims Data with Electronic Medical Records to Improve Estimation and Classification of Rheumatoid Arthritis Disease Activity: A Machine Learning Approach |
Feldman CH1, Yoshida K1, Xu C1, Frits ML1, Shadick NA1, Weinblatt ME1, Connolly SE2, Alemao E2, Solomon DH1. ACR Open Rheumatol. 2019 Sep 4;1(9):552-559. doi: 10.1002/acr2.11068. eCollection 2019 Nov. |
| 62 | |
Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data |
Emery P1, Furst DE2,3,4, Kirchner P5, Melega S5, Lacey S6, Lehane PB7. |
| 63 | |
Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years |
Pope JE1, Keystone E2, Jamal S3, Wang L4, Fallon L5, Woolcott J5, Lazariciu I6, Chapman D7, Haraoui B8. ACR Open Rheumatol. 2019 Mar 28;1(2):73-82. doi: 10.1002/acr2.1010. eCollection 2019 Apr. |
| 64 | |
Safety of Abatacept Versus Placebo in Rheumatoid Arthritis: Integrated Data Analysis of Nine Clinical Trials |
Simon TA1, Soule BP1, Hochberg M2, Fleming D1, Torbeyns A3, Banerjee S1, Boers M4. ACR Open Rheumatol. 2019 May 29;1(4):251-257. doi: 10.1002/acr2.1034. eCollection 2019 Jun. |
| 65 | |
The Impact of Frailty on Changes in Physical Function and Disease Activity Among Adults With Rheumatoid Arthritis |
Andrews JS1, Trupin L2, Wysham KD3, Hough CL1, Yelin EH2, Katz PP2. ACR Open Rheumatol. 2019 Jul 28;1(6):366-372. doi: 10.1002/acr2.11051. eCollection 2019 Aug. |
| 66 | |
Joint Estimation of Remission and Response for Methotrexate-Based DMARD Options in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis |
Pokharel G1, Deardon R1, Barnabe C1, Bykerk V2, Bartlett SJ3, Bessette L4, Boire G5, Hitchon CA6, Keystone E7, Pope J8, Schieir O7, Tin D9, Thorne C9, Hazlewood GS1; Canadian Early Arthritis Cohort (CATCH) Investigators, Baron M1,2,3,4,5,6,7,8,9, Bessette L1,2,3,4,5,6,7,8,9, Boire G1,2,3,4,5,6,7,8,9, Bykerk V1,2,3,4,5,6,7,8,9, Colmegna I1,2,3,4,5,6,7,8,9, Fallavollita S1,2,3,4,5,6,7,8,9, Haaland D1,2,3,4,5,6,7,8,9, Haraoui P1,2,3,4,5,6,7,8,9, Hazlewood G1,2,3,4,5,6,7,8,9, Hitchon C1,2,3,4,5,6,7,8,9, Jamal S1,2,3,4,5,6,7,8,9, Joshi R1,2,3,4,5,6,7,8,9, Keystone E1,2,3,4,5,6,7,8,9, Nair B1,2,3,4,5,6,7,8,9, Panopoulos P1,2,3,4,5,6,7,8,9, Penney C1,2,3,4,5,6,7,8,9, Pope J1,2,3,4,5,6,7,8,9, Rubin L1,2,3,4,5,6,7,8,9, Thorne C1,2,3,4,5,6,7,8,9, Villeneuve E1,2,3,4,5,6,7,8,9, Zummer M1,2,3,4,5,6,7,8,9. ACR Open Rheumatol. 2019 Aug 8;1(8):471-479. doi: 10.1002/acr2.11052. eCollection 2019 Oct. |
| 67 | |
Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials |
Gottlieb AB1, Mease PJ2, Kirkham B3, Nash P4, Balsa AC5, Combe B6, Rech J7, Zhu X8, James D8, Martin R8, Ligozio G8, Abrams K8, Pricop L8. J Clin Rheumatol. 2020 Feb 3. doi: 10.1097/RHU.0000000000001302. [Epub ahead of print] |
| 68 | |
Treatment to Target in Psoriatic Arthritis with Apremilast: Probability of Achieving Targets and Comprehensive Control of Disease Manifestations |
Mease PJ1, Gladman DD2, Ogdie A3, Coates LC4, Behrens F5, Kavanaugh A6, Mcinnes I7, Queiro R8, Guerette B9, Brunori M9, Teng L9, Smolen JS10. Arthritis Care Res (Hoboken). 2020 Jan 7. doi: 10.1002/acr.24134. [Epub ahead of print] |
| 69 | |
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study |
Mease PJ1, Kavanaugh A2, Reimold A3, Tahir H4, Rech J5, Hall S6, Geusens P7, Pellet P8, Delicha EM8, Pricop L9, Mpofu S8; FUTURE 1 study group. ACR Open Rheumatol. 2020 Jan;2(1):18-25. doi: 10.1002/acr2.11097. Epub 2019 Nov 14. |
| 70 | |
Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis |
Gladman D1, Nash P2, Goto H3, Birt JA4, Lin CY4, Orbai AM5, Kvien TK6. RMD Open. 2020 Jan;6(1). pii: e000928. doi: 10.1136/rmdopen-2019-000928. |
| 71 | |
Cardiovascular risk in Psoriatic Arthritis, a narrative review |
Verhoeven F1, Prati C2, Demougeot C3, Wendling D4. Joint Bone Spine. 2020 Jan 17. pii: S1297-319X(20)30004-X. doi: 10.1016/j.jbspin.2019.12.004. [Epub ahead of print] |
| 72 | |
Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis |
Reed GW1,2, Gerber RA3, Shan Y4, Takiya L5, Dandreo KJ4, Gruben D3, Kremer J6, Wallenstein G3. Rheumatol Ther. 2019 Nov 9. doi: 10.1007/s40744-019-00177-4. [Epub ahead of print] |
| 73 | |
Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials |
Smolen J1, Fleischmann R2, Aletaha D3, Li Y4, Zhou Y4, Sainsbury I5, Galindo IL4. Arthritis Res Ther. 2019 Nov 10;21(1):231. doi: 10.1186/s13075-019-2005-9. |
| 74 | |
2019 American College of Rheumatology Recommended Patient-Reported Functional Status Assessment Measures in Rheumatoid Arthritis |
Barber CEH1, Zell J2, Yazdany J3, Davis AM4, Cappelli L5, Ehrlich-Jones L6, Everix D7, Thorne JC8, Bohm V1, Suter L9, Limanni A10, Michaud K11. Arthritis Care Res (Hoboken). 2019 Dec;71(12):1531-1539. doi: 10.1002/acr.24040. Epub 2019 Nov 11. |
| 75 | |
2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures |
England BR1, Tiong BK2, Bergman MJ3, Curtis JR4, Kazi S5, Mikuls TR1, O'Dell JR1, Ranganath VK2, Limanni A6, Suter LG7, Michaud K8. Arthritis Care Res (Hoboken). 2019 Dec;71(12):1540-1555. doi: 10.1002/acr.24042. Epub 2019 Nov 11. |
| 76 | |
An Analysis of Real-World Data on the Safety of Etanercept in Older Patients with Rheumatoid Arthritis |
Edwards CJ1, Bukowski JF2, Burns SM3, Jones HE2, Pedersen R2, Sopczynski J2, Marshall L2. Drugs Aging. 2020 Jan;37(1):35-41. doi: 10.1007/s40266-019-00721-5. |
| 77 | |
A review and meta-analysis of anti-ribosomal P autoantibodies in systemic lupus erythematosus |
Choi MY1, Fitzpatrick RD2, Buhler K1, Mahler M3, Fritzler MJ4. Autoimmun Rev. 2020 Jan 9:102463. doi: 10.1016/j.autrev.2020.102463. [Epub ahead of print] |
| 78 | |
Posttraumatic stress disorder and risk of selected autoimmune diseases among US military personnel |
Bookwalter DB1,2, Roenfeldt KA1,3, LeardMann CA4,5, Kong SY1, Riddle MS6, Rull RP1. BMC Psychiatry. 2020 Jan 15;20(1):23. doi: 10.1186/s12888-020-2432-9. |
| 79 | |
Estimates of Responsiveness, Minimally Important Differences, and Patient Acceptable Symptom State in Five Patient-Reported Outcomes Measurement Information System Short Forms in Systemic Lupus Erythematosus |
Katz P1, Pedro S2, Alemao E3, Yazdany J1, Dall'Era M1, Trupin L1, Rush S1, Michaud K4. ACR Open Rheumatol. 2020 Jan;2(1):53-60. doi: 10.1002/acr2.11100. Epub 2019 Dec 4. |
| 80 | |
Lessons from precision medicine in rheumatology |
2020 Jan 22:1352458519884249. doi: 10.1177/1352458519884249. [Epub ahead of print] |
| 81 | |
Complications of therapy for ANCA-associated vasculitis |
Smith R1,2. Rheumatology (Oxford). 2020 Jan 20. pii: kez618. doi: 10.1093/rheumatology/kez618. [Epub ahead of print] |
| 82 | |
The multifaceted impact of anxiety and depression on patients with rheumatoid arthritis |
Peterson S1, Piercy J2,3, Blackburn S2, Sullivan E2, Karyekar CS1, Li N1. BMC Rheumatol. 2019 Oct 28;3:43. doi: 10.1186/s41927-019-0092-5. eCollection 2019. |
| 83 | |
A biopsychosocial network model of fatigue in rheumatoid arthritis: a systematic review |
Geenen R1, Dures E2,3. Rheumatology (Oxford). 2019 Nov 1;58(Supplement_5):v10-v21. doi: 10.1093/rheumatology/kez403. |
| 84 | |
The role of non-pharmacological interventions in the management of rheumatoid-arthritis-related fatigue |
Cramp F1. Rheumatology (Oxford). 2019 Nov 1;58(Supplement_5):v22-v28. doi: 10.1093/rheumatology/kez310. |
| 85 | |
Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study |
Simon TA1, Boers M2, Hochberg M3, Baker N4, Skovron ML4, Ray N5, Singhal S5, Suissa S6, Gomez-Caminero A4. Arthritis Res Ther. 2019 Nov 8;21(1):228. doi: 10.1186/s13075-019-1992-x. |
| 86 | |
Coronary microvascular dysfunction in rheumatoid arthritis compared to diabetes mellitus and association with all-cause mortality |
Liao KP1, Huang J1, He Z1, Cremone G1, Lam E1, Hainer JM2, Morgan V2, Bibbo C2, Di Carli M2,3. Arthritis Care Res (Hoboken). 2019 Nov 9. doi: 10.1002/acr.24108. [Epub ahead of print] |
| 87 | |
All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type |
Wallace ZS1,2,3,4, Fu X1,2,3, Harkness T1,2,3, Stone JH2,3,4, Zhang Y1,2,3,4, Choi H2,3,4. Rheumatology (Oxford). 2019 Dec 17. pii: kez589. doi: 10.1093/rheumatology/kez589. [Epub ahead of print] |
| 88 | |
Long-term outcomes in elderly patients with ANCA-associated vasculitis |
McGovern D1, Williams SP1, Parsons K2, Farrah TE1,3, Gallacher PJ1,3, Miller-Hodges E1,3, Kluth DC1, Hunter RW1,3, Dhaun N1,3. Rheumatology (Oxford). 2019 Sep 17. pii: kez388. doi: 10.1093/rheumatology/kez388. [Epub ahead of print] |
| 89 | |
Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide? |
Wallace ZS1,2,3,4, Stone JH2,3,4. Front Immunol. 2019 Dec 6;10:2855. doi: 10.3389/fimmu.2019.02855. eCollection 2019. |
| 90 | |
Anti-neutrophil Cytoplasmic Antibodies (ANCA) as Disease Activity Biomarkers in a "Personalized Medicine Approach" in ANCA-Associated Vasculitis |
Osman MS1, Tervaert JWC2. Curr Rheumatol Rep. 2019 Dec 26;21(12):76. doi: 10.1007/s11926-019-0872-3. |
| 91 | |
Remission maintenance in ANCA-associated vasculitis: does one size fit all? |
Berti A1,2, Specks U2. Expert Rev Clin Immunol. 2019 Dec;15(12):1273-1286. doi: 10.1080/1744666X.2020.1693260. Epub 2019 Nov 24. |
| 92 | |
Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis |
Walsh JA1, Pei S2, Penmetsa GK1, Sauer BC2, Patil V2, Walker JH3, Clewell J3, Douglas KM3, Clegg DO1, Cannon GW1, Halwani A4. J Manag Care Spec Pharm. 2019 Nov;25(11):1218-1228. doi: 10.18553/jmcp.2019.25.11.1218 |
| 93 | |
Patient-reported outcomes in RA care improve patient communication, decision-making, satisfaction and confidence: qualitative results |
Bartlett SJ1,2, De Leon E2,3, Orbai AM2, Haque UJ2, Manno RL2, Ruffing V2, Butanis A2, Duncan T2, Jones MR2, Leong A4, Perin J5, Smith KC3, Bingham CO2. Rheumatology (Oxford). 2019 Oct 30. pii: kez506. doi: 10.1093/rheumatology/kez506. [Epub ahead of print] |
| 94 | |
Pregnancy and rheumatoid arthritis |
Littlejohn EA1. Best Pract Res Clin Obstet Gynaecol. 2019 Oct 9. pii: S1521-6934(19)30136-1. doi: 10.1016/j.bpobgyn.2019.09.005. [Epub ahead of print] |
| 95 | |
Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension |
Burmester GR1, Strand V2, Rubbert-Roth A3, Amital H4, Raskina T5, Gómez-Centeno A6, Pena-Rossi C7, Gervitz L8, Thangavelu K9, St John G10, Boklage S10, Genovese MC11. RMD Open. 2019 Oct 18;5(2):e001017. doi: 10.1136/rmdopen-2019-001017. eCollection 2019 |
| 96 | |
Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial |
Strand V1, Mysler E2, Moots RJ3, Wallenstein GV4, DeMasi R5, Gruben D4, Soma K4, Iikuni N6, Smolen JS7, Fleischmann R8. RMD Open. 2019 Oct 1;5(2):e001040. doi: 10.1136/rmdopen-2019-001040. eCollection 2019 |
| 97 | |
Assessing disease severity in bio-naïve patients with RA on treatment with csDMARDs: insights from the Corrona Registry |
Harrold LR1,2, Patel PA3, Griffith J3, Litman HJ4, Feng H4, Schlacher CA3, Kremer JM5. Clin Rheumatol. 2019 Oct 21. doi: 10.1007/s10067-019-04727-7. [Epub ahead of print] |
| 98 | |
Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis |
Conaghan PG1, Østergaard M2, Troum O3, Bowes MA4, Guillard G4, Wilkinson B5, Xie Z5, Andrews J6, Stein A7, Chapman D6, Koenig A8. Arthritis Res Ther. 2019 Oct 21;21(1):214. doi: 10.1186/s13075-019-2000-1. |
| 99 | |
Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE) |
Fleischmann R1, Weinblatt M2, Ahmad H3, Maldonado MA3, Alemao E3, Ye J3, Schiff M4. Rheumatol Ther. 2019 Dec;6(4):559-571. doi: 10.1007/s40744-019-00174-7. Epub 2019 Oct 22. |
| 100 | |
The safety of belimumab for the treatment of systemic lupus erythematosus |
Wise LM1, Stohl W1. Expert Opin Drug Saf. 2019 Dec;18(12):1133-1144. doi: 10.1080/14740338.2019.1685978. Epub 2019 Oct 31. |
| 101 | |
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019 |
Winthrop KL1, Weinblatt ME2, Bathon J3, Burmester GR4, Mease PJ5, Crofford L6, Bykerk V7, Dougados M8, Rosenbaum JT9,10, Mariette X11, Sieper J12, Melchers F13, Cronstein BN14, Breedveld FC15, Kalden J16, Smolen JS17, Furst D5,18,19. Ann Rheum Dis. 2019 Oct 29. pii: annrheumdis-2019-216151. doi: 10.1136/annrheumdis-2019-216151. [Epub ahead of print] |
| 102 | |
Osteoarthritis is as severe as rheumatoid arthritis: evidence over 40 years according to the same measure in each disease |
Pincus T1, Castrejon I2, Yazici Y3, Gibson KA4, Bergman MJ5, Block JA2. Clin Exp Rheumatol. 2019 Sep-Oct;37 Suppl 120(5):7-17. Epub 2019 Oct 14. |
| 103 | |
Real-world outcomes among patients with early rapidly progressive rheumatoid arthritis |
Klink AJ1, Curtice TG, Gupta K, Tuell KW, Szymialis AR, Nero D, Feinberg BA. Am J Manag Care. 2019 Oct 1;25(10):e288-e295. |
| 104 | |
A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis |
Aranow C1, Cush J2, Bolster MB3, Striebich CC4, Dall'era M5, Mackay M1, Olech E6, Frech T7, Box J8, Keating R9, Wasko MC10, St Clair W11, Kivitz A12, Huang W1, Ricketts P1, Welch B13, Callahan S13, Spychala M14, Boyle K14, York K14, Keyes-Elstein L14, Goldmuntz E13, Diamond B1, Davidson A1. Rheumatology (Oxford). 2019 Oct 18. pii: kez471. doi: 10.1093/rheumatology/kez471. [Epub ahead of print] |
| 105 | |
An open-label randomized controlled trial of DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDs |
Pope J1, Rampakakis E2, Vaillancourt J2, Bessette L3, Lazovskis J4, Haraoui B5, Sampalis JS2,6. Rheumatology (Oxford). 2019 Oct 18. pii: kez470. doi: 10.1093/rheumatology/kez470. [Epub ahead of print] |
| 106 | |
Patient questionnaires in osteoarthritis: what patients teach doctors about their osteoarthritis on a multidimensional health assessment questionnaire (MDHAQ) in clinical trials and clinical care |
Pincus T1, Schmukler J2, Castrejon I2. Clin Exp Rheumatol. 2019 Sep-Oct;37 Suppl 120(5):100-111. Epub 2019 Oct 15. |
| 107 | |
Implementation and dissemination of an African American popular opinion model to improve lupus awareness: an academic-community partnership |
Phillip CR1, Mancera-Cuevas K2, Leatherwood C1, Chmiel JS3, Erickson DL3, Freeman E4, Granville G5, Dollear M6, Walker K7, McNeil R8, Correia C2, Canessa P9, Ramsey-Goldman R2, Feldman CH1. Lupus. 2019 Oct;28(12):1441-1451. doi: 10.1177/0961203319878803. Epub 2019 Oct 8. |
| 108 | |
SLE Plasma Profiling Identifies Unique Signatures of Lupus Nephritis and Discoid Lupus |
Smith MA1, Henault J1, Karnell JL1, Parker ML1, Riggs JM1, Sinibaldi D1, Taylor DK1, Ettinger R1, Grant EP1, Sanjuan MA1, Kolbeck R1, Petri MA2, Casey KA3,4. Sci Rep. 2019 Oct 8;9(1):14433. doi: 10.1038/s41598-019-50231-y. |
| 109 | |
Antiphospholipid Antibodies in Patients With Lupus Anticoagulant Prozone Effect |
Murphy CH1, Jin J2, Zehnder JL1. Am J Clin Pathol. 2019 Oct 10. pii: aqz151. doi: 10.1093/ajcp/aqz151. [Epub ahead of print] |
| 110 | |
Treatment target in newly diagnosed Systemic Lupus Erythematosus |
Floris A1, Piga M1, Perra D1, Chessa E1, Congia M1, Mathieu A1, Cauli A1. Arthritis Care Res (Hoboken). 2019 Oct 10. doi: 10.1002/acr.24086. [Epub ahead of print] |
| 111 | |
Development of a Set of Lupus-Specific Ambulatory Care Sensitive, Potentially Preventable Adverse Conditions: A Delphi Consensus Study |
Feldman CH1, Speyer C1, Ashby R2, Bermas B3, Bhattacharyya S4, Chakravarty E5, Everett B6, Ferucci E7, Hersh AO8, Marty FM9, Merola JF1, Ramsey-Goldman R10, Rovin BH11, Son MB12, Tarter L1, Waikar S13, Yazdany J14, Weissman JS15, Costenbader KH1. Arthritis Care Res (Hoboken). 2019 Oct 18. doi: 10.1002/acr.24095. [Epub ahead of print] |
| 112 | |
Association of Seropositivity and Mortality in Rheumatoid Arthritis and the Impact of Treatment With Disease-Modifying Antirheumatic Drugs |
Alemao E1, Bao Y1, Weinblatt ME2, Shadick N2. Arthritis Care Res (Hoboken). 2019 Sep 17. doi: 10.1002/acr.24071. [Epub ahead of print] |
| 113 | |
Rheumatoid arthritis morning stiffness is associated with synovial fibrin and neutrophils |
Orange DE1,2, Blachere NE2, DiCarlo EF3, Mirza S1, Pannellini T3, Jiang CS4, Frank MO2, Parveen S2, Figgie MP5, Gravallese EM6, Bykerk VP1, Orbai AM7, Mackie SL8,9, Goodman SM1. Arthritis Rheumatol. 2019 Oct 15. doi: 10.1002/art.41141. [Epub ahead of print] |
| 114 | |
Role of biological agents in treatment of rheumatoid arthritis |
Law ST1, Taylor PC2. Pharmacol Res. 2019 Dec;150:104497. doi: 10.1016/j.phrs.2019.104497. Epub 2019 Oct 17. |
| 115 | |
Indicator opportunistic infections after biological treatment in rheumatoid arthritis, 10 years follow-up in a real-world setting |
Leon L1, Peñuelas M2, Candel FJ2, Freites D3, Rodriguez-Rodriguez L3, Fernandez-Gutierrez B3, Jover JA3, Abasolo L3. Ther Adv Musculoskelet Dis. 2019 Oct 7;11:1759720X19878004. doi: 10.1177/1759720X19878004. eCollection 2019. |
| 116 | |
Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from Two Corrona Registries |
Mease PJ1, Liu M2, Rebello S2, Kang H2, Yi E3, Park Y3, Greenberg JD2,4. Rheumatol Ther. 2019 Dec;6(4):529-542. doi: 10.1007/s40744-019-00172-9. Epub 2019 Sep 16. |
| 117 | |
The Impact of the ACA Medicaid Expansion on Access to Care and Hospitalization Charges for Lupus Patients |
Brown EA1, Dismuke-Greer CE1, Viswanathan R1, Faith TD1, Williams EM1. Arthritis Care Res (Hoboken). 2019 Sep 28. doi: 10.1002/acr.24080. [Epub ahead of print] |
| 118 | |
Treat to Target in Systemic Lupus Erythematosus |
Aringer M1, Leuchten N2, Schneider M3. Rheum Dis Clin North Am. 2019 Nov;45(4):537-548. doi: 10.1016/j.rdc.2019.07.004. Epub 2019 Aug 22. |
| 119 | |
Systemic Lupus Erythematosus and dysbiosis in the microbiome: cause or effect or both? |
Silverman GJ1, Azzouz DF2, Alekseyenko AV3. Curr Opin Immunol. 2019 Oct 4;61:80-85. doi: 10.1016/j.coi.2019.08.007. [Epub ahead of print] |
| 120 | |
Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE |
Wallace DJ1, Alexander RV2, O'Malley T2, Khosroshahi A3, Hojjati M4, Loupasakis K5, Alper J6, Sherrer Y6, Fondal M6, Kataria R7, Powell T2, Ibarra C2, Narain S8, Massarotti E9, Weinstein A2,10, Dervieux T2. Lupus Sci Med. 2019 Sep 19;6(1):e000349. doi: 10.1136/lupus-2019-000349. eCollection 2019. |
| 121 | |
Prescription Opioid Use in Patients With and Without Systemic Lupus Erythematosus - Michigan Lupus Epidemiology and Surveillance Program, 2014-2015 |
Somers EC, Lee J, Hassett AL, Zick SM, Harlow SD, Helmick CG, Barbour KE, Gordon C, Brummett CM, Minhas D, Padda A, Wang L, McCune WJ, Marder W. MMWR Morb Mortal Wkly Rep. 2019 Sep 27;68(38):819-824. doi: 10.15585/mmwr.mm6838a2. |
| 122 | |
Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis |
Hoffman E1,2,3, Rahat MA4,5, Feld J6, Elias M7, Rosner I8,9, Kaly L10, Lavie I11,12, Gazitt T13, Zisman D14,15. Int J Mol Sci. 2019 Sep 18;20(18). pii: E4633. doi: 10.3390/ijms20184633. |
| 123 | |
What does the patient global health assessment in RA really tell us? Contribution of specific dimensions of health-related quality of life |
Craig ET1,2,3, Perin J4, Zeger S4, Curtis JR5, Bykerk VP6, Bingham CO1, Bartlett SJ1,7. Arthritis Care Res (Hoboken). 2019 Sep 24. doi: 10.1002/acr.24073. [Epub ahead of print] |
| 124 | |
Nutrition Interventions in Rheumatoid Arthritis: The Potential Use of Plant-Based Diets. A Review |
Alwarith J1, Kahleova H1, Rembert E1, Yonas W1, Dort S1, Calcagno M1, Burgess N1, Crosby L1, Barnard ND1,2. Front Nutr. 2019 Sep 10;6:141. doi: 10.3389/fnut.2019.00141. eCollection 2019. |
| 125 | |
Rheumatoid Arthritis Flares after Total Hip and Total Knee Arthroplasty: Outcomes at 1 year |
Goodman SM1,2, Mirza SZ1, DiCarlo EF1, Pearce-Fisher D1, Zhang M3, Mehta B1,2, Donlin LT1,2, Bykerk VP1,2, Figgie MP1,2, Orange DE1,4. Arthritis Care Res (Hoboken). 2019 Oct 14. doi: 10.1002/acr.24091. [Epub ahead of print] |
| 126 | |
Exposure-Response Analyses of Upadacitinib Efficacy and Safety in Phase 2 and 3 Studies to Support Benefit-Risk Assessment in Rheumatoid Arthritis |
Nader A1, Mohamed MF1, Winzenborg I2, Doelger E2, Noertersheuser P2, Pangan AL3, Othman AA1. Clin Pharmacol Ther. 2019 Oct 14. doi: 10.1002/cpt.1671. [Epub ahead of print] |
| 127 | |
Evidence of Diagnostic and Treatment Delay in Seronegative Rheumatoid Arthritis: Missing the Window of Opportunity |
Coffey CM1, Crowson CS2, Myasoedova E3, Matteson EL2, Davis JM 3rd4. Mayo Clin Proc. 2019 Nov;94(11):2241-2248. doi: 10.1016/j.mayocp.2019.05.023. Epub 2019 Oct 13. |
| 128 | |
Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial |
Giles JT1, Sattar N2, Gabriel S3, Ridker PM4, Gay S5, Warne C6, Musselman D7, Brockwell L6, Shittu E6, Klearman M7, Fleming TR8. Arthritis Rheumatol. 2019 Aug 30. doi: 10.1002/art.41095. [Epub ahead of print] |
| 129 | |
When Randomized Clinical Trials and Real-World Evidence Say the Same: Tocilizumab and its Cardiovascular Safety |
Kim SC1,2, Schneeweiss S1. Arthritis Rheumatol. 2019 Aug 30. doi: 10.1002/art.41092. [Epub ahead of print] |
| 130 | |
Influence of prior antibiotic use on risk of rheumatoid arthritis: case control study in general practice |
Armstrong D1, Dregan A2, Ashworth M1, White P1, McGee C3,4, de Lusignan S3,4. Rheumatology (Oxford). 2019 Oct 3. pii: kez452. doi: 10.1093/rheumatology/kez452. [Epub ahead of print] |
| 131 | |
Efficacy and safety of subcutaneous tocilizumab in rheumatoid arthritis over 1 year: a UK real-world, open-label study |
Isaacs JD1,2, Salih A3, Sheeran T4, Patel YI5, Douglas K6, McKay ND7, Naisbett-Groet B8, Choy E9. Rheumatol Adv Pract. 2019 Apr 19;3(1):rkz010. doi: 10.1093/rap/rkz010. eCollection 2019. |
| 132 | |
Update on lupus epidemiology: advancing health disparities research through the study of minority populations |
Drenkard C1,2, Lim SS1,2. Curr Opin Rheumatol. 2019 Nov;31(6):689-696. doi: 10.1097/BOR.0000000000000646. |
| 133 | |
Human Lupus Plasma Pro-Atherogenic Effects on Cultured Macrophages Are Not Mitigated by Statin Therapy: A Mechanistic LAPS Substudy |
Reiss AB1, Arain HA2, Kasselman LJ2, Renna HA2, Zhen J2, Voloshyna I2, DeLeon J2, Carsons SE2, Petri M3. Medicina (Kaunas). 2019 Aug 21;55(9). pii: E514. doi: 10.3390/medicina55090514. |
| 134 | |
Update on pregnancy complications in systemic lupus erythematosus |
Marder W1,2. Curr Opin Rheumatol. 2019 Nov;31(6):650-658. doi: 10.1097/BOR.0000000000000651. |
| 135 | |
The Role of Neutrophils and Neutrophil Extracellular Traps in Vascular Damage in Systemic Lupus Erythematosus |
O'Neil LJ1, Kaplan MJ1, Carmona-Rivera C2. Clin Med. 2019 Aug 28;8(9). pii: E1325. doi: 10.3390/jcm8091325. |
| 136 | |
A phenotypic and genomics approach in a multi-ethnic cohort to subtype systemic lupus erythematosus |
Lanata CM1, Paranjpe I2,3, Nititham J1, Taylor KE1, Gianfrancesco M1, Paranjpe M2, Andrews S2, Chung SA1, Rhead B4, Barcellos LF4, Trupin L1, Katz P1, Dall'Era M1, Yazdany J1, Sirota M2, Criswell LA5,6. Nat Commun. 2019 Aug 29;10(1):3902. doi: 10.1038/s41467-019-11845-y. |
| 137 | |
Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes |
Lewis MJ1, Barnes MR2, Blighe K1, Goldmann K1, Rana S3, Hackney JA4, Ramamoorthi N5, John CR1, Watson DS6, Kummerfeld SK4, Hands R1, Riahi S1, Rocher-Ros V1, Rivellese F1, Humby F1, Kelly S1, Bombardieri M1, Ng N1, DiCicco M1, van der Heijde D7, Landewé R8, van der Helm-van Mil A7, Cauli A9, McInnes IB10, Buckley CD11, Choy E12, Taylor PC13, Townsend MJ14, Pitzalis C15. Cell Rep. 2019 Aug 27;28(9):2455-2470.e5. doi: 10.1016/j.celrep.2019.07.091. |
| 138 | |
Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged |
Tesser J1, Kafka S2, DeHoratius RJ2,3, Xu S4, Hsia EC4,5, Turkiewicz A6. Arthritis Res Ther. 2019 Aug 20;21(1):190. doi: 10.1186/s13075-019-1968-x. |
| 139 | |
Arthritis diagnosis and early-life exposure to air pollution |
Shepherd A1, Mullins JT2. Environ Pollut. 2019 Oct;253:1030-1037. doi: 10.1016/j.envpol.2019.07.054. Epub 2019 Jul 13. |
| 140 | |
Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis |
Edwards CJ1, Monnet J2, Ullmann M2, Vlachos P3, Chyrok V2, Ghori V2. Clin Rheumatol. 2019 Aug 8. doi: 10.1007/s10067-019-04679-y. [Epub ahead of print] |
| 141 | |
Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort |
Favalli EG1, Becciolini A2, Carletto A3, Conti F4, Amato G5, Fusaro E6, Quartuccio L7, Egan CG8, Lo Monaco A9, Benucci M10, Salaffi F11, Semeraro A12, Parisi S6, Ceccarelli F4, Piazza I3, Foti R5. Rheumatol Int. 2019 Aug 21. doi: 10.1007/s00296-019-04416-3. [Epub ahead of print] |
| 142 | |
Factors associated with use of telemedicine for follow-up of rheumatoid arthritis |
Ferucci ED1, Holck P2, Day GM3, Choromanski TL3, Freeman SL4. Arthritis Care Res (Hoboken). 2019 Aug 17. doi: 10.1002/acr.24049. [Epub ahead of print] |
| 143 | |
Comparative Effectiveness of Combining MTX with Biologic Drug Therapy Versus Either MTX or Biologics Alone for Early Rheumatoid Arthritis in Adults: a Systematic Review and Network Meta-analysis |
Donahue KE1,2, Schulman ER3, Gartlehner G4,5, Jonas BL6, Coker-Schwimmer E7, Patel SV4, Weber RP7, Bann CM4, Viswanathan M4. J Gen Intern Med. 2019 Aug 6. doi: 10.1007/s11606-019-05230-0. [Epub ahead of print] |
| 144 | |
Lipid management in rheumatoid arthritis: a position paper by the Cardiovascular Pharmacotherapy Working Group of European Society of Cardiology |
Hollan I1, Ronda N2, Dessein P3, Agewall S4, Karpouzas G5, Tamargo J6, Niessner A7, Savarese G8, Rosano G9, Kaski JC10, Wassmann S11, Meroni PL12. Eur Heart J Cardiovasc Pharmacother. 2019 Aug 9. pii: pvz033. doi: 10.1093/ehjcvp/pvz033. [Epub ahead of print] |
| 145 | |
Performance of Administrative Algorithms to Identify Interstitial Lung Disease in Rheumatoid Arthritis |
England BR1,2, Roul P2, Mahajan TD2, Singh N3,4, Yu F5, Sayles H2,5, Cannon GW6, Sauer BC6, Baker JF7, Curtis JR8, Mikuls TR1,2. Arthritis Care Res (Hoboken). 2019 Aug 17. doi: 10.1002/acr.24043. [Epub ahead of print] |
| 146 | |
Antibiotic use and the risk of rheumatoid arthritis: a population-based case-control study |
Sultan AA1, Mallen C1, Muller S1, Hider S1,2, Scott I1,2, Helliwell T1, Hall LJ3. BMC Med. 2019 Aug 7;17(1):154. doi: 10.1186/s12916-019-1394-6. |
| 147 | |
Lupus nephritis: challenges and progress |
Davidson A1, Aranow C, Mackay M. Curr Opin Rheumatol. 2019 Nov;31(6):682-688. doi: 10.1097/BOR.0000000000000642. |
| 148 | |
Bruton |
Bruton's tyrosine kinase (BTK) inhibitors such as ibrutinib hold a prominent role in the treatment of B cell malignancies. However, further refinement is needed to this class of agents, particularly in terms of adverse events (potentially driven by kinase promiscuity), which preclude their evaluation in nononcology indications. Here, we report the discovery and preclinical characterization of evobrutinib, a potent, obligate covalent inhibitor with high kinase selectivity. Evobrutinib displayed sufficient preclinical pharmacokinetic and pharmacodynamic characteristics which allowed for in vivo evaluation in efficacy models. Moreover, the high selectivity of evobrutinib for BTK over epidermal growth factor receptor and other Tec family kinases suggested a low potential for off-target related adverse effects. Clinical investigation of evobrutinib is ongoing in several autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus. |
| 149 | |
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton |
Caldwell RD1, Qiu H1, Askew BC1, Bender AT1, Brugger N1, Camps M1, Dhanabal M1, Dutt V1, Eichhorn T1, Gardberg AS1, Goutopoulos A1, Grenningloh R1, Head J1, Healey B1, Hodous BL1, Huck BR1, Johnson TL1, Jones C1, Jones RC1, Mochalkin I1, Morandi F1, Nguyen N1, Meyring M1, Potnick JR1, Santos DC1, Schmidt R1, Sherer B1, Shutes A1, Urbahns K1, Follis AV1, Wegener AA1, Zimmerli SC1, Liu-Bujalski L1. J Med Chem. 2019 Sep 12;62(17):7643-7655. doi: 10.1021/acs.jmedchem.9b00794. Epub 2019 Aug 15. |
| 150 | |
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus |
Aringer M1, Costenbader K2, Daikh D3, Brinks R4, Mosca M5, Ramsey-Goldman R6, Smolen JS7, Wofsy D8, Boumpas DT9, Kamen DL10, Jayne D11, Cervera R12, Costedoat-Chalumeau N13, Diamond B14, Gladman DD15, Hahn B16, Hiepe F17, Jacobsen S18, Khanna D19, Lerstrøm K20, Massarotti E2, McCune J19, Ruiz-Irastorza G21, Sanchez-Guerrero J22, Schneider M23, Urowitz M24, Bertsias G25, Hoyer BF26, Leuchten N1, Tani C27, Tedeschi SK2, Touma Z15, Schmajuk G3, Anic B28, Assan F29, Chan TM30, Clarke AE31, Crow MK32, Czirják L33, Doria A34, Graninger W35, Halda-Kiss B33, Hasni S36, Izmirly PM37, Jung M31, Kumánovics G33, Mariette X38, Padjen I28, Pego-Reigosa JM39, Romero-Diaz J40, Rúa-Figueroa Fernández Í41, Seror R29, Stummvoll GH7, Tanaka Y42, Tektonidou MG43, Vasconcelos C44, Vital EM45, Wallace DJ46, Yavuz S47, Meroni PL48, Fritzler MJ31, Naden R49, Dörner T17, Johnson SR50. Arthritis Rheumatol. 2019 Sep;71(9):1400-1412. doi: 10.1002/art.40930. Epub 2019 Aug 6. |
| 151 | |
BAFF inhibition in SLE-Is tolerance restored? |
Jackson SW1,2, Davidson A3. Immunol Rev. 2019 Sep 28. doi: 10.1111/imr.12810. [Epub ahead of print] |
| 152 | |
Is Use of Traditional Chinese Medicine Associated with Non-adherence to Prescribed Western Rheumatic Medications among Chinese-American Patients? A Cross-Sectional Survey |
Sun K1, Szymonifka J2, Tian H3, Chang Y4, Leng JC5, Mandl LA6. Arthritis Care Res (Hoboken). 2019 Jul 19. doi: 10.1002/acr.24031. [Epub ahead of print] |
| 153 | |
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton |
Caldwell RD1, Qiu H1, Askew BC1, Bender AT1, Brugger N1, Camps M1, Dhanabal M1, Dutt V1, Eichhorn T1, Gardberg AS1, Goutopoulos A1, Grenningloh R1, Head J1, Healey B1, Hodous BL1, Huck BR1, Johnson TL1, Jones C1, Jones RC1, Mochalkin I1, Morandi F1, Nguyen N1, Meyring M1, Potnick JR1, Santos DC1, Schmidt R1, Sherer B1, Shutes A1, Urbahns K1, Follis AV1, Wegener AA1, Zimmerli SC1, Liu-Bujalski L1. J Med Chem. 2019 Sep 12;62(17):7643-7655. doi: 10.1021/acs.jmedchem.9b00794. Epub 2019 Aug 15. |
| 154 | |
Industry funding was associated with increased use of core outcome sets |
Kirkham JJ1, Bracken M2, Hind L2, Pennington K2, Clarke M3, Williamson PR2. J Clin Epidemiol. 2019 Jul 18;115:90-97. doi: 10.1016/j.jclinepi.2019.07.007. [Epub ahead of print] |
| 155 | |
Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext) |
Cohen SB1, Czeloth N2, Lee E3, Klimiuk PA4, Peter N5, Jayadeva G2. Expert Opin Biol Ther. 2019 Oct;19(10):1097-1105. doi: 10.1080/14712598.2019.1645114. Epub 2019 Aug 6. |
| 156 | |
Long-term, Real-world Safety of Adalimumab in Rheumatoid Arthritis: Analysis of a Prospective US-Based Registry |
Harrold LR1, Griffith J1, Zueger P1, Litman HJ1, Gershenson B1, Islam SS1, Barr CJ1, Guo D1, Fay J1, Greenberg JD1. J Rheumatol. 2019 Aug 1. pii: jrheum.190260. doi: 10.3899/jrheum.190260. [Epub ahead of print] |
| 157 | |
Mediation of Adverse Pregnancy Outcomes in Autoimmune Conditions by Pregnancy Complications |
Bandoli G1, Singh N2, Strouse J3, Baer RJ4, Donovan BM5, Feuer SK4, Nidey N6, Ryckman KK6, Jelliffe-Pawlowski LL4,7, Chambers CD1. Arthritis Care Res (Hoboken). 2019 Aug 2. doi: 10.1002/acr.24037. [Epub ahead of print] |
| 158 | |
Monotherapy is a relevant option in rheumatoid arthritis treatment: a literature review |
Doria A1, Zavaglia D2. Clin Exp Rheumatol. 2019 Sep-Oct;37(5):862-871. Epub 2019 Jul 22. |
| 159 | |
General theory of inflammation: patient self-administration of hydrocortisone safely achieves superior control of hydrocortisone-responding disorders by matching dosage with symptom intensity |
General theory of inflammation: patient self-administration of hydrocortisone safely achieves superior control of hydrocortisone-responding disorders by matching dosage with symptom intensity |
| 160 | |
Inflammation is associated with pro-nociceptive brain connections in rheumatoid arthritis patients with concomitant fibromyalgia |
Kaplan CM1, Schrepf A1, Ichesco E1, Larkin T1, Harte SE1, Harris RE1, Murray AD2, Waiter GD2, Clauw DJ1, Basu N3. Arthritis Rheumatol. 2019 Aug 5. doi: 10.1002/art.41069. [Epub ahead of print] |
| 161 | |
Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext) |
Cohen SB1, Czeloth N2, Lee E3, Klimiuk PA4, Peter N5, Jayadeva G2. Expert Opin Biol Ther. 2019 Aug 6:1-9. doi: 10.1080/14712598.2019.1645114. [Epub ahead of print] |
| 162 | |
Why Don |
Rosenthal KS1,2, Carambula R3, Zimmerman DH3. J Clin Cell Immunol. 2019;10(1). pii: 574. doi: 10.4172/2155-9899.1000574. Epub 2019 Jan 31. |
| 163 | |
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response |
Fleischmann RM1, Genovese MC2, Enejosa JV3, Mysler E4, Bessette L5,6, Peterfy C7, Durez P8, Ostor A9, Li Y10, Song IH3. Ann Rheum Dis. 2019 Jul 30. pii: annrheumdis-2019-215764. doi: 10.1136/annrheumdis-2019-215764. [Epub ahead of print] |
| 164 | |
Centre effects and case-mix in early rheumatoid arthritis observational cohorts: a narrative review |
Yates M1, Bechman K1, Norton S1, Nikiphorou E1, Galloway J1. Rheumatology (Oxford). 2019 May 6. pii: kez151. doi: 10.1093/rheumatology/kez151. [Epub ahead of print] |
| 165 | |
Patient and caregiver priorities for medication adherence in gout, osteoporosis and rheumatoid arthritis: nominal group technique |
Kelly A1,2,3, Tymms K1,2,4, de Wit M5, Bartlett SJ6,7, Cross M8, Dawson T9,10, De Vera M11,12, Evans V13,14, Gill M15, Hassett G16,17, Lim I18, Manera K3,19, Major G20,21, March L8,22,23, O'Neill S16,17, Scholte-Voshaar M24, Sinnathurai P8,22,23, Sumpton D3,19,25, Teixeira-Pinto A3,19, Tugwell P26, van den Bemt B27,28, Tong A3,19. Arthritis Care Res (Hoboken). 2019 Jul 19. doi: 10.1002/acr.24032. [Epub ahead of print] |
| 166 | |
Long-term, Real-world Safety of Adalimumab in Rheumatoid Arthritis: Analysis of a Prospective US-Based Registry |
Harrold LR1, Griffith J1, Zueger P1, Litman HJ1, Gershenson B1, Islam SS1, Barr CJ1, Guo D1, Fay J1, Greenberg JD1. J Rheumatol. 2019 Aug 1. pii: jrheum.190260. doi: 10.3899/jrheum.190260. [Epub ahead of print] |
| 167 | |
Antibodies to Brewer |
Lichtenstein JR1, Epstein AL2. Cureus. 2019 May 17;11(5):e4691. doi: 10.7759/cureus.4691. |
| 168 | |
Treat-to-target and shared decision making in rheumatoid arthritis treatment: Is it feasible? |
Falzer PR1. Int J Rheum Dis. 2019 Sep;22(9):1706-1713. doi: 10.1111/1756-185X.13664. Epub 2019 Jul 30. |
| 169 | |
Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years |
Fleischmann R1, Genovese MC2, Lin Y3, St John G4, van der Heijde D5, Wang S3, Gomez-Reino JJ6, Maldonado-Cocco JA7, Stanislav M8, Kivitz AJ9, Burmester GR10. Rheumatology (Oxford). 2019 Jul 15. pii: kez265. doi: 10.1093/rheumatology/kez265. [Epub ahead of print] |
| 170 | |
The impact of gender on time to rheumatoid arthritis classification: a retrospective analysis of a population-based cohort |
Coffey CM1, Davis JM 3rd1, Crowson CS2. Rheumatol Int. 2019 Jul 23. doi: 10.1007/s00296-019-04360-2. [Epub ahead of print] |
| 171 | |
A Neutrophil Activation Biomarker Panel in Prognosis and Monitoring of Patients with Rheumatoid Arthritis |
Bach M1, Moon J2, Moore R1, Pan T3, Nelson JL1,3, Lood C1. Arthritis Rheumatol. 2019 Jul 28. doi: 10.1002/art.41062. [Epub ahead of print] |
| 172 | |
Comparison of PREDICTS atherosclerosis biomarker changes after initiation of new treatments in patients with SLE |
McMahon M1, Skaggs B1, Grossman J1, Wong WK2, Sahakian L1, Chen W1, Hahn B1. Lupus Sci Med. 2019 Jun 27;6(1):e000321. doi: 10.1136/lupus-2019-000321. eCollection 2019. |
| 173 | |
Effectiveness of Occupational Therapy Interventions for Adults With Systemic Lupus Erythematosus: A Systematic Review |
Poole JL1, Bradford JD2, Siegel P3. Am J Occup Ther. 2019 Jul/Aug;73(4):7304205020p1-7304205020p21. doi: 10.5014/ajot.2019.030619. |
| 174 | |
Treatment consideration for US military members with skin disease |
Burke KR1, Larrymore DC1, Cho S1. Cutis. 2019 Jun;103(6):329-332. |
| 175 | |
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus |
Aringer M1, Costenbader K2, Daikh D3, Brinks R4, Mosca M5, Ramsey-Goldman R6, Smolen JS7, Wofsy D8, Boumpas DT9,10, Kamen DL11, Jayne D12, Cervera R13, Costedoat-Chalumeau N14, Diamond B15, Gladman DD16, Hahn B17, Hiepe F18, Jacobsen S19, Khanna D20, Lerstrøm K21, Massarotti E22,23, McCune J20, Ruiz-Irastorza G24, Sanchez-Guerrero J25,26, Schneider M27, Urowitz M28, Bertsias G29, Hoyer BF18,30, Leuchten N31, Tani C32, Tedeschi SK23,33, Touma Z34, Schmajuk G3, Anic B35, Assan F36, Chan TM37, Clarke AE38, Crow MK39, Czirják L40, Doria A41, Graninger W42, Halda-Kiss B40, Hasni S43, Izmirly PM44, Jung M38, Kumánovics G40, Mariette X45,46, Padjen I35, Pego-Reigosa JM47, Romero-Diaz J26, Rúa-Figueroa Fernández Í48, Seror R36, Stummvoll GH49, Tanaka Y50, Tektonidou MG51, Vasconcelos C52, Vital EM53,54, Wallace DJ55, Yavuz S56, Meroni PL57, Fritzler MJ58, Naden R59, Dörner T18, Johnson SR60,61. Ann Rheum Dis. 2019 Sep;78(9):1151-1159. doi: 10.1136/annrheumdis-2018-214819. Epub 2019 Aug 5. |
| 176 | |
Socioeconomic status at diagnosis influences the incremental direct medical costs of systemic lupus erythematosus: A longitudinal population-based study |
McCormick N1, Marra CA2, Sadatsafavi M3, Aviña-Zubieta JA4. Semin Arthritis Rheum. 2019 Jun 14. pii: S0049-0172(18)30146-X. doi: 10.1016/j.semarthrit.2019.06.010. [Epub ahead of print] |
| 177 | |
Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine US Clinical Practice |
Pappas DA1,2, Etzel CJ3, Zlotnick S4, Best J4, Blachley T3, Kremer JM3,5. Rheumatol Ther. 2019 Sep;6(3):421-433. doi: 10.1007/s40744-019-0162-6. Epub 2019 Jun 25. |
| 178 | |
Association of Genetic Risk for Rheumatoid Arthritis With Cognitive and Psychiatric Phenotypes Across Childhood and Adolescence |
Jones HJ1,2,3, Hubbard L4, Mitchell RE1, Jones SA5,6, Williams NM4, Zammit S2,3,4, Hall J4,6,7. JAMA Netw Open. 2019 Jun 5;2(6):e196118. doi: 10.1001/jamanetworkopen.2019.6118 |
| 179 | |
The neutrophil-lymphocyte ratio in early rheumatoid arthritis and its ability to predict subsequent failure of triple therapy |
Boulos D1, Proudman SM2, Metcalf RG3, McWilliams L3, Hall C3, Wicks IP4. Semin Arthritis Rheum. 2019 May 31. pii: S0049-0172(19)30109-X. doi: 10.1016/j.semarthrit.2019.05.008. [Epub ahead of print] |
| 180 | |
Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn |
Curtis JR1, Mariette X2, Gaujoux-Viala C3, Blauvelt A4, Kvien TK5, Sandborn WJ6, Winthrop K7, de Longueville M8, Huybrechts I8, Bykerk VP9. RMD Open. 2019 May 31;5(1):e000942. doi: 10.1136/rmdopen-2019-000942. eCollection 2019. |
| 181 | |
Efficacy and safety of long-term baricitinib with and without methotrexate for the treatment of rheumatoid arthritis: experience with baricitinib monotherapy continuation or after switching from methotrexate monotherapy or baricitinib plus methotrexate |
Fleischmann R1, Takeuchi T2, Schiff M3, Schlichting D4, Xie L4, Issa M4, Stoykov I4, Lisse J4, Martinez-Osuna P4, Rooney T4, Zerbini CAF5. Arthritis Care Res (Hoboken). 2019 Jun 24. doi: 10.1002/acr.24007. [Epub ahead of print] |
| 182 | |
"Living a normal life": a qualitative study of patients |
Baker KF1,2, Isaacs JD1,2, Thompson B1,2. BMC Rheumatol. 2019 Jun 13;3:2. doi: 10.1186/s41927-019-0070-y. eCollection 2019. |
| 183 | |
Health Disparities Among Hispanics With Rheumatoid Arthritis: Delay in Presentation to Rheumatologists Contributes to Later Diagnosis and Treatment |
Riad M1, Dunham DP2, Chua JR1, Shakoor N1, Hassan S1, Everakes S1, Block JA1, Castrejon I1. J Clin Rheumatol. 2019 Jun 18. doi: 10.1097/RHU.0000000000001085. [Epub ahead of print] |
| 184 | |
Comparison of Female Sexual Function Index in patients with psoriatic and rheumatoid arthritis and healthy controls |
Boone D1, Ronson A, Karsh J1. Musculoskeletal Care. 2019 Jun 20. doi: 10.1002/msc.1405. [Epub ahead of print] |
| 185 | |
Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial |
Taylor PC1, Lee YC2, Fleischmann R3, Takeuchi T4, Perkins EL5, Fautrel B6, Zhu B7, Quebe AK8, Gaich CL9, Zhang X10, Dickson CL11, Schlichting DE12, Patel H13, Durand F14, Emery P15. J Clin Med. 2019 Jun 12;8(6). pii: E831. doi: 10.3390/jcm8060831. |
| 186 | |
Accelerated Atherosclerosis in Rheumatoid Arthritis: Mechanisms and Treatment |
Reiss AB1, Silverman A1, Khalfan M1, Vernice NA1, Kasselman LJ1, Carsons SE1, De Leon J1. Curr Pharm Des. 2019;25(9):969-986. doi: 10.2174/1381612825666190430113212. |
| 187 | |
Clinical characteristics and renal prognosis associated with interstitial fibrosis and tubular atrophy (IFTA) and vascular injury in lupus nephritis biopsies |
Leatherwood C1, Speyer CB1, Feldman CH1, D'Silva K2, Gómez-Puerta JA3, Hoover PJ1, Waikar SS4, McMahon GM4, Rennke HG5, Costenbader KH6. Semin Arthritis Rheum. 2019 Jun 11. pii: S0049-0172(19)30107-6. doi: 10.1016/j.semarthrit.2019.06.002. [Epub ahead of print] |
| 188 | |
Trends in Maternal and Fetal Outcomes Among Pregnant Women With Systemic Lupus Erythematosus in the United States: A Cross-sectional Analysis |
Mehta B1, Luo Y2, Xu J1, Sammaritano L1, Salmon J1, Lockshin M1, Goodman S1, Ibrahim S3. Ann Intern Med. 2019 Jul 9. doi: 10.7326/M19-0120. [Epub ahead of print] |
| 189 | |
Infertility among African American women with systemic lupus erythematosus compared to healthy women: A pilot study |
Angley M1, Lim SS1,2, Spencer JB3, Howards PP1.Author informationArthritis Care Res (Hoboken). 2019 Jul 8. doi: 10.1002/acr.24022. [Epub ahead of print] |
| 190 | |
An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: A systematic review |
Shipman WD1, Vernice NA2, Demetres M3, Jorizzo JL4. Author informationJ Am Acad Dermatol. 2019 Jul 12. pii: S0190-9622(19)32387-4. doi: 10.1016/j.jaad.2019.07.027. [Epub ahead of print] |
| 191 | |
Is There a Place for Hematopoietic Stem Cell Transplantation in Rheumatology? |
Spierings J1, van Laar JM2. Rheum Dis Clin North Am. 2019 Aug;45(3):399-416. doi: 10.1016/j.rdc.2019.04.003. Epub 2019 May 27. |
| 192 | |
Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis |
Edwards CJ1, Monnet J2, Ullmann M2, Vlachos P3, Chyrok V2, Ghori V2. Clin Rheumatol. 2019 Aug 8. doi: 10.1007/s10067-019-04679-y. [Epub ahead of print] |
| 193 | |
Nomenclature for the Phases of the Development of Rheumatoid Arthritis |
Raza K1, Holers VM2, Gerlag D3. Clin Ther. 2019 Jul;41(7):1279-1285. doi: 10.1016/j.clinthera.2019.04.013. Epub 2019 Jun 10. |
| 194 | |
The Natural History of Rheumatoid Arthritis |
Deane KD1, Holers VM2. Clin Ther. 2019 Jul;41(7):1256-1269. doi: 10.1016/j.clinthera.2019.04.028. Epub 2019 Jun 10. |
| 195 | |
Immunomodulatory nanodiamond aggregate-based platform for the treatment of rheumatoid arthritis |
Pentecost A1,2, Kim MJ3,4, Jeon S4, Ko YJ3,4, Kwon IC3,4, Gogotsi Y1, Kim K4, Spiller KL2. Regen Biomater. 2019 Jun;6(3):163-174. doi: 10.1093/rb/rbz012. Epub 2019 Apr 19. |
| 196 | |
Impact of Adverse Events Associated With Medications in the Treatment and Prevention of Rheumatoid Arthritis |
Costello R1, David T1, Jani M2. Clin Ther. 2019 Jul;41(7):1376-1396. doi: 10.1016/j.clinthera.2019.04.030. Epub 2019 Jun 10. |
| 197 | |
Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupusnephritis in childhood-onset and adult-onset SLE |
Webber D1, Cao J2, Dominguez D1, Gladman DD3, Levy DM1, Ng L1, Paterson AD2, Touma Z3, Urowitz MB3, Wither JE3, Silverman ED1,4, Hiraki LT1,5. Rheumatology (Oxford). 2019 Jun 24. pii: kez220. doi: 10.1093/rheumatology/kez220. [Epub ahead of print] |
| 198 | |
Exposure-Response Analyses of Upadacitinib Efficacy in Phase 2 Trials in Rheumatoid Arthritis and Basis for Phase 3 Dose Selection |
Mohamed MF1, Klünder B2, Camp HS3, Othman AA1. Clin Pharmacol Ther. 2019 Jun 13. doi: 10.1002/cpt.1543. [Epub ahead of print] |
| 199 | |
Considerations for Optimal Trial Design for Rheumatoid Arthritis Prevention Studies |
Cope AP1. Clin Ther. 2019 Jul;41(7):1299-1311. doi: 10.1016/j.clinthera.2019.04.014. Epub 2019 Jun 10. |
| 200 | |
Differentiating Bilateral Symptomatic Hand Osteoarthritis From Rheumatoid Arthritis Using Sonography When Clinical and Radiographic Features Are Nonspecific: A Case Report |
Lewis KL1, Battaglia PJ1. J Chiropr Med. 2019 Mar;18(1):56-60. doi: 10.1016/j.jcm.2018.07.005. Epub 2019 Feb 10. |
| 201 | |
Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study |
Glatt S1, Taylor PC2, McInnes IB3, Schett G4, Landewé R5, Baeten D5,6, Ionescu L6, Strimenopoulou F7, Watling MIL8, Shaw S8. Ann Rheum Dis. 2019 Aug;78(8):1033-1040. doi: 10.1136/annrheumdis-2018-214943. Epub 2019 Jun 8. |
| 202 | |
Potential of Lifestyle Changes for Reducing the Risk of Developing Rheumatoid Arthritis: Is an Ounce of Prevention Worth a Pound of Cure? |
Zaccardelli A1, Friedlander HM1, Ford JA2, Sparks JA3. Clin Ther. 2019 Jul;41(7):1323-1345. doi: 10.1016/j.clinthera.2019.04.021. Epub 2019 Jun 10. |
| 203 | |
Rheumatoid Arthritis: A Severe Disease That Preventive Approaches Would Greatly Benefit |
Davis JM 3rd1. Clin Ther. 2019 Jul;41(7):1240-1245. doi: 10.1016/j.clinthera.2019.04.026. Epub 2019 Jun 10. |
| 204 | |
Preferences of Patients and At-risk Individuals for Preventive Approaches to Rheumatoid Arthritis |
Falahee M1, Finckh A2, Raza K3, Harrison M4. Clin Ther. 2019 Jul;41(7):1346-1354. doi: 10.1016/j.clinthera.2019.04.015. Epub 2019 Jun 10. |
| 205 | |
Osteoporosis Pathophysiology, Epidemiology, and Screening in Rheumatoid Arthritis |
Adami G1,2, Saag KG3. Curr Rheumatol Rep. 2019 May 23;21(7):34. doi: 10.1007/s11926-019-0836-7. |
| 206 | |
Cortisone in Popular Culture: Roueché, Ray, and Hench |
Wijdicks EFM1, Rooke TW2, Hunder GG3, Dacy MD4. Mayo Clin Proc Innov Qual Outcomes. 2019 May 27;3(2):215-220. doi: 10.1016/j.mayocpiqo.2019.04.003. eCollection 2019 Jun. |
| 207 | |
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study |
Smolen JS1, Pangan AL2, Emery P3, Rigby W4, Tanaka Y5, Vargas JI6, Zhang Y2, Damjanov N7, Friedman A2, Othman AA2, Camp HS2, Cohen S8. Lancet. 2019 Jun 8;393(10188):2303-2311. doi: 10.1016/S0140-6736(19)30419-2. Epub 2019 May 23. |
| 208 | |
Lifetime risk of knee and hip replacement following a diagnosis of RA: findings from a cohort of 13 961 patients from England |
Burn E1, Edwards CJ2, Murray DW1, Silman A1, Cooper C1,3, Arden NK1,3, Pinedo-Villanueva R1, Prieto-Alhambra D4. Rheumatology (Oxford). 2019 Apr 23. pii: kez143. doi: 10.1093/rheumatology/kez143. [Epub ahead of print] |
| 209 | |
Preventing Rheumatoid Arthritis: A Global Challenge |
Widdifield J1. Clin Ther. 2019 Jul;41(7):1355-1365. doi: 10.1016/j.clinthera.2019.04.019. Epub 2019 Jun 10. |
| 210 | |
Extra-articular Manifestations and Comorbidity in Rheumatoid Arthritis: Potential Impact of Pre-Rheumatoid Arthritis Prevention |
Giles JT1. Clin Ther. 2019 Jul;41(7):1246-1255. doi: 10.1016/j.clinthera.2019.04.018. Epub 2019 Jun 10. |
| 211 | |
Vasculitis in Juvenile-Onset Systemic Lupus Erythematosus |
Smith EMD1,2, Lythgoe H3, Hedrich CM1,2. Front Pediatr. 2019 May 9;7:149. doi: 10.3389/fped.2019.00149. eCollection 2019. |
| 212 | |
Pulmonary Complications of Systemic Lupus Erythematosus |
Pulmonary Complications of Systemic Lupus Erythematosus |
| 213 | |
The Influence of Diet and Obesity on Gene Expression in SLE |
The Influence of Diet and Obesity on Gene Expression in SLE |
| 214 | |
Management strategies and future directions for systemic lupus erythematosus in adults |
Durcan L1, O'Dwyer T2, Petri M3. Lancet. 2019 Jun 8;393(10188):2332-2343. doi: 10.1016/S0140-6736(19)30237-5. Epub 2019 Jun 6. |
| 215 | |
Impact of autoimmune rheumatic diseases on birth outcomes: a population-based study |
Strouse J1, Donovan BM2, Fatima M3, Fernandez-Ruiz R4, Baer RJ5, Nidey N6, Forbess C7, Bandoli G5, Paynter R8, Parikh N9, Jeliffe-Pawlowski L8, Ryckman KK6, Singh N10,11. RMD Open. 2019 Apr 14;5(1):e000878. doi: 10.1136/rmdopen-2018-000878. eCollection 2019. |
| 216 | |
Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date |
Felten R1,2,3, Scher F4, Sagez F1,2, Chasset F5, Arnaud L1,2,6. Drug Des Devel Ther. 2019 May 8;13:1535-1543. doi: 10.2147/DDDT.S170969. eCollection 2019. |
| 217 | |
Health Care Resource Utilization and Costs Associated With Switching Biologics in Rheumatoid Arthritis |
Vanderpoel J1, Tkacz J2, Brady BL2, Ellis L3. Clin Ther. 2019 Jun;41(6):1080-1089.e5. doi: 10.1016/j.clinthera.2019.04.032. Epub 2019 May 20. |
| 218 | |
Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs |
Wells AF1, Parrino J2, Mangan EK2, Paccaly A2, Lin Y3, Xu C3, Fan C3, Graham NMH2, van Hoogstraten H3, Torri A2. |
| 219 | |
A Population Level Analysis of the Differing Impacts of Rheumatoid Arthritis and Spondyloarthritis on Peripartum Outcomes |
Keeling S1, Bowker S1, Savu A1, Kaul P1. J Rheumatol. 2019 May 1. pii: jrheum.181320. doi: 10.3899/jrheum.181320. [Epub ahead of print] |
| 220 | |
Development and Validation of a microRNA Panel to Differentiate between Patients with Rheumatoid Arthritis or Systemic Lupus Erythematosus and Controls |
Ormseth MJ1, Solus JF1, Sheng Q1, Ye F1, Wu Q1, Guo Y1, Oeser AM1, Allen RM1, Vickers KC1, Stein CM1. J Rheumatol. 2019 May 15. pii: jrheum.181029. doi: 10.3899/jrheum.181029. [Epub ahead of print] |
| 221 | |
Association of central adiposity with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional study of the UK Biobank |
Ferguson LD1, Brown R1, Celis-Morales C1, Welsh P1, Lyall DM2, Pell JP2, McInnes IB3, Siebert S3, Sattar N1. Rheumatology (Oxford). 2019 May 25. pii: kez192. doi: 10.1093/rheumatology/kez192. [Epub ahead of print] |
| 222 | |
Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients with Psoriatic Arthritis: A Pooled Analysis Across Phase 3 and Long-Term Extension Studies |
Gladman DD1, Charles-Schoeman C2, McInnes IB3, Veale DJ4, Thiers B5, Nurmohamed M6, Graham D7, Wang C7, Jones T8, Wolk R7, Demasi R8. Arthritis Care Res (Hoboken). 2019 May 21. doi: 10.1002/acr.23930. [Epub ahead of print] |
| 223 | |
Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohort |
Kiely P1,2, Busby AD3, Nikiphorou E4, Sullivan K3, Walsh DA5, Creamer P6, Dixey J7, Young A3. BMJ Open. 2019 May 5;9(5):e028466. doi: 10.1136/bmjopen-2018-028466. |
| 224 | |
Medications associated with fracture risk in patients with rheumatoid arthritis |
Ozen G1, Pedro S2, Wolfe F2, Michaud K3,2. Ann Rheum Dis. 2019 May 15. pii: annrheumdis-2019-215328. doi: 10.1136/annrheumdis-2019-215328. [Epub ahead of print] |
| 225 | |
Cardiovascular Event Risk in Rheumatoid Arthritis is Higher than in Type 2 Diabetes: a 15 Year Longitudinal Study |
Agca R1, Hopman LHGA1, Laan KCJ1, van Halm VP1, Peters MJL1, Smulders YM1, Dekker JM1, Nijpels G1, Stehouwer CDA1, Voskuyl AE1, Boers M1, Lems WF1, Nurmohamed MT1. J Rheumatol. 2019 May 15. pii: jrheum.180726. doi: 10.3899/jrheum.180726. [Epub ahead of print] |
| 226 | |
Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort Study |
George MD1, Baker JF2, Winthrop K3, Alemao E4, Chen L5, Connolly S4, Hsu JY1, Simon TA4, Wu Q1, Xie F5, Yang S5, Curtis JR5. Ann Intern Med. 2019 May 21. doi: 10.7326/M18-2217. [Epub ahead of print] |
| 227 | |
Arthritis, Sleep Health, and Systemic Inflammation in Older Men |
Lee S1,2, Stone KL3,4, Engeland CG2,5,6, Lane NE7, Buxton OM2,5,8,9,10. Arthritis Care Res (Hoboken). 2019 May 10. doi: 10.1002/acr.23923. [Epub ahead of print] |
| 228 | |
Preventing rheumatoid arthritis: Preferences for and predicted uptake of preventive treatments among high risk individuals |
Harrison M1,2,3, Spooner L1, Bansback N2,3,4, Milbers K2, Koehn C5, Shojania K3,6, Finckh A7, Hudson M8. PLoS One. 2019 Apr 25;14(4):e0216075. doi: 10.1371/journal.pone.0216075. eCollection 2019. |
| 229 | |
Peficitinib: First Global Approval |
Markham A1, Keam SJ2. Drugs. 2019 Jun;79(8):887-891. doi: 10.1007/s40265-019-01131-y. |
| 230 | |
Outcomes of infliximab dose escalation in patients with rheumatoid arthritis |
Cohen SB1, Kremer JM2,3, Dandreo KJ3, Reed GW3, Magner R4, Shan Y3, Kafka S5, DeHoratius RJ5,6, Ellis L5, Parenti D5. Clin Rheumatol. 2019 May 2. doi: 10.1007/s10067-019-04543-z. [Epub ahead of print] |
| 231 | |
Developing a group intervention to manage fatigue in rheumatoid arthritis through modifying physical activity |
Salmon VE1, Hewlett S2,3, Walsh NE2, Kirwan JR4,3, Morris M3, Urban M3, Cramp F2. BMC Musculoskelet Disord. 2019 May 4;20(1):194. doi: 10.1186/s12891-019-2558-4. |
| 232 | |
Attitudes towards Oral Health in Patients with Rheumatoid Arthritis: A Qualitative Study Nested within a Randomized Controlled Trial |
Serban S1,2, Dietrich T1, Lopez-Oliva I1, de Pablo P3,4, Raza K3,4, Filer A3, Chapple ILC1, Hill K1. JDR Clin Trans Res. 2019 Apr 22:2380084419833694. doi: 10.1177/2380084419833694. [Epub ahead of print] |
| 233 | |
Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis(RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial |
Taylor PC1, Saurigny D2,3, Vencovsky J4, Takeuchi T5, Nakamura T6, Matsievskaia G7, Hunt B8, Wagner T9,10, Souberbielle B2,11; NEXUS Study Group. Arthritis Res Ther. 2019 Apr 18;21(1):101. doi: 10.1186/s13075-019-1879. |
| 234 | |
Patient- and Rheumatologist- Perspectives Regarding Challenges to Achieving Optimal Disease Control in Rheumatoid Arthritis |
Owensby JK1, Chen L1, O'Beirne R2, Ruderman E3, Harrold LR4, Melnick JA1, Safford MM5, Curtis JR1, Danila MI1. Arthritis Care Res (Hoboken). 2019 Apr 22. doi: 10.1002/acr.23907. [Epub ahead of print] |
| 235 | |
Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy |
Winthrop KL1, Bingham CO 3rd2, Komocsar WJ3, Bradley J3, Issa M3, Klar R4, Kartman CE3. Arthritis Res Ther. 2019 Apr 18;21(1):102. doi: 10.1186/s13075-019-1883-1. |
| 236 | |
Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study |
Emery P1,2, Burmester GR3, Bykerk VP4, Combe BG5, Furst DE6, Maldonado MA7, Huizinga TW8. RMD Open. 2019 Feb 8;5(1):e000840. doi: 10.1136/rmdopen-2018-000840. eCollection 2019. |
| 237 | |
Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis |
Bechman K1, Clarke BD1, Rutherford AI1, Yates M1, Nikiphorou E1, Molokhia M2, Norton S1, Cope AP1, Hyrich KL3,4, Galloway JB1. Author informationRheumatology (Oxford). 2019 Apr 14. pii: kez037. doi: 10.1093/rheumatology/kez037. [Epub ahead of print] |
| 238 | |
How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?-MTX in the Treat-to-Target Strategy |
Taylor PC1, Balsa Criado A2, Mongey AB3, Avouac J4, Marotte H5, Mueller RB6. J Clin Med. 2019 Apr 15;8(4). pii: E515. doi: 10.3390/jcm8040515. |
| 239 | |
A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis |
Bechman K1, Subesinghe S1, Norton S2, Atzeni F3, Galli M4,5, Cope AP1, Winthrop KL5, Galloway JB1. Rheumatology (Oxford). 2019 Apr 14. pii: kez087. doi: 10.1093/rheumatology/kez087. [Epub ahead of print] |
| 240 | |
Patient preferences for disease modifying anti-rheumatic drug treatment in rheumatoid arthritis: A systematic review |
Durand C1, Eldoma M1, Marshall DA1, Bansback N1, Hazlewood GS1. J Rheumatol. 2019 Apr 15. pii: jrheum.181165. doi: 10.3899/jrheum.181165. [Epub ahead of print] |
| 241 | |
Trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis (TRACE RA): A multicenter, randomized, placebo controlled trial |
Kitas GD1,2, Nightingale P3, Armitage J4, Sattar N5,6, Belch JJF7, Symmons DPM2,8; TRACE RA consortium. Arthritis Rheumatol. 2019 Apr 15. doi: 10.1002/art.40892. [Epub ahead of print] |
| 242 | |
A review of the evidence and cost of therapies for cutaneous lupus erythematosus |
Rosen JD1, Paul S1, Maderal A1. Lupus. 2019 May 1:961203319846397. doi: 10.1177/0961203319846397. [Epub ahead of print] |
| 243 | |
Racial Discrimination, Disease Activity, and Organ Damage: The Black Women |
Chae DH1, Martz CD1, Fuller-Rowell TE1, Spears EC1, Smith TTG2, Hunter EA3, Drenkard C4, Lim SS4. Am J Epidemiol. 2019 May 7. pii: kwz105. doi: 10.1093/aje/kwz105. [Epub ahead of print] |
| 244 | |
Examining Uncertainty in Illness in Parents and Children With Chronic Kidney Disease and Systemic Lupus Erythematosus: A Mediational Model of Internalizing Symptoms and Health-Related Quality of Life |
Petrongolo JL1, Zelikovsky N2,3, Keegan RM2, Furth SL3, Knight A3. J Clin Psychol Med Settings. 2019 Apr 15. doi: 10.1007/s10880-019-09617-3. [Epub ahead of print] |
| 245 | |
Basophil involvement in lupus nephritis: a basis for innovation in daily care |
Charles N1, Chemouny JM2,3, Daugas E1,2. Nephrol Dial Transplant. 2019 May 1;34(5):750-756. doi: 10.1093/ndt/gfy245. |
| 246 | |
Diet and lupus: what do the patients think? |
Robinson GA1,2, Mcdonnell T1, Wincup C1, Martin-Gutierrez L1, Wilton J2, Kalea AZ3, Ciurtin C1,2, Pineda-Torra I4, Jury EC4. Lupus. 2019 May;28(6):755-763. doi: 10.1177/0961203319845473. Epub 2019 Apr 26. |
| 247 | |
Tools and Methods for Real-World Evidence Generation: Pragmatic Trials, Electronic Consent, and Data Linkages |
Curtis JR1, Foster PJ2, Saag KG2. Rheum Dis Clin North Am. 2019 May;45(2):275-289. doi: 10.1016/j.rdc.2019.01.010. |
| 248 | |
Exploring Dimensions of Stiffness in Rheumatoid and Psoriatic Arthritis: The ARAD and OMERACT Stiffness Special Interest Group collaboration |
Sinnathura P1, Bartlett SJ1, Halls S1, Hewlett S1, Orbai AM1, Buchbinder R1, Henderson L1, Hill CL1, Lassere M1, March L1. J Rheumatol. 2019 Apr 1. pii: jrheum.181251. doi: 10.3899/jrheum.181251. [Epub ahead of print] |
| 249 | |
Trajectories of pain predict disabilities affecting daily living in arthritis |
James RJE1,2,3, Walsh DA2,3,4, Ferguson E1,2. Br J Health Psychol. 2019 Apr 7. doi: 10.1111/bjhp.12364. [Epub ahead of print] |
| 250 | |
Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review |
Jegatheeswaran J1, Turk M1, Pope JE1,2. Immunotherapy. 2019 Jun;11(8):737-754. doi: 10.2217/imt-2018-0178. Epub 2019 Apr 8. |
| 251 | |
Latent autoimmunity across disease-specific boundaries in at-risk first-degree relatives of SLE and RA patients |
James JA1, Chen H2, Young KA3, Bemis EA3, Seifert J3, Bourn RL2, Deane KD3, Demoruelle MK3, Feser M3, O'Dell JR4, Weisman MH5, Keating RM6, Gaffney PM2, Kelly JA2, Langefeld CD7, Harley JB8, Robinson W9, Hafler DA10, O'Connor KC10, Buckner J11, Guthridge JM2, Norris JM3, Holers VM3. EBioMedicine. 2019 Apr;42:76-85. doi: 10.1016/j.ebiom.2019.03.063. Epub 2019 Apr 3. |
| 252 | |
Longitudinal profiling of human blood transcriptome in healthy and lupuspregnancy |
Hong S#1,2,3, Banchereau R#3,4, Maslow BL#5, Guerra MM6, Cardenas J3, Baisch J1,2,3, Branch DW7,8, Porter TF7,8, Sawitzke A7, Laskin CA9, Buyon JP10, Merrill J11, Sammaritano LR6,12, Petri M13, Gatewood E3, Cepika AM3, Ohouo M1,2,3, Obermoser G3, Anguiano E3, Kim TW1,2,3, Nulsen J14, Nehar-Belaid D5, Blankenship D3, Turner J3, Banchereau J#5, Salmon JE#6,12, Pascual V#1,2,3. J Exp Med. 2019 May 6;216(5):1154-1169. doi: 10.1084/jem.20190185. Epub 2019 Apr 8. |
| 253 | |
Non-pharmacologic therapies for systemic lupus erythematosus |
Fangtham M1, Kasturi S2, Bannuru RR3, Nash JL4, Wang C3. Lupus. 2019 May;28(6):703-712. doi: 10.1177/0961203319841435. Epub 2019 Apr 8. |
| 254 | |
Challenges of achieving clinical remission in a national cohort of juvenile-onset systemic lupus erythematosus patients |
Abdelrahman N1, Beresford MW2,3, Leone V1; UK Juvenile-onset Systemic Lupus Erythematosus Study Group. Lupus. 2019 Apr;28(5):667-674. doi: 10.1177/0961203319840699. Epub 2019 Apr 3. |
| 255 | |
Construction of a frailty index as a novel health measure in systemic lupus erythematosus |
Legge A1, Kirkland S1, Rockwood K1, Andreou P1, Bae SC1, Gordon C1, Romero-Diaz J1, Sanchez-Guerrero J1, Wallace DJ1, Bernatsky S1, Clarke AE1, Merrill JT1, Ginzler EM1, Fortin P1, Gladman DD1, Urowitz MB1, Bruce IN1, Isenberg DA1, Rahman A1, Alarcón GS1, Petri M1, Khamashta MA1, Dooley MA1, Ramsey-Goldman R1, Manzi S1, Zoma AA1, Aranow C1, Mackay M1, Ruiz-Irastorza G1, Lim SS1, Inanc M1, van Vollenhoven RF1, Jonsen A1, Nived O1, Ramos-Casals M1, Kamen DL1, Kalunian KC1, Jacobsen S1, Peschken CA1, Askanase A1, Hanly JG1. J Rheumatol. 2019 Apr 15. pii: jrheum.181338. doi: 10.3899/jrheum.181338. [Epub ahead of print] |
| 256 | |
Altered cognitive function in systemic lupus erythematosus and associations with inflammation and functional and structural brain changes |
Barraclough M1,2, McKie S3, Parker B2,4, Jackson A5, Pemberton P6, Elliott R7, Bruce IN8,2. Ann Rheum Dis. 2019 Apr 12. pii: annrheumdis-2018-214677. doi: 10.1136/annrheumdis-2018-214677. [Epub ahead of print] |
| 257 | |
Sex Differences in the Achievement of Remission and Low Disease Activity in Rheumatoid Arthritis |
Maynard C1, Mikuls TR2,3, Cannon GW4, England BR2,3, Conaghan PG5, Østergaard M6,7, Baker DG8, Kerr G9, George MD, Barton JL10, Baker JF1,11,12. Arthritis Care Res (Hoboken). 2019 Mar 15. doi: 10.1002/acr.23873. [Epub ahead of print] |
| 258 | |
Effects of Sarilumab on Patient-Reported Impact of Rheumatoid Arthritis Using the Rheumatoid Arthritis Impact of Disease Scale |
Gossec L1, Strand V1, Proudfoot C1, Chen CI1, Guillonneau S1, Kimura T1, van Hoogstraten H1, Mangan E1, Reaney M1. J Rheumatol. 2019 Mar 15. pii: jrheum.180904. doi: 10.3899/jrheum.180904. [Epub ahead of print] |
| 259 | |
Opioid use in rheumatoid arthritis: trends, efficacy, safety, and best practices |
Day AL1, Curtis JR. Curr Opin Rheumatol. 2019 May;31(3):264-270. doi: 10.1097/BOR.0000000000000602. |
| 260 | |
Prevalence of Arthritis and Rheumatoid Arthritis in Coal Mining Counties of the U.S |
Schmajuk G1, Trupin L2, Yelin E3, Blanc PD4. Arthritis Care Res (Hoboken). 2019 Mar 15. doi: 10.1002/acr.23874. [Epub ahead of print] |
| 261 | |
Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases |
Mayence A1, Vanden Eynde JJ2. Pharmaceuticals (Basel). 2019 Mar 12;12(1). pii: E37. doi: 10.3390/ph12010037. |
| 262 | |
Rheumatoid arthritis (RA) |
Wells PM1, Williams FMK2, Matey-Hernandez ML2, Menni C2, Steves CJ3. Author informationJ Autoimmun. 2019 May;99:104-115. doi: 10.1016/j.jaut.2019.02.004. Epub 2019 Mar 5. |
| 263 | |
A prospective study of the development of inflammatory arthritis in the family members of Indigenous North American people with rheumatoid arthritis |
Tanner S1, Dufault B2, Smolik I1, Meng X1, Anaparti V1, Hitchon C1, Robinson DB1, William R3, Sokolove J3, Lahey L3, Ferucci ED4, El-Gabalawy H1. Arthritis Rheumatol. 2019 Mar 12. doi: 10.1002/art.40880. [Epub ahead of print] |
| 264 | |
Is it time to banish composite measures for remission in RA? |
Pope JE1, Michaud K2. Arthritis Care Res (Hoboken). 2019 Mar 1. doi: 10.1002/acr.23862. [Epub ahead of print] |
| 265 | |
Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry |
Harrold LR1,2, Litman HJ3, Connolly SE4, Alemao E4, Kelly S4, Rebello S3, Hua W3, Kremer JM5. Rheumatol Ther. 2019 Mar 13. doi: 10.1007/s40744-019-0149-3. [Epub ahead of print] |
| 266 | |
New relationships for old autoantibodies in rheumatoid arthritis |
Shelef MA1,2. Arthritis Rheumatol. 2019 Mar 12. doi: 10.1002/art.40879. [Epub ahead of print] |
| 267 | |
Patient reported outcome data from the Care in Early Rheumatoid Arthritis trial: Opportunities for broadening the scope of treating to target |
Van der Elst K1,2, Verschueren P1,2, Stouten V2, Pazmino S2, De Groef A3,4, De Cock D2, Joly J1, Moons P5,6,7, Westhovens R1,2. Arthritis Care Res (Hoboken). 2019 Apr 5. doi: 10.1002/acr.23900. [Epub ahead of print] |
| 268 | |
Motivational Counseling and Text Message Reminders: For Reduction of Daily Sitting Time and Promotion of Everyday Physical Activity in People with Rheumatoid Arthritis |
Thomsen T1, Esbensen BA2, Hetland ML3, Aadahl M4. Rheum Dis Clin North Am. 2019 May;45(2):231-244. doi: 10.1016/j.rdc.2019.01.005. |
| 269 | |
Rheumatoid arthritis disease activity predicting incident clinically-apparent RA-associated interstitial lung disease: A prospective cohort study |
Sparks JA1,2, He X1, Huang J1, Fletcher EA3, Zaccardelli A1, Friedlander HM1, Gill RR2,4, Hatabu H2,5, Nishino M2,5,6, Murphy DJ7, Iannaccone CK2, Mahmoud TG2, Frits ML2, Lu B1,2, Rosas IO2,3, Dellaripa PF1,2, Weinblatt ME1,2, Karlson EW1,2, Shadick NA1,2, Doyle TJ2,3. Arthritis Rheumatol. 2019 Apr 5. doi: 10.1002/art.40904. [Epub ahead of print] |
| 270 | |
Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction? |
Day AL1, Singh JA2,3,4,5. Drugs Aging. 2019 Apr 5. doi: 10.1007/s40266-019-00653-0. [Epub ahead of print] |
| 271 | |
Mobile Apps for Rheumatoid Arthritis: Opportunities and Challenges |
Mollard E1, Michaud K2. Rheum Dis Clin North Am. 2019 May;45(2):197-209. doi: 10.1016/j.rdc.2019.01.011. Epub 2019 Mar 8. |
| 272 | |
Incidence and predictors of dyspnea on exertion in a prospective cohort of patients with rheumatoid arthritis |
Sparks JA1,2, Doyle TJ2,3, He X1, Pan B1, Iannaccone C1, Frits ML1, Dellaripa PF1,2, Rosas IO2,3, Lu B1,2, Weinblatt ME1,2, Shadick NA1,2, Karlson EW1,2. ACR Open Rheumatol. 2019 Mar;1(1):4-15. doi: 10.1002/acr2.1001. Epub 2019 Mar 15. |
| 273 | |
Digital Interventions to Build a Patient Registry for Rheumatology Research |
Nowell WB1, Curtis D2, Thai M3, Wiedmeyer C2, Gavigan K2, Venkatachalam S2, Ginsberg S2, Curtis JR4. Rheum Dis Clin North Am. 2019 May;45(2):173-186. doi: 10.1016/j.rdc.2019.01.009. |
| 274 | |
Perioperative management of immunosuppression in patients with rheumatoid arthritis |
George MD1, Baker JF1,2. Curr Opin Rheumatol. 2019 May;31(3):300-306. doi: 10.1097/BOR.0000000000000589. |
| 275 | |
Decreased Injection Site Pain Associated with Phosphate-Free Etanercept Formulation in Rheumatoid Arthritis or Psoriatic Arthritis Patients: A Randomized Controlled Trial |
Cohen S1, Samad A2, Karis E2, Stolshek BS2, Trivedi M2, Zhang H3, Aras GA3, Kricorian G2, Chung JB2. Rheumatol Ther. 2019 Mar 27. doi: 10.1007/s40744-019-0152-8. [Epub ahead of print] |
| 276 | |
An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis |
Cohen S1, Pablos JL2, Pavelka K3, Müller GA4, Matsumoto A5, Kivitz A6, Wang H7, Krishnan E7. Arthritis Res Ther. 2019 Mar 29;21(1):84. doi: 10.1186/s13075-019-1857-3. |
| 277 | |
Clinical outcomes and predictors of maternal and fetal complications in pregnancies of patients with systemic lupus erythematosus |
Larosa M1, Del Ross T1, Calligaro A1, Favaro M1, Zanatta E1, Iaccarino L1, Doria A1. Expert Rev Clin Immunol. 2019 Apr 1. doi: 10.1080/1744666X.2019.1601557. [Epub ahead of print] |
| 278 | |
Rheumatologic Diseases and the Liver |
Gebreselassie A1, Aduli F2, Howell CD3. Clin Liver Dis. 2019 May;23(2):247-261. doi: 10.1016/j.cld.2018.12.007. Epub 2019 Mar 8. |
| 279 | |
The Fatigue Assessment Scale as a simple and reliable tool in systemic lupus erythematosus: a cross-sectional study |
Horisberger A1, Courvoisier D2, Ribi C3.Author informationArthritis Res Ther. 2019 Mar 25;21(1):80. doi: 10.1186/s13075-019-1864-4. |
| 280 | |
Self-management and adherence in childhood-onset systemic lupus erythematosus: what are we missing? |
Harry O1, Crosby LE2,3, Smith AW2, Favier L1, Aljaberi N1, Ting TV1,3, Huggins JL1,3, Modi AC2,3. Lupus. 2019 Mar 24:961203319839478. doi: 10.1177/0961203319839478. [Epub ahead of print] |
| 281 | |
Rheumatology Care in Under-Resourced Areas Utilizing the ECHO Model |
Bankhurst A1, Olivas C2, Larson JH3, Bradford A1, Fields R4, Kalishman S1, Marquez M1, Gonzales Van Horn S1, Swift R1, Rochelle R1, Jones J1, Burke T1, Snead J1, Arora S1. Arthritis Care Res (Hoboken). 2019 Mar 30. doi: 10.1002/acr.23889. [Epub ahead of print] |
| 282 | |
Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies |
Curtis JR1, Brahe CH2,3, Østergaard M2,3, Lund Hetland M2,3, Hambardzumyan K4, Saevarsdottir S4,5, Wang X6, Flake Ii DD7, Sasso EH6, Huizinga TW8. Curr Med Res Opin. 2019 Mar 14:1-11. doi: 10.1080/03007995.2019.1585064. [Epub ahead of print] |
| 283 | |
Siblings of patients with rheumatoid arthritis are at increased risk of acute coronary syndrome |
Westerlind H1, Holmqvist M2, Ljung L2,3, Frisell T2, Askling J2,4. Ann Rheum Dis. 2019 Feb 20. pii: annrheumdis-2018-214828. doi: 10.1136/annrheumdis-2018-214828. [Epub ahead of print] |
| 284 | |
Farming tasks and the development of rheumatoid arthritis in the agricultural health study |
Parks CG1, Meyer A2, Beane Freeman LE3, Hofmann JN3, Sandler DP1. Occup Environ Med. 2019 Apr;76(4):243-249. doi: 10.1136/oemed-2018-105361. Epub 2019 Feb 13. |
| 285 | |
The Association Between Yoga Use, Physical Function, and Employment in Adults With Rheumatoid Arthritis |
Greysen HM1, Hong OS, Katz P. Holist Nurs Pract. 2019 Mar/Apr;33(2):71-79. doi: 10.1097/HNP.0000000000000296. |
| 286 | |
Three Quality Improvement Initiatives Improved Performance of Rheumatoid Arthritis Disease Activity Measures in Electronic Health Records: Results from an Interrupted Time Series Study |
Gandrup J1, Li J1, Izadi Z2, Gianfrancesco M1, Ellingsen T3, Yazdany J1, Schmajuk G4. Arthritis Care Res (Hoboken). 2019 Feb 11. doi: 10.1002/acr.23848. [Epub ahead of print] |
| 287 | |
Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient |
Fournier M1, Chen CI2, Kuznik A2, Proudfoot C3, Mallya UG4, Michaud K5,6. Clinicoecon Outcomes Res. 2019 Feb 5;11:117-128. doi: 10.2147/CEOR.S183076. eCollection 2019. |
| 288 | |
PROMIS Fatigue short forms are reliable and valid in adults with rheumatoid arthritis |
Bingham Iii CO1, Gutierrez AK2, Butanis A2, Bykerk VP3, Curtis JR4, Leong A5, Lyddiatt A6, Nowell WB7, Orbai AM2, Bartlett SJ2,8. J Patient Rep Outcomes. 2019 Feb 21;3(1):14. doi: 10.1186/s41687-019-0105-6. |
| 289 | |
Depression and the risk of rheumatoid arthritis |
Vallerand IA1,2, Patten SB2,3, Barnabe C2,4. Curr Opin Rheumatol. 2019 May;31(3):279-284. doi: 10.1097/BOR.0000000000000597. |
| 290 | |
Current and early life weight and associations with mortality in rheumatoid arthritis |
Baker JF1, Stokes A2, Mikuls TR3, George M4, England BR3, Sayles H5, Michaud K5. Clin Exp Rheumatol. 2019 Jan 18. [Epub ahead of print] |
| 291 | |
Practical Guidelines for Managing Patients With Psoriasis on Biologics: An Update |
Poelman SM1, Keeling CP2, Metelitsa AI1. J Cutan Med Surg. 2019 Jan/Feb;23(1_suppl):3S-12S. doi: 10.1177/1203475418811347. |
| 292 | |
Timing of Abatacept Before Elective Arthroplasty and Risk of Post-operative Outcomes |
George MD1, Baker JF1,2,3, Winthrop K4, Alemao E5, Chen L6, Connolly S5, Hsu JY1,3, Simon TA5, Wu Q3, Xie F6, Yang S6, Curtis JR6. Arthritis Care Res (Hoboken). 2019 Feb 11. doi: 10.1002/acr.23843. [Epub ahead of print] |
| 293 | |
Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis |
Simpson EL1, Ren S1, Hock ES1, Stevens JW1, Binard A2, Pers YM3, Archer R4, Paisley S4, Stevenson MD4, Herpin C5, Ghabri S5. Int J Technol Assess Health Care. 2019 Feb 6:1-9. doi: 10.1017/S0266462318003628. [Epub ahead of print] |
| 294 | |
Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor |
Ogdie A1, Palmer JL1, Greenberg J1, Curtis JR1, Harrold LR1, Solomon DH1, Kavanaugh A1, Kremer JM1, Mease PJ1. J Rheumatol. 2019 Jan 15. pii: jrheum.171034. doi: 10.3899/jrheum.171034. [Epub ahead of print] |
| 295 | |
A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis |
Incerti D1, Curtis JR2, Shafrin J1, Lakdawalla DN3, Jansen JP4,5. Pharmacoeconomics. 2019 Feb 9. doi: 10.1007/s40273-018-00765-2. [Epub ahead of print] |
| 296 | |
Contraception methods used by women with rheumatoid arthritis and psoriatic arthritis |
Leverenz DL1, Eudy AM2, Jayasundara M2, Haroun T2, McDaniel G2, Benjamin Nowell W3, Curtis JR4, Crow-Hercher R3, White W3,5, Ginsberg S3, Clowse MEB2. Clin Rheumatol. 2019 Apr;38(4):1207-1212. doi: 10.1007/s10067-018-04420-1. Epub 2019 Jan 16. |
| 297 | |
Refractory lupus nephritis: When, why and how to treat |
Kronbichler A1, Brezina B2, Gauckler P3, Quintana LF4, Jayne DRW5. Autoimmun Rev. 2019 Mar 4. pii: S1568-9972(19)30057-6. doi: 10.1016/j.autrev.2019.03.004. [Epub ahead of print] |
| 298 | |
The impact of different classes of lupus nephritis on maternal and fetal outcomes: a cohort study of 147 pregnancies |
Rodrigues BC1, Lacerda MI1, Ramires de Jesús GR1, Cunha Dos Santos F1, Ramires de Jesús N1, Levy RA2, Klumb EM2. Lupus. 2019 Feb 18:961203319829825. doi: 10.1177/0961203319829825. [Epub ahead of print] |
| 299 | |
The study of interactions between genome and exposome in the development of systemic lupus erythematosus |
Leffers HCB1, Lange T2, Collins C3, Ulff-Møller CJ1, Jacobsen S4. Autoimmun Rev. 2019 Feb 14. pii: S1568-9972(19)30040-0. doi: 10.1016/j.autrev.2018.11.005. [Epub ahead of print] |
| 300 | |
Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis |
Smith E1,2, Al-Abadi E3, Armon K4, Bailey K5, Ciurtin C6, Davidson J7, Gardner-Medwin J8, Haslam K9, Hawley D10, Leahy A11, Leone V12, McErlane F13, Mewar D14, Modgil G15, Moots R16, Pilkington C17, Ramanan A18, Rangaraj S19, Riley P20, Sridhar A21, Wilkinson N22, Beresford MW1,2, Hedrich CM1,2. Lupus. 2019 Mar 14:961203319836712. doi: 10.1177/0961203319836712. [Epub ahead of print] |
| 301 | |
Development and pilot testing of the treatment and education approach for childhood-onset lupus (TEACH): a cognitive behavioral treatment |
Cunningham NR1,2, Fussner LM3, Moorman E3, Avar Aydin PO4,5, Brunner HI4,5, Kashikar-Zuck S4,3. Pediatr Rheumatol Online J. 2019 Feb 18;17(1):9. doi: 10.1186/s12969-019-0307-8. |
| 302 | |
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018 |
Winthrop KL1, Weinblatt ME2, Crow MK3, Burmester GR4, Mease PJ5, So AK6, Bykerk V3, Van Vollenhoven RF7, Dougados M8, Kay J9, Mariette X10, Sieper J11, Melchers F12,13, Cronstein BN14, Shevach E15, Breedfeld FC16, Kalden J17, Smolen JS18, Furst DE5,19,20. Ann Rheum Dis. 2019 Feb 2. pii: annrheumdis-2018-214280. doi: 10.1136/annrheumdis-2018-214280. [Epub ahead of print] |
| 303 | |
Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab |
Ellis LA1, Malangone-Monaco E2, Varker H3, Stetsovsky D3, Kubacki M1, DeHoratius RJ1,4, Kafka S1. Clinicoecon Outcomes Res. 2019 Jan 15;11:99-110. doi: 10.2147/CEOR.S185547. eCollection 2019. |
| 304 | |
Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study |
Pawar A1, Desai RJ1, Solomon DH1,2, Santiago Ortiz AJ1, Gale S3, Bao M3, Sarsour K3, Schneeweiss S1, Kim SC4,2. Ann Rheum Dis. 2019 Jan 24. pii: annrheumdis-2018-214367. doi: 10.1136/annrheumdis-2018-214367. [Epub ahead of print] |
| 305 | |
The frequency of remission and low disease activity in patients with rheumatoid arthritis, and their ability to identify people with low disability and normal quality of life |
Scott IC1, Ibrahim F2, Panayi G3, Cope AP4, Garrood T3, Vincent A3, Scott DL2, Kirkham B4; TITRATE Programme Investigators. Semin Arthritis Rheum. 2018 Dec 28. pii: S0049-0172(18)30536-5. doi: 10.1016/j.semarthrit.2018.12.006. [Epub ahead of print] |
| 306 | |
Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study |
Smolen JS1, Gladman D2, McNeil HP3, Mease PJ4, Sieper J5, Hojnik M6, Nurwakagari P7, Weinman J8. RMD Open. 2019 Jan 11;5(1):e000585. doi: 10.1136/rmdopen-2017-000585. eCollection 2019. |
| 307 | |
Inflammation beyond the Joints: Rheumatoid Arthritis and Cardiovascular Disease |
Urman A1, Taklalsingh N1, Sorrento C1, McFarlane IM1. Scifed J Cardiol. 2018;2(3). pii: 1000019. Epub 2018 Oct 31. |
| 308 | |
Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study |
Gottenberg JE1,2, Morel J3, Perrodeau E4, Bardin T5, Combe B3, Dougados M6, Flipo RM7, Saraux A8, Schaeverbeke T9, Sibilia J10, Soubrier M11, Vittecoq O12, Baron G4, Constantin A13, Ravaud P4, Mariette X14; French Society of Rheumatology and the investigators participating in AIR, ORA, and REGATE registries. BMJ. 2019 Jan 24;364:l67. doi: 10.1136/bmj.l67. |
| 309 | |
Cardiovascular Safety During Treatment with Baricitinib in Rheumatoid Arthritis |
Taylor PC1, Weinblatt ME2, Burmester GR3, Rooney TP4, Witt S4, Walls CD4, Issa M4, Salinas CA4, Saifan C4, Zhang X4, Cardoso A4, González-Gay MA5,6,7, Takeuchi T8. Arthritis Rheumatol. 2019 Jan 21. doi: 10.1002/art.40841. [Epub ahead of print] |
| 310 | |
Rheumatoid Arthritis |
Sparks JA1. Ann Intern Med. 2019 Jan 1;170(1):ITC1-ITC16. doi: 10.7326/AITC201901010.a |
| 311 | |
Incidence rates of comorbidities among patients with psoriasis in the United States |
Feldman SR1, Hur P, Zhao Y, Tian H, Wei Z, Wang X, Herrera V. Dermatol Online J. 2018 Oct 15;24(10). pii: 13030/qt2m18n6vj. |
| 312 | |
Effect of pericardial effusion on outcomes in children admitted with systemic lupus erythematosus: a multicenter retrospective cohort study from the United States |
Dalby ST1, Tang X1, Daily JA1, Sukumaran S1, Collins RT2, Bolin EH1. Lupus. 2019 Feb 11:961203319828523. doi: 10.1177/0961203319828523. [Epub ahead of print] |
| 313 | |
Evaluating the properties of a frailty index and its association with mortality risk among patients with systemic lupus erythematosus |
Legge A1, Kirkland S2, Rockwood K3, Andreou P2, Bae SC4, Gordon C5, Romero-Diaz J6, Sanchez-Guerrero J6, Wallace DJ7, Bernatsky S8, Clarke AE9, Merrill JT10, Ginzler EM11, Fortin P12, Gladman DD13, Urowitz MB13, Bruce IN14, Isenberg DA15, Rahman A15, Alarcón GS16, Petri M17, Khamashta MA18, Dooley MA19, Ramsey-Goldman R20, Manzi S21, Steinsson K22, Zoma AA23, Aranow C24, Mackay M24, Ruiz-Irastorza G25, Lim SS26, Inanc M27, van Vollenhoven RF28, Jonsen A29, Nived O29, Ramos-Casals M30, Kamen DL31, Kalunian KC32, Jacobsen S33, Peschken CA34, Askanase A35, Hanly JG36. Arthritis Rheumatol. 2019 Feb 16. doi: 10.1002/art.40859. |
| 314 | |
10 most important contemporary challenges in the management of SLE |
Felten R#1,2, Sagez F#1,2, Gavand PE2,3, Martin T2,3, Korganow AS2,3, Sordet C1,2, Javier RM1,2, Soulas-Sprauel P2,3, Rivière M4, Scher F5, Poindron V2,3, Guffroy A2,3, Arnaud L1,2. Lupus Sci Med. 2019 Jan 10;6(1):e000303. doi: 10.1136/lupus-2018-000303. eCollection 2019. |
| 315 | |
The American College of Rheumatology Provisional criteria for clinically relevant improvement in children & adolescents with childhood-onset systemic lupus erythematosus |
Brunner HI1, Holland MJ1, Beresford MW2,3, Ardoin SP4, Appenzeller S5, Silva CA6, Flores F7, Goilav B8, Avar Aydin PO1, Wenderfer SE9, Levy DM10, Ravelli A11, Khubchandani R12, Avcin T13, Klein-Gitelman MS14, Ruperto N11, Feldman BM10, Ying J15; Paediatric Rheumatology International Trial Organisation & the Pediatric Rheumatology Collaborative Study Group. Arthritis Care Res (Hoboken). 2019 Jan 25. doi: 10.1002/acr.23834. |
| 316 | |
Safety and efficacy of belimumab plus standard therapy for up to 13 years in patients with systemic lupus erythematosus |
Wallace DJ1, Ginzler EM2, Merrill JT3, Furie RA4, Stohl W5, Chatham WW6, Weinstein A7, McKay JD8, McCune WJ9, Petri M10, Fettiplace J11,12, Roth DA13, Ji B11, Heath A14,15. Arthritis Rheumatol. 2019 Feb 16. doi: 10.1002/art.40861. |
| 317 | |
Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis |
Emery P1, Rondon J2, Parrino J3, Lin Y4, Pena-Rossi C4, van Hoogstraten H4, Graham NMH3, Liu N4, Paccaly A3, Wu R3, Spindler A5. Rheumatology (Oxford). 2018 Dec 19. doi: 10.1093/rheumatology/key361. [Epub ahead of print] |
| 318 | |
Association of fish intake and smoking with risk of rheumatoid arthritis and age of onset: a prospective cohort study |
Sparks JA1,2, O'Reilly ÉJ3,4, Barbhaiya M5, Tedeschi SK6,7, Malspeis S6, Lu B6,7, Willett WC7,3,8, Costenbader KH6,7, Karlson EW6,7. BMC Musculoskelet Disord. 2019 Jan 5;20(1):2. doi: 10.1186/s12891-018-2381-3. |
| 319 | |
Clinical Outcomes After Hip Arthroscopy for Patients With Rheumatoid Arthritis: A Matched-Pair Control Study With Minimum 2-Year Follow-Up |
Ashberg L1, Yuen LC2, Close MR2, Perets I3, Mohr MR2, Chaharbakhshi EO4, Domb BG5. Arthroscopy. 2019 Feb;35(2):434-442. doi: 10.1016/j.arthro.2018.08.054. Epub 2019 Jan 4. |
| 320 | |
Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis |
Whittington MD1, McQueen RB1, Ollendorf DA2, Chapman RH2, Kumar VM2, Synnott PG2, Agboola F2, Campbell JD1. J Manag Care Spec Pharm. 2019 Jan;25(1):80-87. doi: 10.18553/jmcp.2019.25.1.080. |
| 321 | |
Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United States |
Teeple A1, Ginsburg S2, Howard L3, Huff L4, Reynolds C4, Walls D5, Ellis LA1, Curtis JR6. Curr Med Res Opin. 2019 Jan 8:1-7. doi: 10.1080/03007995.2018.1560221. [Epub ahead of print] |
| 322 | |
Effect of communicating personalized rheumatoid arthritis risk on concern for developing RA: A randomized controlled trial |
Marshall AA1, Zaccardelli A2, Yu Z3, Prado MG4, Liu X5, Miller Kroouze R6, Kalia SS7, Green RC8, Triedman NA9, Lu B10, Deane KD11, Iversen MD12, Karlson EW13, Sparks JA14. Patient Educ Couns. 2018 Dec 10. pii: S0738-3991(18)30557-3. doi: 10.1016/j.pec.2018.12.011. [Epub ahead of print] |
| 323 | |
Rheumatoid Arthritis and Mortality in End Stage Renal Disease |
Paudyal S, Waller JL1, Oliver A2, Le B, Zleik N, Nahman NS Jr, Carbone L. J Clin Rheumatol. 2018 Dec 5. doi: 10.1097/RHU.0000000000000916. [Epub ahead of print] |
| 324 | |
Is a Fundamental Change in the Interpretation of Rheumatoid Arthritis Disease Activity Necessary? |
Wilke WS1. J Clin Rheumatol. 2018 Dec 18. doi: 10.1097/RHU.0000000000000937. [Epub ahead of print] |
| 325 | |
Investigating sirukumab for rheumatoid arthritis: 2-year results from the phase III SIRROUND-D study |
Thorne C1, Takeuchi T2, Karpouzas GA3, Sheng S4, Kurrasch R5, Fei K4, Hsu B4. RMD Open. 2018 Nov 16;4(2):e000731. doi: 10.1136/rmdopen-2018-000731. eCollection 2018. |
| 326 | |
Associations Between Methotrexate Use and the Risk of Cardiovascular Events in Patients with Elderly-onset Rheumatoid Arthritis |
Widdifield J1, Abrahamowicz M1, Paterson JM1, Huang A1, Thorne JC1, Pope JE1, Kuriya B1, Beauchamp ME1, Bernatsky S1. J Rheumatol. 2018 Dec 1. pii: jrheum.180427. doi: 10.3899/jrheum.180427. [Epub ahead of print] |
| 327 | |
Patient involvement in medical research: what patients and physicians learn from each other |
Young K1, Kaminstein D2, Olivos A2, Burroughs C3, Castillo-Lee C1, Kullman J1, McAlear C4, Shaw DG1, Sreih A4, Casey G1; Vasculitis Patient-Powered Research Network, Merkel PA5. Orphanet J Rare Dis. 2019 Jan 24;14(1):21. doi: 10.1186/s13023-018-0969-1. Collaborators (13) Abonia PJ, Aines N, Brown P, Cardone A, Fernandez M, Fingar J, Gorman C, Hakkarinen I, Hatfield S, Hennessy S, Jacobsen P, Kermani T, Vennitti M. |
| 328 | |
Updating OMERACT Core Set of Domains for ANCA-Associated Vasculitis: Patient Perspective Using the International Classification of Function, Disability and Health |
Milman N1, McConville E1, Robson JC1, Boonen A1, Tugwell P1, Wells GA1, Chaudhuri D1, Dawson J1, Tomasson G1, Ashdown S1, Gebhart D1, Lanier G1, Peck J1, McAlear CA1, Kellom KS1, Cronholm PF1, Merkel PA1. J Rheumatol. 2019 Feb 1. pii: jrheum.181073. doi: 10.3899/jrheum.181073. [Epub ahead of print] |
| 329 | |
Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in ANCA-Associated Vasculitis: A Randomized Controlled Study |
Jayne D1, Blockmans D2, Luqmani R3, Moiseev S4, Ji B5, Green Y5, Hall L6, Roth D7, Henderson RB6, Merkel PA8; Collaborators, Lozano JA, Becker H, Quiroz AC, Carette S, Carrillo-Vazquez S, Cid MC, D'Cruz D, Deodhar A, Flossman O, Garibotto G, Gesualdo L, Hall S, Hauser T, Hellmich B, Kidder D, Kimmel M, Little M, Majdan M, Maksimowicz-McKinnon K, Marder G, Matsievskaia G, Meneses AS, Molloy E, Mueller R, Neuwelt C, Hernandez JR, Specks U, Tesar V, Walsh M. Arthritis Rheumatol. 2019 Jan 22. doi: 10.1002/art.40802. [Epub ahead of print] |
| 330 | |
Patient Positioning in Arthroscopic Management of Posterior-Inferior Shoulder Instability: A Systematic Review Comparing Beach Chair and Lateral Decubitus Approaches |
de Sa D1, Sheean AJ2, Morales-Restrepo A3, Dombrowski M3, Kay J4, Vyas D5. Arthroscopy. 2019 Jan;35(1):214-224.e3. doi: 10.1016/j.arthro.2018.06.057. Epub 2018 Nov 16. |
| 331 | |
The dimensions of the hip capsule can be measured using magnetic resonance imaging and may have a role in arthroscopic planning |
Kay J1, Memon M1, Rubin S2, Simunovic N1, Nho SJ3, Belzile EL4, Ayeni OR5. Knee Surg Sports Traumatol Arthrosc. 2018 Sep 27. doi: 10.1007/s00167-018-5162-5. [Epub ahead of print] |
| 332 | |
Renal Transplantation and Survival Among Patients With Lupus Nephritis: A Cohort Study |
Jorge A1, Wallace ZS1, Lu N1, Zhang Y1, Choi HK1. Ann Intern Med. 2019 Jan 22. doi: 10.7326/M18-1570. [Epub ahead of print] |
| 333 | |
Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies |
Bangert E1, Wakani L2, Merchant M3, Strand V4, Touma Z2. Patient Relat Outcome Meas. 2019 Jan 9;10:1-7. doi: 10.2147/PROM.S134326. eCollection 2019. |
| 334 | |
Uncertainty and Quality of Life in Systemic Lupus Erythematosus: A Cross-sectional Study |
Delis PC1. Rehabil Nurs. 2019 Jan/Feb;44(1):2-10. doi: 10.1097/rnj.0000000000000118. |
| 335 | |
Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews |
Archer R1, Hock E1, Hamilton J1, Stevens J1, Essat M1, Poku E1, Clowes M1, Pandor A1, Stevenson M1. Health Technol Assess. 2018 Nov;22(66):1-294. doi: 10.3310/hta22660. |
| 336 | |
Nurse telephone education for promoting a treat-to-target approach in recently diagnosed rheumatoid arthritis patients: A pilot project |
Farley S1, Libman B1, Edwards M1, Possidente CJ2, Kennedy AG3. Musculoskeletal Care. 2018 Dec 5. doi: 10.1002/msc.1376. [Epub ahead of print] |
| 337 | |
Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis |
Moran SM1, Monach PA2,3, Zgaga L4, Cuthbertson D5, Carette S6, Khalidi NA7, Koening CL8, Langford CA9, McAlear CA10, Moreland L11, Pagnoux C6, Seo P12, Specks U13, Sreih A10, Wyse J14, Ytterberg SR15, Merkel PA10,11, Little MA1,16. Nephrol Dial Transplant. 2018 Oct 31. doi: 10.1093/ndt/gfy300. [Epub ahead of print] |
| 338 | |
Italian Consensus Recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis |
Sebastiani M1, Milazzo L2, Atzeni F3, Vacchi C1, Manfredi A1, Quartuccio L4, Scirè C5, Gaeta GB6, Lapadula G7, Armignacco O8, Tavio M9, D'Angelo S10, Meroni P11, Bazzichi L12, Grassi W13, Mathieu A14, Mastroianni C15, Sagnelli E16, Santantonio T17, Uberti Foppa C18, Puoti M19, Sarmati L20, Airò P21, Epis OM22, Scrivo R23, Gargiulo M24, Riva A3, Ciancio G25, Zehender G26, Taliani G15, Meroni L3, Sollima S3, Sarzi-Puttini P2, Galli M3. Mod Rheumatol. 2018 Dec 22:1-23. doi: 10.1080/14397595.2018.1558918. [Epub ahead of print] |
| 339 | |
Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis |
Curtis JR1, Flake DD 2nd2, Weinblatt ME3, Shadick NA3, Østergaard M4, Hetland ML4, Brahe CH4, Hwang YG5, Furst DE6, Strand V7, Etzel CJ8, Pappas DA9, Wang X10, Hwang CC10, Sasso EH10, Gutin A2, Hitraya E10, Lanchbury JS2. Rheumatology (Oxford). 2018 Dec 24. doi: 10.1093/rheumatology/key367. [Epub ahead of print] |
| 340 | |
Evaluation of clinical benefit from treatment with mepolizumab for eosinophilic granulomatosis with polyangiitis |
Steinfeld J1, Bradford ES2, Brown J3, Mallett S4, Yancey SW2, Akuthota P5, Cid MC6, Gleich GJ7, Jayne D8, Khoury P9, Langford CA10, Merkel PA11, Moosig F12, Specks U13, Weller PF14, Wechsler ME15. J Allergy Clin Immunol. 2018 Dec 19. pii: S0091-6749(18)32783-0. doi: 10.1016/j.jaci.2018.11.041. [Epub ahead of print] |
| 341 | |
Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma |
Pagnoux C1, Nair P2, Xi Y3, Khalidi NA4, Carette S5, Cuthbertson D6, Grayson PC7, Koening CL8, Langford CA9, McAlear CA10, Moreland LW11, Monach PA12, Seo P13, Specks U14, Sreih AG10, Ytterberg SR15, Tyrrell PN3, Merkel PA16; Vasculitis Clinical Research Consortium. Clin Exp Rheumatol. 2019 Jan 14. [Epub ahead of print] |
| 342 | |
Predictors of fatigue and severe fatigue in a large international cohort of patients with systemic lupus erythematosus and a systematic review of the literature |
Arnaud L1, Gavand PE1,2, Voll R3, Schwarting A4, Maurier F5, Blaison G6, Magy-Bertrand N7, Pennaforte JL8, Peter HH9, Kieffer P10, Bonnotte B11, Poindron V1,2, Fiehn C12, Lorenz H13, Amoura Z14, Sibilia J1,15, Martin T1,2. Rheumatology (Oxford). 2018 Dec 27. doi: 10.1093/rheumatology/key398. [Epub ahead of print] |
| 343 | |
Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature |
Kello N1, Khoury LE2, Marder G2, Furie R2, Zapantis E2, Horowitz DL2. Semin Arthritis Rheum. 2018 Dec 4. pii: S0049-0172(18)30493-1. doi: 10.1016/j.semarthrit.2018.11.005. [Epub ahead of print] |
| 344 | |
Safety and Tolerability of Omalizumab, A Randomized Clinical Trial of Humanized anti-IgE Monoclonal Antibody in Systemic Lupus Erythematosus (STOP LUPUS) |
Hasni S1, Gupta S1, Davis M1, Poncio E1, Temesgen-Oyelakin Y1, Joyal E1, Fike A1, Manna Z1, Auh S2, Shi Y1, Chan D1, Carlucci P1, Biehl A3, Dema B1,4, Charles N1,4, Balow JE2, Waldman M2, Siegel RM1, Kaplan MJ1, Rivera J1. Arthritis Rheumatol. 2018 Dec 29. doi: 10.1002/art.40828. [Epub ahead of print] |
| 345 | |
Fatigue in systemic lupus: the role of disease activity and its correlates |
Azizoddin DR1,2, Gandhi N3, Weinberg S2, Sengupta M3, Nicassio PM4, Jolly M2. Lupus. 2018 Dec 22:961203318817826. doi: 10.1177/0961203318817826. [Epub ahead of print] |
| 346 | |
Engaging African ancestry participants in SLE clinical trials |
Anjorin A1, Lipsky P2. Lupus Sci Med. 2018 Dec 11;5(1):e000297. doi: 10.1136/lupus-2018-000297. eCollection 2018. |
| 347 | |
Perioperative Management of the Rheumatoid Patient |
Wolfe J1, Wolfe J1, Visser HJ2. Clin Podiatr Med Surg. 2019 Jan;36(1):115-130. doi: 10.1016/j.cpm.2018.08.005. Epub 2018 Oct 25. |
| 348 | |
Am I OK?" using human centered design to empower rheumatoid arthritis patients through patient reported outcomes |
Ragouzeos D1, Gandrup J2, Berrean B3, Li J4, Murphy M5, Trupin L6, Yazdany J7, Schmajuk G8. Patient Educ Couns. 2018 Oct 28. pii: S0738-3991(18)30939-X. doi: 10.1016/j.pec.2018.10.016. [Epub ahead of print] |
| 349 | |
Uptake and Clinical Utility of Multibiomarker Disease Activity Testing in the United States |
Curtis JR1, Xie F1, Yang S1, Danila MI1, Owensby JK1, Chen L1. J Rheumatol. 2018 Nov 15. pii: jrheum.180071. doi: 10.3899/jrheum.180071. [Epub ahead of print] |
| 350 | |
Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality |
Raimundo K1, Solomon JJ1, Olson AL1, Kong AM1, Cole AL1, Fischer A1, Swigris JJ1. J Rheumatol. 2018 Nov 15. pii: jrheum.171315. doi: 10.3899/jrheum.171315. [Epub ahead of print] |
| 351 | |
Fertility and Ovarian Reserve among Women with Rheumatoid Arthritis |
Eudy AM1, McDaniel G1, Hurd WW1, Clowse MEB1. J Rheumatol. 2018 Nov 15. pii: jrheum.180176. doi: 10.3899/jrheum.180176. [Epub ahead of print] |
| 352 | |
The impact of obesity on SLE disease activity: findings from the Southern California LupusRegistry (SCOLR) |
Teh P1, Zakhary B2, Sandhu VK3. Clin Rheumatol. 2018 Oct 24. doi: 10.1007/s10067-018-4336-3. [Epub ahead of print] |
| 353 | |
A Novel System to Categorize the Symptoms of Systemic Lupus Erythematosus |
Pisetsky DS1,2, Clowse MEB1, Criscione-Schreiber LG1, Rogers JL1. Arthritis Care Res (Hoboken). 2018 Oct 24. doi: 10.1002/acr.23794. [Epub ahead of print] |
| 354 | |
The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis |
Song L1, Wang Y2, Zhang J2, Song N2, Xu X3, Lu Y4. |
| 355 | |
To eat the elephant |
Lockshin MD1. Arthritis Rheumatol. 2018 Oct 22. doi: 10.1002/art.40761. [Epub ahead of print] |
| 356 | |
Azathioprine and Mycophenolate Mofetil Adherence Patterns and Predictors among Medicaid Beneficiaries with Systemic Lupus Erythematosus |
Feldman CH1, Collins J2, Zhang Z1, Xu C1, Subramanian SV3, Kawachi I3, Solomon DH1, Costenbader KH1. Arthritis Care Res (Hoboken). 2018 Oct 24. doi: 10.1002/acr.23792. [Epub ahead of print] |
| 357 | |
Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab |
Feagan BG1, Lam G2, Ma C3, Lichtenstein GR4. Aliment Pharmacol Ther. 2019 Jan;49(1):31-40. doi: 10.1111/apt.14997. Epub 2018 Nov 8. |
| 358 | |
Body mass index and persistence of conventional DMARDs and TNF inhibitors in rheumatoid arthritis |
McCulley CB1, Barton JL2, Cannon GW3, Sauer BC3, Teng CC3, George MD4, Caplan L5, England BR6, Mikuls TR6, Baker JF7. Clin Exp Rheumatol. 2018 Nov 7. [Epub ahead of print] |
| 359 | |
Utility of administrative and clinical data to predict major change in medical treatment in US Veterans enrolled in the Veterans Affairs Rheumatoid Arthritis (VARA) registry |
Stever JR1, Cannon GW2, Teng CC2, Accortt NA3, Collier DH3, Sauer BC2. Clin Exp Rheumatol. 2018 Nov 12. [Epub ahead of print] |
| 360 | |
Genetic Influences on Susceptibility to Rheumatoid Arthritis in African-Americans |
Laufer VA1, Tiwari HK2, Reynolds RJ1, Danila MI1, Wang J2, Edberg JC1, Kimberly RP1, Kottyan LC3, Harley JB4,5, Mikuls TR6, Gregersen PK7, Absher DM8, Langefeld CD9, Arnett DK10, Louis Bridges S Jr1. Hum Mol Genet. 2018 Nov 13. doi: 10.1093/hmg/ddy395. [Epub ahead of print] |
| 361 | |
Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis |
Chadwick L1, Zhao S1, Mysler E2, Moots RJ3,4. Curr Rheumatol Rep. 2018 Nov 9;20(12):84. doi: 10.1007/s11926-018-0799-0. |
| 362 | |
Association of Psoriasis With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis |
Fu Y1, Lee CH2, Chi CC1,3. JAMA Dermatol. 2018 Oct 24. doi: 10.1001/jamadermatol.2018.3631. [Epub ahead of print] |
| 363 | |
Incidence and Risk of Inflammatory Bowel Disease in Patients With Psoriasis-A Nationwide 20-Year Cohort Study |
Egeberg A1, Thyssen JP2, Burisch J3, Colombel JF4. J Invest Dermatol. 2018 Aug 18. pii: S0022-202X(18)32483-7. doi: 10.1016/j.jid.2018.07.029. [Epub ahead of print] |
| 364 | |
Lack of confidence interval reporting in dermatology: a call to action |
Hopkins ZH1, Moreno C2, Secrest AM3. Br J Dermatol. 2018 Sep 1. doi: 10.1111/bjd.17126. [Epub ahead of print] |
| 365 | |
Adherence and resource use among psoriasis patients treated with biologics |
Aleshaki JS1, Cardwell LA1, Muse ME1, Feldman SR1,2,3. Expert Rev Pharmacoecon Outcomes Res. 2018 Dec;18(6):609-617. doi: 10.1080/14737167.2018.1512408. Epub 2018 Sep 10. |
| 366 | |
Type I Interferons in Autoimmune Disease |
Crow MK1, Olferiev M1, Kirou KA1. Annu Rev Pathol. 2018 Oct 17. doi: 10.1146/annurev-pathol-020117-043952. [Epub ahead of print] |
| 367 | |
An Analytic Approach Using Candidate Gene Selection and Logic Forest to Identify Gene by Environment Interactions (G × E) for Systemic Lupus Erythematosus in African Americans |
Wolf BJ1, Ramos PS2,3, Hyer JM4, Ramakrishnan V5, Gilkeson GS6, Hardiman G7,8,9,10, Nietert PJ11, Kamen DL12. Genes (Basel). 2018 Oct 15;9(10). pii: E496. doi: 10.3390/genes9100496. |
| 368 | |
Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report |
Fontana F1,2, Alfano G3, Leonelli M3, Cerami C4, Ligabue G4, Spinella A5, Citriniti G5, Manzini CU5, Ferri C5, Cappelli G4,3. BMC Nephrol. 2018 Oct 20;19(1):276. doi: 10.1186/s12882-018-1066-3. |
| 369 | |
Systemic lupus erythematosus and antineutrophilic cytoplasmic antibody-associated vasculitis overlap syndrome complicated by subarachnoid hemorrhage: case-based review |
Khorolsky C1, Castellano A2, Comstock D2, Brinster NK3, See SY4, Garner BF5. Rheumatol Int. 2018 Dec;38(12):2329-2335. doi: 10.1007/s00296-018-4169-z. Epub 2018 Oct 16. |
| 370 | |
Herpes Zoster in Tofacitinib: Risk is Further Increased with Glucocorticoids but not Methotrexate |
Curtis JR1, Xie F1, Yang S1, Bernatsky S2, Chen L1, Yun H1, Winthrop K3. Arthritis Care Res (Hoboken). 2018 Oct 8. doi: 10.1002/acr.23769. [Epub ahead of print] |
| 371 | |
Screening of Hyperlipidemia among Patients with Rheumatoid Arthritis in the United States |
Navarro-Millán I1,2, Yang S3, Chen L3, Yun H3, Jagpal A3, Bartels CM4, Fraenkel L5, Safford MM1, Curtis JR3. Arthritis Care Res (Hoboken). 2018 Nov 10. doi: 10.1002/acr.23810. [Epub ahead of print] |
| 372 | |
Importance of Recent Fracture as Predictor of Imminent Fracture Risk |
Schnell AD1, Curtis JR1, Saag KG2. Curr Osteoporos Rep. 2018 Dec;16(6):738-745. doi: 10.1007/s11914-018-0487-z. |
| 373 | |
Assessing a novel way to measure step count while walking using a custom mobile phone application |
Hurt CP1, Lein DH Jr1, Smith CR2, Curtis JR3, Westfall AO4, Cortis J5, Rice C5, Willig JH6. PLoS One. 2018 Nov 6;13(11):e0206828. doi: 10.1371/journal.pone.0206828. eCollection 2018. |
| 374 | |
The International Consortium for Health Outcome Measurement (ICHOM)Set of Outcomes that Matter to People Living with Inflammatory Arthritis Consensus from an international Working Group |
Oude Voshaar MAH1, Das Gupta Z2, Bijlsma JWJ3, Boonen A4, Chau J5, Courvoisier DS6, Curtis JR7, Ellis B8, Ernestam S9, Gossec L10, Hale C11, Hornjeff J12, Leung KYY13, Lidar M14, Mease P15, Michaud K16, Mody GM17, Ndosi M18, Opava CH19, Pinheiro GRC20, Salt M2, Soriano ER21, Taylor WJ22, Voshaar MJH1, Weel AEAM23, de Wit M24, Wulffraat N25, van de Laar MAFJ1,2, Vonkeman HE1,2. Arthritis Care Res (Hoboken). 2018 Oct 24. doi: 10.1002/acr.23799. [Epub ahead of print] |
| 375 | |
Upadacitinib for the treatment of rheumatoid arthritis |
Serhal L1, Edwards CJ2. Expert Rev Clin Immunol. 2018 Nov 3:1-13. doi: 10.1080/1744666X.2019.1544892. [Epub ahead of print] |
| 376 | |
Does Rheumatoid Arthritis Really Improve During Pregnancy? A Systematic Review and Metaanalysis |
Jethwa H1, Lam S1, Smith C1, Giles I1. J Rheumatol. 2018 Nov 1. pii: jrheum.180226. doi: 10.3899/jrheum.180226. [Epub ahead of print] |
| 377 | |
Ultrasound of Subtalar Joint Synovitis in Patients with Rheumatoid Arthritis: Results of an OMERACT Reliability Exercise Using Consensual Definitions |
Bruyn GAW1, Siddle HJ1, Hanova P1, Costantino F1, Iagnocco A1, Delle Sedie A1, Gutierrez M1, Hammer HB1, Jernberg E1, Loeille D1, Micu MC1, Moller I1, Pineda C1, Richards B1, Stoenoiu MS1, Suzuki T1, Terslev L1, Vlad V1, Wonink R1, d'Agostino J Rheumatol. 2018 Nov 1. pii: jrheum.171490. doi: 10.3899/jrheum.171490. [Epub ahead of print] MA1, Wakefield RJ1. |
| 378 | |
Intensive therapy and remissions in rheumatoid arthritis: a systematic review |
Hughes CD1, Scott DL2, Ibrahim F2; TITRATE Programme Investigators. Collaborators (10) BMC Musculoskelet Disord. 2018 Oct 30;19(1):389. doi: 10.1186/s12891-018-2302-5. |
| 379 | |
Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials |
Tarp S1, Jørgensen TS2, Furst DE3, Dossing A2, Taylor PC4, Choy EH5, Suarez-Almazor ME6, Lyddiatt A7, Kristensen LE2, Bliddal H2, Christensen R2. Semin Arthritis Rheum. 2018 Oct 9. pii: S0049-0172(18)30093-3. doi: 10.1016/j.semarthrit.2018.10.002. [Epub ahead of print] |
| 380 | |
Minimal Clinically Important Improvement of Routine Assessment of Patient Index Data 3 in Rheumatoid Arthritis |
Ward MM1, Castrejon I1, Bergman MJ1, Alba MI1, Guthrie LC1, Pincus T1. J Rheumatol. 2018 Oct 15. pii: jrheum.180153. doi: 10.3899/jrheum.180153. [Epub ahead of print] |
| 381 | |
Magnetic Resonance Imaging in Rheumatology |
Lambert RGW1, Østergaard M2, Jaremko JL3. Magn Reson Imaging Clin N Am. 2018 Nov;26(4):599-613. doi: 10.1016/j.mric.2018.06.008. |
| 382 | |
Health care utilization and expenditures among adults with rheumatoid arthritisusing specialty pharmaceuticals |
Park T1. Res Social Adm Pharm. 2018 Sep 12. pii: S1551-7411(18)30312-7. doi: 10.1016/j.sapharm.2018.09.003. [Epub ahead of print] |
| 383 | |
Correlation of the Multi-Biomarker Disease Activity Score with Rheumatoid ArthritisDisease Activity Measures: A Systematic Review and Meta-Analysis |
Johnson TM1,2, Register KA3, Schmidt CM4, O'Dell JR1,2, Mikuls TR1,2, Michaud K1,5, England BR1,2. Arthritis Care Res (Hoboken). 2018 Oct 15. doi: 10.1002/acr.23785. [Epub ahead of print] |
| 384 | |
Keeping physically active with rheumatoid arthritis: semi-structured interviews to explore patient perspectives, experiences and strategies |
Thomas R1, Hewlett S2, Swales C3, Cramp F2. Physiotherapy. 2018 Sep 6. pii: S0031-9406(18)30225-6. doi: 10.1016/j.physio.2018.09.001. [Epub ahead of print] |
| 385 | |
Persistently Frequent Emergency Department Utilization among Persons with Systemic Lupus Erythematosus |
Lee J1,2, Lin J1, Suter LG1,3, Fraenkel L1,3. Arthritis Care Res (Hoboken). 2018 Oct 8. doi: 10.1002/acr.23777. [Epub ahead of print] |
| 386 | |
The heart in systemic lupus erythematosus - A comprehensive approach by cardiovascular magnetic resonance tomography |
Burkard T1,2,3, Trendelenburg M3,4, Daikeler T3,5, Hess C2,3, Bremerich J3,6, Haaf P1,3, Buser P1,3, Zellweger MJ1,3. PLoS One. 2018 Oct 1;13(10):e0202105. doi: 10.1371/journal.pone.0202105. eCollection 2018. |
| 387 | |
Catatonia Associated With Systemic Lupus Erythematosus (SLE): A Report of 2 Cases and a Review of the Literature |
Boeke A1, Pullen B1, Coppes L1, Medina M1, Cooper JJ2. Psychosomatics. 2018 Jun 27. pii: S0033-3182(18)30314-1. doi: 10.1016/j.psym.2018.06.007. [Epub ahead of print] |
| 388 | |
Long-term impact of belimumab on health-related quality of life and fatigue in patients with systemic lupus erythematosus: 6 years of treatment |
Strand V1, Berry P2, Lin X2, Asukai Y3, Punwaney R4, Ramachandran S2. Arthritis Care Res (Hoboken). 2018 Oct 15. doi: 10.1002/acr.23788. [Epub ahead of print] |
| 389 | |
Increased alloreactive and autoreactive antihuman leucocyte antigen antibodies associated with systemic lupus erythematosus and rheumatoid arthritis |
Jackman RP1,2, Cruz GI3, Nititham J2, Triulzi DJ4,5, Barcellos LF3, Criswell LA4, Norris PJ1,2, Busch MP1,2. Lupus Sci Med. 2018 Sep 25;5(1):e000278. doi: 10.1136/lupus-2018-000278. eCollection 2018. |
| 390 | |
Spousal Support for Patients With Rheumatoid Arthritis: Getting the Wrong Kind Is a Pain |
Pow J1, Stephenson E1, Hagedoorn M2, DeLongis A1. Front Psychol. 2018 Sep 20;9:1760. doi: 10.3389/fpsyg.2018.01760. eCollection 2018. |
| 391 | |
Sonography of active rheumatoid arthritis during pregnancy: a case report and literature review |
Baffour FI1, McKenzie GA1, Bekele DI2, Glazebrook KN1. Radiol Case Rep. 2018 Sep 20;13(6):1233-1237. doi: 10.1016/j.radcr.2018.08.027. eCollection 2018 Dec. |
| 392 | |
Rheumatoid arthritis - a mathematical model |
Moise N1, Friedman A2. J Theor Biol. 2018 Oct 19. pii: S0022-5193(18)30521-6. doi: 10.1016/j.jtbi.2018.10.039. [Epub ahead of print] |
| 393 | |
Emergent Complications of Rheumatoid Arthritis |
Berman S1, Bucher J2, Koyfman A3, Long BJ4. J Emerg Med. 2018 Sep 22. pii: S0736-4679(18)30748-0. doi: 10.1016/j.jemermed.2018.07.030. [Epub ahead of print] |
| 394 | |
Biologic and Glucocorticoid Use after Methotrexate Initiation in Patients with Rheumatoid Arthritis |
George MD1, Sauer BC1, Teng CC1, Cannon GW1, England BR1, Kerr GS1, Mikuls TR1, Baker JF1. J Rheumatol. 2018 Oct 1. pii: jrheum.180178. doi: 10.3899/jrheum.180178. [Epub ahead of print] |
| 395 | |
Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis |
Rhee RL1, Holweg CTJ2, Wong K2, Cuthbertson D3, Carette S4, Khalidi NA5, Koening CL6, Langford CA7, McAlear CA1, Monach PA8, Moreland LW9, Pagnoux C4, Seo P10, Specks U11, Sreih AG1, Ytterberg SR12, Merkel PA13; Vasculitis Clinical Research Consortium. PLoS One. 2018 Oct 11;13(10):e0205768. doi: 10.1371/journal.pone.0205768. eCollection 2018. |
| 396 | |
Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized, Controlled Trial |
Kremer JM1, Rigby W2, Singer NG3, Birchwood C4, Gill D4, Reiss W4, Pei J4, Michalska M4. Arthritis Rheumatol. 2018 Aug;70(8):1200-1208. doi: 10.1002/art.40493. Epub 2018 Jun 14. |
| 397 | |
Long-Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry |
Winthrop KL1, Saag K2, Cascino MD3, Pei J3, John A3, Jahreis A3, Haselkorn T3, Furst DE4. Arthritis Care Res (Hoboken). 2018 Oct 8. doi: 10.1002/acr.23781. [Epub ahead of print] |
| 398 | |
Changes in Care After Implementing a Multifaceted Intervention to Improve Preventive Cardiology Practice in Rheumatoid Arthritis |
Majka DS1, Lee JY2, Peprah YA2, Lipiszko D2, Friesema E2, Ruderman EM2, Persell SD2. Am J Med Qual. 2018 Sep 9:1062860618798719. doi: 10.1177/1062860618798719. [Epub ahead of print] |
| 399 | |
No Effects of Black Tea on Cognitive Decline Among Older US Men: A Prospective Cohort Study |
Feng L, Langsetmo L, Yaffe K, Sun Y, Fink HA, Shikany JM, Leung PC, Lane J Alzheimers Dis. 2018;65(1):99-105. doi: 10.3233/JAD-180103. NE, Cauley JA; Osteoporotic Fractures in Men (MrOS) Study Group. |
| 400 | |
Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis |
Massey J1, Plant D2, Hyrich K2,3, Morgan AW4, Wilson AG5, Spiliopoulou A6,7, Colombo M6, McKeigue P6, Isaacs J8, Cordell H9, Pitzalis C10, Barton A11,12; BRAGGSS, MATURA Consortium. Pharmacogenomics J. 2018 Sep;18(5):657-664. doi: 10.1038/s41397-018-0040-6. Epub 2018 Aug 31. |
| 401 | |
Using subcutaneous methotrexate to prolong duration of methotrexate therapy in rheumatoid arthritis |
Harris E1, Ng B2. Eur J Rheumatol. 2018 Jul;5(2):85-91. doi: 10.5152/eurjrheum.2018.17113. Epub 2018 Feb 13. |
| 402 | |
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment |
Smolen JS1, Genovese MC1, Takeuchi T1, Hyslop DL1, Macias WL1, Rooney T1, Chen L1, Dickson CL1, Riddle Camp J1, Cardillo TE1, Ishii T1, Winthrop KL1. J Rheumatol. 2018 Sep 15. pii: jrheum.171361. doi: 10.3899/jrheum.171361. [Epub ahead of print] |
| 403 | |
Adverse Events and Resource Use Before and After Treat to Target in Rheumatoid Arthritis:A Post-Hoc Analysis of a Randomized Controlled Trial |
Solomon DH1, Yu Z1, Katz JN1,2, Bitton A3, Corrigan C1, Fraenkel L4, Harrold LR5, Smolen JS6, Losina E2, Lu B1. Arthritis Care Res (Hoboken). 2018 Sep 17. doi: 10.1002/acr.23755. [Epub ahead of print] |
| 404 | |
Association of Medication Beliefs, Self-efficacy, and Adherence in a Diverse Cohort of Adults with Rheumatoid Arthritis |
McCulley C1, Katz P1, Trupin L1, Yelin EH1, Barton JL1. J Rheumatol. 2018 Sep 15. pii: jrheum.171339. doi: 10.3899/jrheum.171339. [Epub ahead of print] |
| 405 | |
Systemic Lupus Erythematosus is a Risk Factor for Complications in Total Joint Arthroplasty |
Gholson JJ1, Wilkinson BG1, Brown TS1, Gao Y1, Dowdle SB1, Callaghan JJ1. Iowa Orthop J. 2018;38:183-190. |
| 406 | |
Measuring Disease Activity and Damage with Validated Metrics: A Systematic Review on Mortality and Damage in Systemic Lupus Erythematosus |
Keeling SO1,2,3, Vandermeer B4,5,6, Medina J4,5,6, Chatterley T4,5,6, Nevskaya T4,5,6, Pope J4,5,6, Alaburubalnabi Z4,5,6, Bissonauth A4,5,6, Touma Z4,5,6. J Rheumatol. 2018 Oct;45(10):1448-1461. doi: 10.3899/jrheum.171310. Epub 2018 Aug 15. |
| 407 | |
Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus |
Keeling SO1,2, Alabdurubalnabi Z3,4, Avina-Zubieta A3,4, Barr S3,4, Bergeron L3,4, Bernatsky S3,4, Bourre-Tessier J3,4, Clarke A3,4, Baril-Dionne A3,4, Dutz J3,4, Ensworth S3,4, Fifi-Mah A3,4, Fortin PR3,4, Gladman DD3,4, Haaland D3,4, Hanly JG3,4, Hiraki LT3,4, Hussein S3,4, Legault K3,4, Levy D3,4, Lim L3,4, Matsos M3,4, McDonald EG3,4, Medina-Rosas J3,4, Pardo Pardi J3,4, Peschken C3,4, Pineau C3,4, Pope J3,4, Rader T3,4, Reynolds J3,4, Silverman E3,4, Tselios K3,4, Suitner M3,4, Urowitz M3,4, Touma Z3,4, Vinet E3,4, Santesso N3,4. J Rheumatol. 2018 Oct;45(10):1426-1439. doi: 10.3899/jrheum.171459. Epub 2018 Sep 1. |
| 408 | |
The Mediterranean diet, fish oil supplements and Rheumatoid arthritis outcomes: evidence from clinical trials |
Petersson S1, Philippou E2, Rodomar C3, Nikiphorou E4. Autoimmun Rev. 2018 Sep 10. pii: S1568-9972(18)30217-9. doi: 10.1016/j.autrev.2018.06.007. [Epub ahead of print] |
| 409 | |
The Effect of Statin Use on Mortality in Systemic Autoimmune Rheumatic Diseases |
Jorge AM1, Lu N1, Keller SF1, Rai SK1, Zhang Y1, Choi HK1. J Rheumatol. 2018 Sep 1. pii: jrheum.171389. doi: 10.3899/jrheum.171389. [Epub ahead of print] |
| 410 | |
Delay in initiation of DMARD or anti-inflammatory therapy in patients newly diagnosed with rheumatoid arthritis: An analysis of United States Military Health System TRICARE beneficiaries |
Kimsey L1, Weissman JS2, Patel A3, Drew A4, Koehlmoos T3, Sparks JA2. Semin Arthritis Rheum. 2018 Jul 18. pii: S0049-0172(18)30305-6. doi: 10.1016/j.semarthrit.2018.07.003. [Epub ahead of print] |
| 411 | |
Using a ResearchKit Smartphone App to Collect Rheumatoid Arthritis Symptoms From Real-World Participants: Feasibility Study |
Crouthamel M1, Quattrocchi E2, Watts S3, Wang S1, Berry P1, Garcia-Gancedo L3, Hamy V2, Williams RE1. JMIR Mhealth Uhealth. 2018 Sep 13;6(9):e177. doi: 10.2196/mhealth.9656. |
| 412 | |
Elucidating the environmental risk factors for rheumatic diseases: An umbrella review of meta-analyses |
Belbasis L1, Dosis V1, Evangelou E1,2. Int J Rheum Dis. 2018 Aug;21(8):1514-1524. doi: 10.1111/1756-185X.13356. |
| 413 | |
Are we really what we eat? Nutrition and its role in the onset of rheumatoid arthritis |
Philippou E1, Nikiphorou E2. Autoimmun Rev. 2018 Sep 10. pii: S1568-9972(18)30210-6. doi: 10.1016/j.autrev.2018.05.009. [Epub ahead of print] |
| 414 | |
Low Persistence Rates in Rheumatoid Arthritis Patients Treated with Triple Therapy are Attributed to Adverse Drug Events Associated with Sulfasalazine |
Erhardt DP1, Cannon GW2, Teng CC3, Mikuls TR4, Curtis JR5, Sauer BC3. Arthritis Care Res (Hoboken). 2018 Sep 17. doi: 10.1002/acr.23759. [Epub ahead of print] |
| 415 | |
Correction to: White paper: statement on conflicts of interest |
Bion J1, Antonelli M2, Blanch L3, Curtis JR4, Druml C5, Du B6, Machado FR7, Gomersall C8, Hartog C9, Levy M10, Myburgh J11, Rubenfeld G12, Sprung C13. Intensive Care Med. 2018 Sep 17. doi: 10.1007/s00134-018-5373-8. [Epub ahead of print] |
| 416 | |
Enthesitis and Dactylitis in Psoriatic Disease: A Guide for Dermatologists |
Bagel J1, Schwartzman S2. Am J Clin Dermatol. 2018 Aug 16. doi: 10.1007/s40257-018-0377-2. [Epub ahead of print] |
| 417 | |
Primary Thrombosis Prophylaxis in Persistently Antiphospholipid Antibody-Positive Individuals: Where Do We Stand in 2018? |
Zuo Y1, Barbhaiya M2, Erkan D3. Curr Rheumatol Rep. 2018 Sep 10;20(11):66. doi: 10.1007/s11926-018-0775-8. |
| 418 | |
Factors Associated with First Thrombosis in Patients Presenting with Obstetric Antiphospholipid Syndrome in APS Alliance For Clinical Trials & International Networking (APS ACTION) Clinical Database And Repository: a retrospective study |
de Jesús GR1, Sciascia S2, Andrade D3, Nascimento IS3, Rosa R3, Barbhaiya M4, Tektonidou M5, Banzato A6, Pengo V6, Ji L7, Meroni PL8, Ugarte A9, Cohen H10, Branch DW11, Andreoli L12, Belmont HM13, Fortin PR14, Petri M15, Rodriguez E16, Cervera R17, Knight JS18, Atsumi T19, Willis R20, Erkan D4, Levy RA21,22; APS ACTION. BJOG. 2018 Sep 17. doi: 10.1111/1471-0528.15469. [Epub ahead of print] |
| 419 | |
Tocilizumab and the risk for cardiovascular disease: a direct comparison among biologic disease-modifying antirheumatic drugs for rheumatoid arthritis patients |
Xie F1,2, Yun H1,2, Levitan EB2, Muntner P2, Curtis JR1,2. Arthritis Care Res (Hoboken). 2018 Sep 3. doi: 10.1002/acr.23737. [Epub ahead of print] |
| 420 | |
Determination of the minimally important difference (MID) in multi-biomarker disease activity (MBDA) test scores: impact of diurnal and daily biomarker variation patterns on MBDA scores |
Chernoff D1, Scott Eastman P2, Hwang CC2, Flake DD 2nd3, Wang X2, Kivitz A4, Curtis JR5. Clin Rheumatol. 2018 Aug 29. doi: 10.1007/s10067-018-4276-y. [Epub ahead of print] |
| 421 | |
White paper: statement on conflicts of interest |
Bion J1, Antonelli M2, Blanch L3, Curtis JR4, Druml C5, Du B6, Machado FR7, Gomersall C8, Hartog C9, Levy M10, Myburgh J11, Rubenfeld G12, Sprung C13. Intensive Care Med. 2018 Sep 6. doi: 10.1007/s00134-018-5349-8. [Epub ahead of print] |
| 422 | |
Longitudinal evaluation of diffusion tensor imaging and cognition in systemic lupus erythematosus |
Kozora E1,2,3,4,5, Filley CM2,3,6, Erkan D4,5, Ulu? AM7,8, Vo A9, Ramon G4, Burleson A10, Zimmerman RD5, Lockshin MD4,5. Lupus. 2018 Aug 13:961203318793215. doi: 10.1177/0961203318793215. [Epub ahead of print] |
| 423 | |
Infodemiology of antiphospholipid syndrome: Merging informatics and epidemiology |
Sciascia S1,2, Radin M1, Unlu O3, Erkan D3, Roccatello D1,2. Eur J Rheumatol. 2018 Jul;5(2):92-95. doi: 10.5152/eurjrheum.2018.17105. Epub 2018 Jan 22. |
| 424 | |
Discordance Between Patient Reported Motivations to Seek Treatment for Psoriasis Compared to Television Advertisements |
Golbari NM, Porter ML, Kimball AB. J Drugs Dermatol. 2018 Aug 1;17(8):886-887. |
| 425 | |
Efficacy and Safety of Toreforant, a Selective Histamine H4 Receptor Antagonist, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results from a Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Trial |
Frankel E, Song M, Li S, Jiang J, Thurmond RL, Randazzo B. J Drugs Dermatol. 2018 Aug 1;17(8):873-879. |
| 426 | |
Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies |
Sugarman JL, Weiss J, Tanghetti EA, Bagel J, Yamauchi PS, Stein Gold L, Lin T, Martin G, Pillai R, Israel R. J Drugs Dermatol. 2018 Aug 1;17(8):855-861. |
| 427 | |
Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination |
Stein Gold L, Kircik LH, Pariser D, Sugarman JL, Lin T, Kang R, Pillai R. Drugs Dermatol. 2018 Aug 1;17(8):863-868. |
| 428 | |
Patient-Reported Satisfaction With the Fixed Combination Calcipotriene/Betamethasone Dipropionate Foam for Plaque Psoriasis |
Gorelick J, Cantrell W, Kucera K, Veverka KA, Gooding K. J Drugs Dermatol. 2018 Aug 1;17(8):880-884. |
| 429 | |
A Prospective, Open-Label Study Evaluating Adjunctive Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Psoriasis Patients With Inadequate Response to Biologic Therapy |
Bagel J, Zapata J, Nelson E. J Drugs Dermatol. 2018 Aug 1;17(8):845-850. |
| 430 | |
Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment |
Mori S1, Arima N2, Ito M3, Fujiyama S4, Kamo Y5, Ueki Y6. PLoS One. 2018 Aug 24;13(8):e0203084. doi: 10.1371/journal.pone.0203084. eCollection 2018. |
| 431 | |
Tofacitinib for the treatment of psoriasis and psoriatic arthritis |
Berekmeri A1, Mahmood F2, Wittmann M3, Helliwell P4. Expert Rev Clin Immunol. 2018 Aug 17. doi: 10.1080/1744666X.2018.1512404. [Epub ahead of print] |
| 432 | |
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials |
Gordon KB1, Strober B2, Lebwohl M3, Augustin M4, Blauvelt A5, Poulin Y6, Papp KA7, Sofen H8, Puig L9, Foley P10, Ohtsuki M11, Flack M12, Geng Z13, Gu Y13, Valdes JM13, Thompson EHZ14, Bachelez H15. Lancet. 2018 Aug 25;392(10148):650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7. |
| 433 | |
Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years |
Griffiths CEM, Papp KA, Kimball AB, Randazzo B, Song M, Li S, Shen YK, Blauvelt A. J Drugs Dermatol. 2018 Aug 1;17(8):826-832. |
| 434 | |
Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal |
Wade R1, Grosso A2, South E3, Rothery C2, Saramago P2, Schmitt L2, Wright K3, Palmer S2. Pharmacoeconomics. 2018 Aug 16. doi: 10.1007/s40273-018-0698-2. [Epub ahead of print] |
| 435 | |
Rheumatoid Arthritis-Associated Orbital Vasculitis |
Weber AC1, Shetlar DJ, Yen MT. Ophthalmic Plast Reconstr Surg. 2018 Aug 6. doi: 10.1097/IOP.0000000000001192. [Epub ahead of print] |
| 436 | |
Factors associated with preterm delivery among women with rheumatoid arthritis and juvenile idiopathic arthritis |
Smith CJF1,2, Förger F3, Bandoli G4, Chambers CD4. Arthritis Care Res (Hoboken). 2018 Aug 21. doi: 10.1002/acr.23730. [Epub ahead of print] |
| 437 | |
Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review |
Emery P1, Pope JE2, Kruger K3, Lippe R4, DeMasi R5, Lula S6, Kola B7. Adv Ther. 2018 Aug 20. doi: 10.1007/s12325-018-0757-2. [Epub ahead of print] |
| 438 | |
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis |
Fleischmann RM1, Alten R2, Pileckyte M3, Lobello K4, Hua SY5, Cronenberger C4, Alvarez D4, Bock AE6, Sewell KL6. Arthritis Res Ther. 2018 Aug 15;20(1):178. doi: 10.1186/s13075-018-1676-y. |
| 439 | |
Systematic review and network meta-analysis: effect of biologics on radiographic progression in rheumatoid arthritis |
Murray E1, Ellis A1, Butylkova Y1, Skup M2, Kalabic J3, Garg V2. J Comp Eff Res. 2018 Aug 21. doi: 10.2217/cer-2017-0106. [Epub ahead of print] |
| 440 | |
Effects of language, insurance and race/ethnicity on measurement properties of the PROMIS Physical Function Short Form 10a in rheumatoid arthritis |
Izadi Z1, Katz PP2, Schmajuk G3, Gandrup J2, Li J2, Gianfrancesco M2, Yazdany J2. Arthritis Care Res (Hoboken). 2018 Aug 12. doi: 10.1002/acr.23723. [Epub ahead of print] |
| 441 | |
Methotrexate Mechanism in Treatment of Rheumatoid Arthritis |
Friedman B1, Cronstein B2. Joint Bone Spine. 2018 Aug 3. pii: S1297-319X(18)30181-7. doi: 10.1016/j.jbspin.2018.07.004. [Epub ahead of print] |
| 442 | |
Inflammatory dietary pattern and risk of developing rheumatoid arthritis in women |
Sparks JA1,2, Barbhaiya M3, Tedeschi SK4,5, Leatherwood CL4,5, Tabung FK6,7, Speyer CB4, Malspeis S4, Costenbader KH4,5, Karlson EW4,5, Lu B4,5. Clin Rheumatol. 2018 Aug 14. doi: 10.1007/s10067-018-4261-5. [Epub ahead of print] |
| 443 | |
Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis |
Tanaka Y1, McInnes IB2, Taylor PC3, Byers NL4, Chen L4, de Bono S4, Issa M4, Macias WL4, Rogai V4, Rooney TP4, Schlichting DE4, Zuckerman SH4, Emery P5. Arthritis Rheumatol. 2018 Jul 29. doi: 10.1002/art.40680. [Epub ahead of print] |
| 444 | |
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis |
Zhao S1, Chadwick L1, Mysler E2, Moots RJ3.Author informationCurr Rheumatol Rep. 2018 Aug 9;20(10):57. doi: 10.1007/s11926-018-0769-6. |
| 445 | |
Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort |
Choi MY1, Clarke AE1, St Pierre Y2, Hanly JG3, Urowitz MB4, Romero-Diaz J5, Gordon C6, Bae SC7, Bernatsky S8, Wallace DJ9, Merrill JT10, Isenberg DA11, Rahman A11, Ginzler EM12, Petri M13, Bruce IN14, Dooley MA15, Fortin PR16, Gladman DD4, Sanchez-Guerrero J17, Steinsson K18, Ramsey-Goldman R19, Khamashta MA20, Aranow C21, Alarcón GS22, Manzi S23, Nived O24, Zoma AA25, van Vollenhoven RF26, Ramos-Casals M27, Ruiz-Irastorza G28, Lim SS29, Kalunian KC30, Inanc M31, Kamen DL32, Peschken CA33, Jacobsen S34, Askanase A35, Stoll T36, Buyon J37, Mahler M38, Fritzler MJ1. Arthritis Care Res (Hoboken). 2018 Jul 25. doi: 10.1002/acr.23712. [Epub ahead of print] |
| 446 | |
Patient Governance in a Patient-Powered Research Network for Adult Rheumatologic Conditions |
Nowell WB1, Curtis JR2, Crow-Hercher R3. Med Care. 2018 Aug 2. doi: 10.1097/MLR.0000000000000814. [Epub ahead of print] |
| 447 | |
Exercise for rheumatoid arthritis of the hand |
Williams MA1, Srikesavan C, Heine PJ, Bruce J, Brosseau L, Hoxey-Thomas N, Lamb SE. Cochrane Database Syst Rev. 2018 Jul 31;7:CD003832. doi: 10.1002/14651858.CD003832.pub3. |
| 448 | |
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy |
Cohen SB1, Alten R2, Kameda H3, Hala T4, Radominski SC5, Rehman MI6, Palaparthy R7, Schumacher K8, Schmitt S8, Hua SY7, Ianos C9, Sewell KL10. Arthritis Res Ther. 2018 Jul 27;20(1):155. doi: 10.1186/s13075-018-1646-4. |
| 449 | |
A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences |
Maniadakis N1, Toth E2, Schiff M3, Wang X4, Nassim M4, Szegvari B5, Mountian I5, Curtis JR6. Adv Ther. 2018 Aug 4. doi: 10.1007/s12325-018-0759-0. [Epub ahead of print] |
| 450 | |
Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach to Care of US Patients With Rheumatoid Arthritis |
Harrold LR1, Reed GW1, John A2, Barr CJ3, Soe K3, Magner R4, Saunders KC3, Ruderman EM5, Haselkorn T2, Greenberg JD6, Gibofsky A7, Harrington JT8, Kremer JM9. Arthritis Care Res (Hoboken). 2018 Mar;70(3):379-387. doi: 10.1002/acr.23294. Epub 2018 Feb 6. |
| 451 | |
Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database |
Clowse MEB1, Scheuerle AE2, Chambers C3, Afzali A4, Kimball AB5, Cush JJ6, Cooney M7, Shaughnessy L7, Vanderkelen M8, Förger F9. Arthritis Rheumatol. 2018 Apr 5. doi: 10.1002/art.40508. [Epub ahead of print] |
| 452 | |
Current management of sarcoidosis I: pulmonary, cardiac, and neurologic manifestations |
West SG1. Curr Opin Rheumatol. 2018 May;30(3):243-248. doi: 10.1097/BOR.0000000000000489. |
| 453 | |
Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review |
Ford AR1, Siegel M2, Bagel J3, Cordoro KM4,5, Garg A6, Gottlieb A7,8, Green LJ9, Gudjonsson JE10, Koo J4, Lebwohl M11, Liao W4, Mandelin AM 2nd12, Markenson JA13, Mehta N14, Merola JF15, Prussick R9, Ryan C16, Schwartzman S13, Siegel EL17,18, Van Voorhees AS19, Wu JJ20, Armstrong AW1. JAMA Dermatol. 2018 Jun 20. doi: 10.1001/jamadermatol.2018.1412. [Epub ahead of print] |
| 454 | |
The Effect of Pre-appointment Consult Triage on Patient Selection and Revenue Generation in a University Rheumatology Practice |
West SG1, Pearson DW1, Striebich CC1, Goecker R1, Kolfenbach JR1. Arthritis Care Res (Hoboken). 2018 Jul 12. doi: 10.1002/acr.23701. [Epub ahead of print] |
| 455 | |
Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire |
Robson JC#1,2, Dawson J#3, Doll H4, Cronholm PF5, Milman N6, Kellom K7, Ashdown S8, Easley E9, Gebhart D10, Lanier G11, Mills J12, Peck J8, Luqmani RA13, Shea J14, Tomasson G15, Merkel PA16. Ann Rheum Dis. 2018 Aug;77(8):1157-1164. doi: 10.1136/annrheumdis-2017-212713. Epub 2018 Apr 25. |
| 456 | |
Metabolic pathways and immunometabolism in rare kidney diseases |
Grayson PC1,2, Eddy S3,4, Taroni JN2,5, Lightfoot YL1, Mariani L3,4, Parikh H2,6, Lindenmeyer MT7, Ju W3,4, Greene CS2,5, Godfrey B3,4, Cohen CD7, Krischer J2,6, Kretzler M3,4, Merkel PA2,8; Vasculitis Clinical Research Consortium, the European Renal cDNA Bank cohort, and the Nephrotic Syndrome Study Network. Ann Rheum Dis. 2018 Aug;77(8):1226-1233. doi: 10.1136/annrheumdis-2017-212935. Epub 2018 May 3. |
| 457 | |
Transcriptional Profiling of Synovial Macrophages Using Minimally Invasive Ultrasound-Guided Synovial Biopsies in Rheumatoid Arthritis |
Mandelin AM 2nd1, Homan PJ1, Shaffer AM1, Cuda CM1, Dominguez ST1, Bacalao E1, Carns M1, Hinchcliff M1, Lee J1, Aren K1, Thakrar A1, Montgomery AB1, Bridges SL Jr2, Bathon JM3, Atkinson JP4, Fox DA5, Matteson EL6, Buckley CD7, Pitzalis C8, Parks D4, Hughes LB2, Geraldino-Pardilla L3, Ike R5, Phillips K5, Wright K6, Filer A7, Kelly S8, Ruderman EM1, Morgan V1, Abdala-Valencia H1, Misharin AV1, Budinger GS1, Bartom ET1, Pope RM1, Perlman H1, Winter DR1. Arthritis Rheumatol. 2018 Jun;70(6):841-854. doi: 10.1002/art.40453. Epub 2018 May 3. |
| 458 | |
Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis |
Wells AF1, Greenwald M2, Bradley JD3, Alam J3, Arora V3, Kartman CE4. Rheumatol Ther. 2018 Jun;5(1):43-55. doi: 10.1007/s40744-018-0110-x. Epub 2018 Apr 21. |
| 459 | |
Comparison of magnetic resonance angiography and 18F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis |
Quinn KA1,2, Ahlman MA3, Malayeri AA3, Marko J3, Civelek AC3, Rosenblum JS2, Bagheri AA2, Merkel PA4, Novakovich E2, Grayson PC2. Ann Rheum Dis. 2018 Aug;77(8):1165-1171. doi: 10.1136/annrheumdis-2018-213102. Epub 2018 Apr 17. |
| 460 | |
Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis |
Berti A1, Warner R2, Johnson K2, Cornec D3, Schroeder D4, Kabat B4, Langford CA5, Hoffman GS5, Fervenza FC4, Kallenberg CGM6, Seo P7, Spiera R8, St Clair EW9, Brunetta P10, Stone JH11, Merkel PA12, Specks U4, Monach PA13; RAVE-ITN Research Group. Arthritis Rheumatol. 2018 Jul;70(7):1114-1121. doi: 10.1002/art.40471. Epub 2018 May 7. |
| 461 | |
Lupus community panel proposals for optimising clinical trials: 2018 |
Merrill JT1, Manzi S2, Aranow C3, Askenase A4, Bruce I5, Chakravarty E1, Chong B6, Costenbader K7, Dall'Era M8, Ginzler E9, Hanrahan L10, Kalunian K11, Merola J7, Raymond S12, Rovin B13, Saxena A14, Werth VP15. Lupus Sci Med. 2018 Mar 23;5(1):e000258. doi: 10.1136/lupus-2018-000258. eCollection 2018. |
| 462 | |
Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort |
Little J1,2, Parker B2, Lunt M1, Hanly JG3, Urowitz MB4, Clarke AE5, Romero-Diaz J6, Gordon C7,8, Bae SC9, Bernatsky S10, Wallace DJ11, Merrill JT12, Buyon J13, Isenberg DA14, Rahman A14, Ginzler EM15, Petri M16, Dooley MA17, Fortin P18, Gladman DD4, Steinsson K19, Ramsey-Goldman R20, Khamashta MA21, Aranow C22, Mackay M22, Alarcón GS23, Manzi S24, Nived O25, Jönsen A25, Zoma AA26, van Vollenhoven RF27, Ramos-Casals M28, Ruiz-Irastorza G29, Sam Lim S30, Kalunian KC31, Inanc M32, Kamen DL33, Peschken CA34, Jacobsen S35, Askanase A36, Sanchez-Guerrero J37, Bruce IN1,2. Rheumatology (Oxford). 2018 Apr 1;57(4):677-687. doi: 10.1093/rheumatology/kex444. |
| 463 | |
Role of macrophage migration inhibitory factor in granulomatosis with polyangiitis |
Sreih AG1, Ezzedine R2, Leng L3, Fan J3, Yao J3, Reid D3, Piecychna M3, Carette S4, Cuthbertson D5, Dellaripa P6, Hoffman GS7, Khalidi NA8, Koening CL9, Langford CA7, Mahr A10, McAlear CA1, Maksimowicz-Mckinnon K11, Monach PA12, Seo P13, Specks U14, St Clair W15, Stone JH16, Ytterberg SR14, Edberg J17, Merkel PA1,18, Bucala R3. Arthritis Rheumatol. 2018 Jun 28. doi: 10.1002/art.40655. [Epub ahead of print] |
| 464 | |
Arterial lesions in giant cell arteritis: A longitudinal study |
Kermani TA1, Diab S2, Sreih AG3, Cuthbertson D4, Borchin R4, Carette S5, Forbess L6, Koening CL7, McAlear CA3, Monach PA8, Moreland L9, Pagnoux C5, Seo P10, Spiera RF11, Warrington KJ12, Ytterberg SR12, Langford CA13, Merkel PA14, Khalidi NA2; Vasculitis Clinical Research Consortium. Semin Arthritis Rheum. 2018 May 9. pii: S0049-0172(18)30094-5. doi: 10.1016/j.semarthrit.2018.05.002. [Epub ahead of print] |
| 465 | |
Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study |
van der Heijde D1, Braun J2, Rudwaleit M3, Purcaru O4, Kavanaugh AF5. RMD Open. 2018 Apr 9;4(1):e000659. doi: 10.1136/rmdopen-2018-000659. eCollection 2018. |
| 466 | |
Arthroscopic-Assisted Latissimus Dorsi Tendon Transfer for Massive Rotator Cuff Tears: A Systematic Review |
Memon M1, Kay J1, Quick E2, Simunovic N3, Duong A1, Henry P4, Ayeni OR1. Orthop J Sports Med. 2018 Jun 11;6(6):2325967118777735. doi: 10.1177/2325967118777735. eCollection 2018 Jun. |
| 467 | |
Incident fracture is associated with a period of accelerated loss of hip BMD: the Study of Osteoporotic Fractures |
Christiansen BA1, Harrison SL2, Fink HA3, Lane NE4; Study of Osteoporotic Fractures Research Group. Osteoporos Int. 2018 Jul 10. doi: 10.1007/s00198-018-4606-6. [Epub ahead of print] |
| 468 | |
Earlier anterior cruciate ligament reconstruction is associated with a decreased risk of medial meniscal and articular cartilage damage in children and adolescents: a systematic review and meta-analysis |
Kay J1, Memon M1, Shah A2, Yen YM3, Samuelsson K4, Peterson D1, Simunovic N5, Flageole H6, Ayeni OR7. Knee Surg Sports Traumatol Arthrosc. 2018 Jun 6. doi: 10.1007/s00167-018-5012-5. [Epub ahead of print] |
| 469 | |
The involvement of Toll-like receptor 9 in the pathogenesis of erosive autoimmune arthritis |
Fischer A1, Abdollahi-Roodsaz S2,3, Böhm C1, Niederreiter B1, Meyer B1, Yau ACY4, Lönnblom E4, Joosten LAB2, Koenders M2, Lehmann CHK5, Dudziak D5, Krönke G6, Holmdahl R4, Steiner G1,7. J Cell Mol Med. 2018 Jul 11. doi: 10.1111/jcmm.13735. [Epub ahead of print] |
| 470 | |
OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis |
Robson JC1,2, Tomasson G1,2, Milman N1,2, Ashdown S1,2, Boonen A1,2, Casey GC1,2, Cronholm PF1,2, Cuthbertson D1,2, Dawson J1,2, Direskeneli H1,2, Easley E1,2, Kermani TA1,2, Farrar JT1,2, Gebhart D1,2, Lanier G1,2, Luqmani RA1,2, Mahr A1,2, McAlear CA1,2, Peck J1,2, Shea B1,2, Shea JA1,2, Sreih AG1,2, Tugwell PS1,2, Merkel PA3,4. J Rheumatol. 2017 Oct;44(10):1529-1535. doi: 10.3899/jrheum.161139. Epub 2017 Sep 1. |
| 471 | |
Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016 |
Sreih AG1,2, Alibaz-Oner F1,2, Kermani TA1,2, Aydin SZ1,2, Cronholm PF1,2, Davis T1,2, Easley E1,2, Gul A1,2, Mahr A1,2, McAlear CA1,2, Milman N1,2, Robson JC1,2, Tomasson G1,2, Direskeneli H1,2, Merkel PA3,4. J Rheumatol. 2017 Dec;44(12):1933-1937. doi: 10.3899/jrheum.161467. Epub 2017 Sep 1. |
| 472 | |
Cervical Epidural Injection in the Management of Refractory Pain and Stiffness in Spondyloarthropathy: A Case Report Series |
Gungor S1, Aiyer R2, Erkan D3. Pain Pract. 2018 Apr;18(4):532-538. doi: 10.1111/papr.12616. Epub 2017 Nov 20. |
| 473 | |
Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach to Care of US Patients With Rheumatoid Arthritis |
Harrold LR1, Reed GW1, John A2, Barr CJ3, Soe K3, Magner R4, Saunders KC3, Ruderman EM5, Haselkorn T2, Greenberg JD6, Gibofsky A7, Harrington JT8, Kremer JM9. Arthritis Care Res (Hoboken). 2018 Mar;70(3):379-387. doi: 10.1002/acr.23294. Epub 2018 Feb 6. |
| 474 | |
Non-classical monocytes as mediators of tissue destruction in arthritis |
Puchner A1, Saferding V1, Bonelli M1, Mikami Y2, Hofmann M1, Brunner JS1, Caldera M3, Goncalves-Alves E1, Binder NB1, Fischer A1, Simader E1, Steiner CW1, Leiss H1, Hayer S1, Niederreiter B1, Karonitsch T1, Koenders MI4, Podesser BK5, O'Shea JJ2, Menche J3, Smolen JS1, Redlich K1, Blüml S1,6. Ann Rheum Dis. 2018 Jun 29. pii: annrheumdis-2018-213250. doi: 10.1136/annrheumdis-2018-213250. [Epub ahead of print] |
| 475 | |
Role of macrophage migration inhibitory factor in granulomatosis with polyangiitis |
Sreih AG1, Ezzedine R2, Leng L3, Fan J3, Yao J3, Reid D3, Piecychna M3, Carette S4, Cuthbertson D5, Dellaripa P6, Hoffman GS7, Khalidi NA8, Koening CL9, Langford CA7, Mahr A10, McAlear CA1, Maksimowicz-Mckinnon K11, Monach PA12, Seo P13, Specks U14, St Clair W15, Stone JH16, Ytterberg SR14, Edberg J17, Merkel PA1,18, Bucala R3. Arthritis Rheumatol. 2018 Jun 28. doi: 10.1002/art.40655. [Epub ahead of print] |
| 476 | |
Arterial lesions in giant cell arteritis: A longitudinal study |
Kermani TA1, Diab S2, Sreih AG3, Cuthbertson D4, Borchin R4, Carette S5, Forbess L6, Koening CL7, McAlear CA3, Monach PA8, Moreland L9, Pagnoux C5, Seo P10, Spiera RF11, Warrington KJ12, Ytterberg SR12, Langford CA13, Merkel PA14, Khalidi NA2; Vasculitis Clinical Research Consortium. Semin Arthritis Rheum. 2018 May 9. pii: S0049-0172(18)30094-5. doi: 10.1016/j.semarthrit.2018.05.002. [Epub ahead of print] |
| 477 | |
Fluid Extravasation in Shoulder Arthroscopic Surgery: A Systematic Review |
Memon M1, Kay J1, Gholami A2, Simunovic N3, Ayeni OR4. Orthop J Sports Med. 2018 May 14;6(5):2325967118771616. doi: 10.1177/2325967118771616. eCollection 2018 May. |
| 478 | |
Arthroscopic-Assisted Latissimus Dorsi Tendon Transfer for Massive Rotator Cuff Tears: A Systematic Review |
Memon M1, Kay J1, Quick E2, Simunovic N3, Duong A1, Henry P4, Ayeni OR1. Orthop J Sports Med. 2018 Jun 11;6(6):2325967118777735. doi: 10.1177/2325967118777735. eCollection 2018 Jun. |
| 479 | |
Earlier anterior cruciate ligament reconstruction is associated with a decreased risk of medial meniscal and articular cartilage damage in children and adolescents: a systematic review and meta-analysis |
Kay J1, Memon M1, Shah A2, Yen YM3, Samuelsson K4, Peterson D1, Simunovic N5, Flageole H6, Ayeni OR7. Knee Surg Sports Traumatol Arthrosc. 2018 Jun 6. doi: 10.1007/s00167-018-5012-5. [Epub ahead of print] |
| 480 | |
Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic options |
Strauß R1, Rose T1, Flint SM2, Klotsche J3, Häupl T1, Peck-Radosavljevic M4, Yoshida T5, Kyogoku C6, Flechsig A1, Becker AM7, Dao KH7, Radbruch A3, Burmester GR1, Lyons PA2, Davis LS7, Hiepe F1, Grützkau A3, Biesen R8. J Mol Med (Berl). 2017 Jul;95(7):753-765. doi: 10.1007/s00109-017-1515-7. Epub 2017 Mar 29. |
| 481 | |
The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody Positive Patients: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository |
Unlu O1, Erkan D2, Barbhaiya M2, Andrade D3, Nascimento I3, Rosa R3, Banzato A4, Pengo V4, Ugarte A5, Gerosa M6, Ji L7, Efthymiou M8, Branch DW9, de Jesus GR10, Tincani A11, Belmont HM12, Fortin PR13, Petri M14, Rodriguez E15, Pons-Estel GJ16, Knight JS17, Atsumi T18, Willis R19, Zuily S20, Tektonidou MG21; TheBehalf of APS ACTION. Arthritis Care Res (Hoboken). 2018 Apr 18. doi: 10.1002/acr.23584. [Epub ahead of print] |
| 482 | |
The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients |
Rodríguez-Pintó I1, Espinosa G1, Erkan D2, Shoenfeld Y3, Cervera R1; CAPS Registry Project Group. Rheumatology (Oxford). 2018 Apr 11. doi: 10.1093/rheumatology/key082. [Epub ahead of print] |
| 483 | |
Treatment of antiphospholipid syndrome beyond anticoagulation |
Dobrowolski C1, Erkan D2. Clin Immunol. 2018 Mar 3. pii: S1521-6616(18)30119-0. doi: 10.1016/j.clim.2018.03.001. [Epub ahead of print] |
| 484 | |
Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy |
Jackson WG1, Oromendia C2, Unlu O3, Erkan D4, DeSancho MT5; Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking. Collaborators (55) Blood Adv. 2017 Nov 16;1(25):2320-2324. doi: 10.1182/bloodadvances.2017008185. eCollection 2017 Nov 28. |
| 485 | |
Use of Scribes for Documentation Assistance in Rheumatology and Endocrinology Clinics: Impact on Clinic Workflow and Patient and Physician Satisfaction |
Danila MI, Melnick JA, Curtis JR, Menachemi N, Saag KG. J Clin Rheumatol. 2018 Apr;24(3):116-121. doi: 10.1097/RHU.0000000000000620. |
| 486 | |
Defining and characterizing sustained remission in patients with rheumatoid arthritis |
Curtis JR1, Trivedi M2, Haraoui B3, Emery P4, Park GS2, Collier DH2, Aras GA2, Chung J2. Clin Rheumatol. 2018 Apr;37(4):885-893. doi: 10.1007/s10067-017-3923-z. Epub 2017 Dec 9. |
| 487 | |
Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population-based study |
Curtis JR1,2, Xie F1, Chen L1, Saag KG1,2, Yun H1,2, Muntner P2. Ann Rheum Dis. 2018 Mar;77(3):386-392. doi: 10.1136/annrheumdis-2017-211727. Epub 2017 Dec 21. |
| 488 | |
Diet and exercise changes following bone densitometry in the Patient Activation After DXA Result Notification (PAADRN) study |
Roblin DW1,2, Cram P3,4,5, Lou Y6, Edmonds SW3,7, Hall SF7, Jones MP6, Saag KG8, Wright NC8,9, Wolinsky FD3,7,10; PAADRN Investigators. Collaborators (5) Curtis JR, Morgan SL, Schlechte JA, Williams JH, Zelman DJ. Arch Osteoporos. 2018 Jan 6;13(1):4. doi: 10.1007/s11657-017-0402-8. |
| 489 | |
Hip fracture trends in the United States, 2002 to 2015 |
Michael Lewiecki E1, Wright NC2, Curtis JR3, Siris E4, Gagel RF5, Saag KG3, Singer AJ6,7, Steven PM8, Adler RA9,10. Osteoporos Int. 2018 Mar;29(3):717-722. doi: 10.1007/s00198-017-4345-0. Epub 2017 Dec 27. |
| 490 | |
Combining online and in-person methods to evaluate the content validity of PROMIS fatigue short forms in rheumatoid arthritis |
Bartlett SJ1,2, Gutierrez AK3,4, Butanis A3, Bykerk VP5, Curtis JR6, Ginsberg S7, Leong AL8, Lyddiatt A9, Nowell WB7, Orbai AM3, Smith KC10, Bingham CO 3rd3. Qual Life Res. 2018 May 24. doi: 10.1007/s11136-018-1880-x. [Epub ahead of print] |
| 491 | |
Gastrointestinal Perforations with Biologics in Patients with Rheumatoid Arthritis: Implications for Clinicians |
Jagpal A1, Curtis JR2. Drug Saf. 2018 Jun;41(6):545-553. doi: 10.1007/s40264-018-0639-1. |
| 492 | |
Evaluation of a Methodological Approach to Define An Inception Cohort of Rheumatoid Arthritis Patients Using Administrative Data |
Curtis JR1,2, Xie F1, Chen L1, Greenberg JD3, Zhang J2. Arthritis Care Res (Hoboken). 2018 Feb 6. doi: 10.1002/acr.23533. [Epub ahead of print] |
| 493 | |
Evaluation of a Multimodal, Direct-to-Patient Educational Intervention Targeting Barriers to Osteoporosis Care: A Randomized Clinical Trial |
Danila MI1, Outman RC1, Rahn EJ1, Mudano AS1, Redden DT1, Li P1, Allison JJ2, Anderson FA2, Wyman A2, Greenspan SL3, LaCroix AZ4,5, Nieves JW6, Silverman SL7, Siris ES8, Watts NB9, Miller MJ10, Curtis JR1, Warriner AH1, Wright NC1, Saag KG1. J Bone Miner Res. 2018 May;33(5):763-772. doi: 10.1002/jbmr.3395. Epub 2018 Feb 26. |
| 494 | |
Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors |
Beukelman T1, Xie F2, Chen L2, Horton DB3, Lewis JD4, Mamtani R4, Mannion MM1, Saag KG2, Curtis JR2. Ann Rheum Dis. 2018 Feb 9. pii: annrheumdis-2017-212613. doi: 10.1136/annrheumdis-2017-212613. [Epub ahead of print] |
| 495 | |
Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis |
Pearce FA1,2, Craven A3, Merkel PA4, Luqmani RA3, Watts RA5,6. Rheumatology (Oxford). 2017 Nov 1;56(11):1962-1969. doi: 10.1093/rheumatology/kex293. |
| 496 | |
Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials |
Moots RJ1, Sebba A2, Rigby W3, Ostor A4, Porter-Brown B5, Donaldson F5, Dimonaco S5, Rubbert-Roth A6, van Vollenhoven R7, Genovese MC8. Rheumatology (Oxford). 2017 Apr 1;56(4):541-549. doi: 10.1093/rheumatology/kew370. |
| 497 | |
The combination of three autoantibodies, ACPA, RF and anti-CarP antibodies is highly specific for rheumatoid arthritis: implications for very early identification of individuals at risk to develop rheumatoid arthritis |
Verheul MK1, Böhringer S2, van Delft MAM1, Jones JD3, Rigby WFC3, Gan RW4, Holers VM5, Edison JD6, Deane KD5, Janssen KMJ7, Westra J8, Brink M9, Rantapää-Dahlqvist S9, Huizinga TWJ1, van der Helm-van Mil AHM1, van der Woude D1, Toes REM1, Trouw LA1,10. Arthritis Rheumatol. 2018 May 21. doi: 10.1002/art.40562. [Epub ahead of print] |
| 498 | |
Treatment algorithms for systemic sclerosis according to experts |
Fernández-Codina A1,2, Walker KM3, Pope JE1; Scleroderma Algorithm Group. Collaborators (47) Hughes M, van den Hoogen FH, Vonk M, Valentini G, Tafazzul-E-Haque M, Proudman SM, Mayes MD, Baron M, Orzechowski N, Simeón-Aznar CP, Francesca I, Hsu V, Seibold JR, Steen V, Murdaca G, Walker UA, Silver RM, Pauling JD, Larché M, Khalidi N, Merkel PA, Koenig M, Lally T, Gordon J, Fortin PR, Hayat S, Masetto A, Jacobsen S, Walker J, Denton C, Hesselstrand R, Gabrielli A, Wigley FM, Hunzelmann N, Castelino FV, Douglas Smith C, Johnson SR, Farge D, Boin F, Chung L, Furst DE, Clements P, Vacca A, Riccieri V, Shah A, Inanc M, Nevskaya T. Arthritis Rheumatol. 2018 May 21. doi: 10.1002/art.40560. [Epub ahead of print] |
| 499 | |
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors |
Gladman D1, Rigby W1, Azevedo VF1, Behrens F1, Blanco R1, Kaszuba A1, Kudlacz E1, Wang C1, Menon S1, Hendrikx T1, Kanik KS1. N Engl J Med. 2017 Oct 19;377(16):1525-1536. doi: 10.1056/NEJMoa1615977. |
| 500 | |
Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire |
Robson JC#1,2, Dawson J#3, Doll H4, Cronholm PF5, Milman N6, Kellom K7, Ashdown S8, Easley E9, Gebhart D10, Lanier G11, Mills J12, Peck J8, Luqmani RA13, Shea J14, Tomasson G15, Merkel PA16. Ann Rheum Dis. 2018 Apr 25. pii: annrheumdis-2017-212713. doi: 10.1136/annrheumdis-2017-212713. [Epub ahead of print] |
| 501 | |
Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis |
Berti A1, Warner R2, Johnson K2, Cornec D3, Schroeder D4, Kabat B4, Langford CA5, Hoffman GS5, Fervenza FC4, Kallenberg CGM6, Seo P7, Spiera R8, St Clair EW9, Brunetta P10, Stone JH11, Merkel PA12, Specks U4, Monach PA13; RAVE-ITN Research Group. Arthritis Rheumatol. 2018 Apr 25. doi: 10.1002/art.40471. [Epub ahead of print] |
| 502 | |
Pharmacogenomic Primer for the Pediatrician-What Is Really Important? |
Manzi S. Pediatr Ann. 2018 May 1;47(5):e217-e219. doi: 10.3928/19382359-20180429-01. |
| 503 | |
Lupus community panel proposals for optimising clinical trials: 2018 |
Merrill JT1, Manzi S2, Aranow C3, Askenase A4, Bruce I5, Chakravarty E1, Chong B6, Costenbader K7, Dall'Era M8, Ginzler E9, Hanrahan L10, Kalunian K11, Merola J7, Raymond S12, Rovin B13, Saxena A14, Werth VP15. Lupus Sci Med. 2018 Mar 23;5(1):e000258. doi: 10.1136/lupus-2018-000258. eCollection 2018. |
| 504 | |
Metabolic pathways and immunometabolism in rare kidney diseases |
Grayson PC1,2, Eddy S3,4, Taroni JN2,5, Lightfoot YL1, Mariani L3,4, Parikh H2,6, Lindenmeyer MT7, Ju W3,4, Greene CS2,5, Godfrey B3,4, Cohen CD7, Krischer J2,6, Kretzler M3,4, Merkel PA2,8; Vasculitis Clinical Research Consortium, the European Renal cDNA Bank cohort, and the Nephrotic Syndrome Study Network. Ann Rheum Dis. 2018 May 3. pii: annrheumdis-2017-212935. doi: 10.1136/annrheumdis-2017-212935. [Epub ahead of print] |
| 505 | |
Factors associated with physicians' prescriptions for rheumatoid arthritis drugs not filled by patients |
Kan HJ1, Dyagilev K2, Schulam P3, Saria S3, Kharrazi H4, Bodycombe D4, Molta CT5, Curtis JR6. Arthritis Res Ther. 2018 May 2;20(1):79. doi: 10.1186/s13075-018-1580-5. |
| 506 | |
Perspectives of Rheumatoid Arthritis Patients on Electronic Communication and Patient Reported Outcome Data Collection: A Qualitative Study |
Navarro-Millán I1,2, Zinski A3, Shurbaji S4, Johnson B4, Fraenkel L5, Willig J4, Danila MI6, Yun H7, Curtis JR6, Safford MM1. Arthritis Care Res (Hoboken). 2018 Apr 18. doi: 10.1002/acr.23580. [Epub ahead of print] |
| 507 | |
A novel method to combine assessment of benefit and harm: OMERACT 3x3 methodology applied to two active comparator trials |
Boers M1, Singh JA2,3,4, Cofield SS5, Louis Bridges S Jr5, Moreland LW6, O'Dell JR7, Wu H8, Leatherman S8, Curtis JR5. Arthritis Care Res (Hoboken). 2018 Apr 25. doi: 10.1002/acr.23590. [Epub ahead of print] |
| 508 | |
Obesity and response to anti-tumor necrosis factor-? agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis |
Singh S1,2, Facciorusso A3, Singh AG4, Casteele NV1, Zarrinpar A1,5,6, Prokop LJ7, Grunvald EL8, Curtis JR9, Sandborn WJ1. PLoS One. 2018 May 17;13(5):e0195123. doi: 10.1371/journal.pone.0195123. eCollection 2018. |
| 509 | |
Serious infections in rheumatoid arthritis offspring exposed to tumour necrosis factor ? inhibitors: cohort study |
Vinet É1,2, De Moura C2, Pineau CA1, Abrahamowicz M1, Curtis JR3, Bernatsky S1,2. Arthritis Rheumatol. 2018 May 17. doi: 10.1002/art.40536. [Epub ahead of print] |
| 510 | |
Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab |
Burmester GR1, Kaeley GS2, Kavanaugh AF3, Gabay C4, MacCarter DK5, Nash P6, Takeuchi T7, Goss SL8, Rodila R8, Chen K8, Kupper H9, Kalabic J9. RMD Open. 2017 Sep 17;3(2):e000465. doi: 10.1136/rmdopen-2017-000465. eCollection 2017. |
| 511 | |
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2) |
Kavanaugh A1, Kremer J2, Ponce L3, Cseuz R4, Reshetko OV5, Stanislavchuk M6, Greenwald M7, Van der Aa A8, Vanhoutte F8, Tasset C8, Harrison P8. Ann Rheum Dis. 2017 Jun;76(6):1009-1019. doi: 10.1136/annrheumdis-2016-210105. Epub 2016 Dec 19. |
| 512 | |
Rheumatoid Arthritis: Common Questions About Diagnosis and Management |
Wasserman A1. Am Fam Physician. 2018 Apr 1;97(7):455-462. |
| 513 | |
Leg Length Inequality and Hip Osteoarthritis in the Multicenter Osteoarthritis Study and the Osteoarthritis Initiative |
Kim C1, Nevitt M2, Guermazi A3, Niu J1, Clancy M1, Tolstykh I2, Jungmann PM4, Lane NE5, Segal NA6, Harvey WF7, Lewis CE8, Felson DT1,9. Arthritis Rheumatol. 2018 Apr 26. doi: 10.1002/art.40537. [Epub ahead of print] |
| 514 | |
Dysmobility Syndrome Independently Increases Fracture Risk in the Osteoporotic Fractures in Men (MrOS) Prospective Cohort Study |
Buehring B1, Hansen KE1, Lewis BL1, Cummings SR2, Lane NE3, Binkley N1, Ensrud KE4, Cawthon PM2; Osteoporotic Fractures in Men (MrOS) Study Research Group. J Bone Miner Res. 2018 Apr 27. doi: 10.1002/jbmr.3455. [Epub ahead of print] |
| 515 | |
Associations between lean mass, muscle strength and power, and skeletal size, density and strength in older men |
Chalhoub D1, Boudreau R2, Greenspan S2, Newman AB2, Zmuda J2, Frank-Wilson AW1, Nagaraj N2, Hoffman AR3, Lane NE4, Stefanick ML3, Barrett-Connor E5, Dam T5,6, Cawthon P7, Orwoll E8, Cauley JA2; Osteoporotic Fractures in Men (MrOS) Study Research Group.. J Bone Miner Res. 2018 Apr 27. doi: 10.1002/jbmr.3458. [Epub ahead of print] |
| 516 | |
Rheumatoid Arthritis: Common Questions About Diagnosis and Management |
Wasserman A1. Am Fam Physician. 2018 Apr 1;97(7):455-462. |
| 517 | |
Three-dimensional ultrashort echo time cones (3D UTE-Cones) magnetic resonance imaging of entheses and tendons |
Chen B1, Zhao Y2, Cheng X3, Ma Y4, Chang EY5, Kavanaugh A6, Liu S7, Du J8. Magn Reson Imaging. 2018 Jun;49:4-9. doi: 10.1016/j.mri.2017.12.034. Epub 2018 Jan 5. |
| 518 | |
Change in cardiovascular risk factors in patients who develop psoriatic arthritis: longitudinal data from the Nord-Trøndelag Health Study (HUNT) |
Gulati AM1,2, Salvesen Ø3, Thomsen RS1,4, Kavanaugh A5, Semb AG6, Rollefstad S6, Haugeberg G7,8, Hoff M1,4. RMD Open. 2018 Mar 14;4(1):e000630. doi: 10.1136/rmdopen-2017-000630. eCollection 2018. |
| 519 | |
Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry |
Mease PJ1, Karki C2, Liu M2, Kavanaugh A3, Ritchlin CT4, Huynh DH5, Palmer JB6, Greenberg JD2,7. RMD Open. 2018 Apr 25;4(1):e000638. doi: 10.1136/rmdopen-2017-000638. eCollection 2018. |
| 520 | |
Risk of infantile hemangiomas in the offspring of women with autoimmune disease and the pathogenic implications of these lesions |
Smith CJF1, Jones KL2, Johnson DL2, Bandoli G2, Robinson LK2, Kavanaugh A1, Chambers CD2. Am J Med Genet A. 2018 Mar;176(3):570-577. doi: 10.1002/ajmg.a.38594. Epub 2018 Jan 17. |
| 521 | |
Pregnancy Outcomes after Exposure to Certolizumab Pegol: Updated Results from a Pharmacovigilance Safety Database |
Clowse MEB1, Scheuerle AE2, Chambers C3, Afzali A4, Kimball AB5, Cush JJ6, Cooney M7, Shaughnessy L7, Vanderkelen M8, Förger F9. Arthritis Rheumatol. 2018 Apr 5. doi: 10.1002/art.40508. [Epub ahead of print] |
| 522 | |
Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study |
Pappas DA1,2, Nyberg F3,4, Kremer JM5, Lampl K6, Reed GW7,8, Horne L9, Ho M10, Onofrei A7, Malaviya AN11, Rillo OL12, Radominski SC13, Gal J14, Gibofsky A15, Popkova TV16, Laurindo L17, Kerzberg EM18, Zahora R19, Pons-Estel BA20, Curtis JR21, Furst DE22, Greenberg JD7,23. Clin Rheumatol. 2018 Apr 25. doi: 10.1007/s10067-018-4113-3. [Epub ahead of print] |
| 523 | |
Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis |
Wells AF1, Greenwald M2, Bradley JD3, Alam J3, Arora V3, Kartman CE4. Rheumatol Ther. 2018 Apr 21. doi: 10.1007/s40744-018-0110-x. [Epub ahead of print] |
| 524 | |
Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance |
Ghosh N1, Ruderman EM2. Arthritis Res Ther. 2017 Dec 22;19(1):286. doi: 10.1186/s13075-017-1493-8. |
| 525 | |
Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial |
Wells AF1, Edwards CJ2, Kivitz AJ3, Bird P4, Nguyen D5, Paris M5, Teng L5, Aelion JA6. Rheumatology (Oxford). 2018 Apr 4. doi: 10.1093/rheumatology/key032. [Epub ahead of print] |
| 526 | |
Comparison of magnetic resonance angiography and 18F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis |
Quinn KA1,2, Ahlman MA3, Malayeri AA3, Marko J3, Civelek AC3, Rosenblum JS2, Bagheri AA2, Merkel PA4, Novakovich E2, Grayson PC2. Ann Rheum Dis. 2018 Apr 17. pii: annrheumdis-2018-213102. doi: 10.1136/annrheumdis-2018-213102. [Epub ahead of print] |
| 527 | |
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors) |
Winthrop KL1, Mariette X2, Silva JT3, Benamu E4, Calabrese LH5, Dumusc A6, Smolen JS7, Aguado JM8, Fernández-Ruiz M8. Clin Microbiol Infect. 2018 Feb 12. pii: S1198-743X(18)30150-2. doi: 10.1016/j.cmi.2018.02.002. [Epub ahead of print] |
| 528 | |
T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment |
Winthrop KL1, Korman N2, Abramovits W3, Rottinghaus ST4, Tan H4, Gardner A5, Mukwaya G6, Kaur M7, Valdez H6. J Am Acad Dermatol. 2018 Mar 1. pii: S0190-9622(17)32583-5. doi: 10.1016/j.jaad.2017.09.076. [Epub ahead of print] |
| 529 | |
Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis |
Papp KA1,2, Bachelez H3, Blauvelt A4, Winthrop KL5, Romiti R6, Ohtsuki M7, Acharya N8, Braun DK8, Mallbris L8, Zhao F8, Xu W8, Walls CD8, Strober B2,9. Br J Dermatol. 2017 Dec;177(6):1537-1551. doi: 10.1111/bjd.15723. Epub 2017 Nov 16. |
| 530 | |
Herpes zoster in psoriasis patients treated with tofacitinib |
Winthrop KL1, Lebwohl M2, Cohen AD3, Weinberg JM2, Tyring SK4, Rottinghaus ST5, Gupta P5, Ito K5, Tan H5, Kaur M6, Egeberg A7, Mallbris L6, Valdez H8. J Am Acad Dermatol. 2017 Aug;77(2):302-309. doi: 10.1016/j.jaad.2017.03.023. |
| 531 | |
Nomenclature of Cutaneous Vasculitis: Dermatologic Addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides |
Sunderkötter CH1, Zelger B2, Chen KR3, Requena L4, Piette W5, Carlson JA6, Dutz J7, Lamprecht P8, Mahr A9, Aberer E10, Werth VP11, Wetter DA12, Kawana S13, Luqmani R14, Frances C15, Jorizzo J16, Watts JR17, Metze D18, Caproni M19, Alpsoy E20, Callen JP21, Fiorentino D22, Merkel PA23, Falk RJ24, Jennette JC24. |
| 532 | |
Health-related outcomes of importance to patients with Takayasu's arteritis |
Sreih AG1, Alibaz-Oner F2, Easley E3, Davis T3, Mumcu G2, Milman N4, Robson J5, Direskeneli H2, Merkel PA6, Cronholm P3. Clin Exp Rheumatol. 2017 Sep 18. [Epub ahead of print] |
| 533 | |
Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis |
Robson JC1,2, Dawson J3, Cronholm PF4, Ashdown S5, Easley E6, Kellom KS7, Gebhart D8, Lanier G9, Milman N10, Peck J5, Luqmani RA11, Shea JA12, Tomasson G13, Merkel PA14. Rheumatol Int. 2018 Apr;38(4):675-682. doi: 10.1007/s00296-017-3855-6. Epub 2017 Nov 9. |
| 534 | |
18 F-Fluorodeoxyglucose-Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis |
Grayson PC1, Alehashemi S1, Bagheri AA1, Civelek AC2, Cupps TR3, Kaplan MJ1, Malayeri AA2, Merkel PA4, Novakovich E1, Bluemke DA2, Ahlman MA2. Arthritis Rheumatol. 2018 Mar;70(3):439-449. doi: 10.1002/art.40379. Epub 2018 Feb 6. |
| 535 | |
Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial |
Park JK1, Lee YJ2, Shin K3, Ha YJ2, Lee EY1, Song YW1, Choi Y4, Winthrop KL5, Lee EB1. Ann Rheum Dis. 2018 Mar 23. pii: annrheumdis-2018-213222. doi: 10.1136/annrheumdis-2018-213222. [Epub ahead of print] |
| 536 | |
Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized, Controlled Trial |
Kremer JM1, Rigby W2, Singer NG3, Birchwood C4, Gill D4, Reiss W4, Pei J4, Michalska M4. Arthritis Rheumatol. 2018 Mar 25. doi: 10.1002/art.40493. [Epub ahead of print] |
| 537 | |
Standardizing and personalizing the treat to target (T2T) approach for rheumatoid arthritis using the Patient-Reported Outcomes Measurement Information System (PROMIS): baseline findings on patient-centered treatment priorities |
Bacalao EJ1, Greene GJ2, Beaumont JL2, Eisenstein A2,3, Muftic A2, Mandelin AM1, Cella D2, Ruderman EM4. Clin Rheumatol. 2017 Aug;36(8):1729-1736. doi: 10.1007/s10067-017-3731-5. Epub 2017 Jun 26. |
| 538 | |
Plasma complement and vascular complement deposition in patients with coronary artery disease with and without inflammatory rheumatic diseases |
Shields KJ1, Mollnes TE2,3,4, Eidet JR5, Mikkelsen K6, Almdahl SM7, Bottazzi B8, Lyberg T5, Manzi S1, Ahearn JM1, Hollan I6,9,10,11. S One. 2017 Mar 31;12(3):e0174577. doi: 10.1371/journal.pone.0174577. eCollection 2017. |
| 539 | |
Current management of sarcoidosis I: pulmonary, cardiac, and neurologic manifestations |
West SG1. Curr Opin Rheumatol. 2018 May;30(3):243-248. doi: 10.1097/BOR.0000000000000489 |
| 540 | |
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial |
Nash P1, Kirkham B2, Okada M3, Rahman P4, Combe B5, Burmester GR6, Adams DH7, Kerr L7, Lee C7, Shuler CL7, Genovese M8; SPIRIT-P2 Study Group. Collaborators (75) Ahmed K, Alper J, Barkham N, Bennett RE, García FJB, Alonso RB, Blumstein HB, Brooks MS, Burmester GR, Cagnoli P, Caldron PH, Cantagrel A, Chen DY, Churchill MA Jr, Codding CE, Combe B, Deane PMG, Del Giudice J, Deodhar AA, Dhar RK, Dokoupilova E, Egan RM, Everding A, Galíndez E, Genovese M, Goddard DH, Gottlieb A, Goupille P, Griffin RM, Gupta RC, Hall S, Hatti K, Howell MP, Huang YH, Jajoo R, Janssen NM, Kiltz U, Kivitz AJ, Klein SJ, Korkosz MP, Kotha R, Kremer JM, Lue C, de la Fuente JLM, Marzo-Ortega H, Masmitja JG, Mease PJ, Meroni PL, Mueller EC, Nandagudi AC, Nash P, Fernández-Nebro A, Neuwelt CM, Orbai AM, Oza MR, Parks DL, Pattanaik D, Rell-Bakalarska ME, Rosmarin D, Roussou E, Rychlewska-Hanczewksa AI, Sikes DH, Stack MT, Sunkureddi P, Tahir H, Thaçi D, Tsai TF, Turkiewicz AM, Unger L, Cabello RV, Wagner U, Wei CC, Wells AF, Youssef P, Zielinska A. Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24. |
| 541 | |
Anti-Citrullinated Protein Antibodies Are Associated With Neutrophil Extracellular Traps in the Sputum in Relatives of Rheumatoid Arthritis Patients |
Demoruelle MK1, Harrall KK1, Ho L1, Purmalek MM2, Seto NL2, Rothfuss HM3, Weisman MH4, Solomon JJ5, Fischer A1, Okamoto Y1, Kelmenson LB1, Parish MC1, Feser M1, Fleischer C1, Anderson C1, Mahler M6, Norris JM1, Kaplan MJ2, Cherrington BD3, Holers VM1, Deane KD1. Arthritis Rheumatol. 2017 Jun;69(6):1165-1175. doi: 10.1002/art.40066. Epub 2017 May 2. |
| 542 | |
Value of RAPID3 in patients with PsA: results from the TICOPA and LOPAS II databases |
Coates LC1,2, Tillett W3, Shaddick G4, Pincus T5, Kavanaugh A6, Helliwell PS1. Arthritis Care Res (Hoboken). 2017 Nov 7. doi: 10.1002/acr.23460. [Epub ahead of print] |
| 543 | |
Rheumatoid arthritis |
Smolen JS1, Aletaha D1, Barton A2, Burmester GR3, Emery P4,5, Firestein GS6, Kavanaugh A6, McInnes IB7, Solomon DH8, Strand V9, Yamamoto K10. Nat Rev Dis Primers. 2018 Feb 8;4:18001. doi: 10.1038/nrdp.2018.1. |
| 544 | |
Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes |
Genovese M1,2, Westhovens R3, Meuleners L4, Van der Aa A4, Harrison P4, Tasset C4, Kavanaugh A5. Arthritis Res Ther. 2018 Mar 23;20(1):57. doi: 10.1186/s13075-018-1541-z. |
| 545 | |
Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone |
Keystone EC1, Breedveld FC2, van der Heijde D2, van Vollenhoven RF3,4, Emery P5, Smolen JS6,7, Sainsbury I8, Florentinus S9, Kupper H10, Chen K11, Kavanaugh A12. RMD Open. 2017 Sep 26;3(2):e000445. doi: 10.1136/rmdopen-2017-000445. eCollection 2017. |
| 546 | |
Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis |
Cohen S1, Curtis JR2, DeMasi R3, Chen Y4, Fan H4, Soonasra A5, Fleischmann R1,6. Rheumatol Ther. 2018 Feb 22. doi: 10.1007/s40744-018-0097-3. [Epub ahead of print] |
| 547 | |
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group |
Fleischmann R1, Mease PJ2, Schwartzman S3, Hwang LJ4, Soma K5, Connell CA5, Takiya L6, Bananis E7. Clin Rheumatol. 2017 Jan;36(1):15-24. doi: 10.1007/s10067-016-3436-1. Epub 2016 Oct 12. |
| 548 | |
Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study |
Machado MAÁ1, Moura CS1, Guerra SF1, Curtis JR2, Abrahamowicz M1,3, Bernatsky S4,5. Arthritis Res Ther. 2018 Mar 23;20(1):60. doi: 10.1186/s13075-018-1539-6. |
| 549 | |
Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept |
Dehoratius RJ1,2, Brent LH3, Curtis JR4,5, Ellis LA1, Tang KL6. Patient. 2018 Feb 9. doi: 10.1007/s40271-018-0297-5. [Epub ahead of print] |
| 550 | |
Is Rheumatoid Arthritis a Cardiovascular Risk Equivalent to Diabetes? |
Curtis JR1,2, Yang S1, Singh JA1, Xie F1, Chen L1, Yun H1, Muntner P1, Kent ST1, Levitan EB1, Safford MM1, Saag KG1, Zhang J1,2. Arthritis Care Res (Hoboken). 2018 Feb 6. doi: 10.1002/acr.23535. [Epub ahead of print] |
| 551 | |
Evaluation of damage in giant cell arteritis |
Kermani TA1, Sreih AG2, Cuthbertson D3, Carette S4, Hoffman GS5, Khalidi NA6, Koening CL7, Langford CA5, McAlear CA2, Monach PA8, Moreland L9, Pagnoux C4, Seo P10, Warrington KJ11, Ytterberg SR11, Merkel PA12; Vasculitis Clinical Research Consortium. Rheumatology (Oxford). 2018 Feb 1;57(2):322-328. doi: 10.1093/rheumatology/kex397. |
| 552 | |
Vaccines and Disease-Modifying Antirheumatic Drugs: Practical Implications for the Rheumatologist |
Friedman MA1, Winthrop KL2. Rheum Dis Clin North Am. 2017 Feb;43(1):1-13. doi: 10.1016/j.rdc.2016.09.003. Epub 2016 Oct 22. |
| 553 | |
The unmet need in rheumatology: Reports from the targeted therapies meeting 2017 |
Winthrop KL1, Strand V2, van der Heijde D3, Mease P4, Crow M5, Weinblatt M6, Bathon J7, Burmester GR8, Dougados M9, Kay J10, Mariette X11, Van Vollenhoven R12, Sieper J13, Melchers F14, Breedfeld FC15, Kalden J16, Smolen JS17, Furst DE18. Clin Immunol. 2018 Jan;186:87-93. doi: 10.1016/j.clim.2017.08.009. Epub 2017 Aug 12. |
| 554 | |
Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial |
Park JK1, Lee MA1, Lee EY1, Song YW1, Choi Y2, Winthrop KL3, Lee EB1. Ann Rheum Dis. 2017 Sep;76(9):1559-1565. doi: 10.1136/annrheumdis-2017-211128. Epub 2017 May 3. |
| 555 | |
Transcriptional Profiling of Synovial Macrophages using Minimally Invasive Ultrasound-Guided Synovial Biopsies in Rheumatoid Arthritis |
Mandelin AM 2nd1, Homan PJ1, Shaffer AM1, Cuda CM1, Dominguez ST1, Bacalao E1, Carns M1, Hinchcliff M1, Lee J2, Aren K1, Thakrar A1, Montgomery AB1, Louis Bridges S Jr.3, Bathon JM4, Atkinson JP5, Fox DA6, Matteson EL7, Buckley CD8, Pitzalis C9, Parks D5, Hughes LB3, Geraldino-Pardilla L4, Ike R6, Phillips K6, Wright K7, Filer A8, Kelly S9, Ruderman EM1, Morgan V1, Abdala-Valencia H1, Misharin AV10, Budinger GS10, Bartom ET11, Pope RM1, Perlman H1, Winter DR1. Arthritis Rheumatol. 2018 Feb 13. doi: 10.1002/art.40453. [Epub ahead of print] |
| 556 | |
NETtling the host: Breaking of tolerance in chronic inflammation and chronic infection |
Skopelja-Gardner S1, Jones JD2, Rigby WFC3. J Autoimmun. 2018 Mar;88:1-10. doi: 10.1016/j.jaut.2017.10.008. |
| 557 | |
Review of Routine Laboratory Monitoring for Patients with Rheumatoid ArthritisReceiving Biologic or Nonbiologic DMARDs |
Rigby WFC1, Lampl K2, Low JM3, Furst DE4,5,6. Int J Rheumatol. 2017;2017:9614241. doi: 10.1155/2017/9614241. Epub 2017 Oct 31. |
| 558 | |
Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial |
Burmester GR1, Rigby WF2, van Vollenhoven RF3, Kay J4, Rubbert-Roth A5, Blanco R6, Kadva A7, Dimonaco S8. Ann Rheum Dis. 2017 Jul;76(7):1279-1284. doi: 10.1136/annrheumdis-2016-210561. Epub 2017 Apr 7. |
| 559 | |
Brief Report: Anti-Carbamylated Protein Antibodies in Rheumatoid ArthritisPatients Are Reactive With Specific Epitopes of the Human Fibrinogen ?-Chain |
Jones JD1, Hamilton BJ2, Rigby WFC1. Arthritis Rheumatol. 2017 Jul;69(7):1381-1386. doi: 10.1002/art.40098. Epub 2017 Jun 5. |
| 560 | |
Persistence of Disease-Associated Anti-Citrullinated Protein Antibody-Expressing Memory B Cells in Rheumatoid Arthritis in Clinical Remission |
Pelzek AJ1, Grönwall C1, Rosenthal P1, Greenberg JD1, McGeachy M2, Moreland L2, Rigby WFC3, Silverman GJ1. Arthritis Rheumatol. 2017 Jun;69(6):1176-1186. doi: 10.1002/art.40053. Epub 2017 May 3. |
| 561 | |
Impact of vasculitis on employment and income |
Barra L1, Borchin RL2, Burroughs C2, Casey GC3, McAlear CA4, Sreih AG4, Young K3, Merkel PA5, Pagnoux C6; Vasculitis Clinical Research Consortium and the Vasculitis Patient-Powered Research Network.. Clin Exp Rheumatol. 2018 Jan 10. [Epub ahead of print] |
| 562 | |
Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure |
Robson JC1,2, Dawson J3, Cronholm PF4, Milman N5, Kellom KS6, Ashdown S7, Easley E8, Farrar JT9, Gebhart D10,11, Lanier G10,11, McAlear CA12, Peck J7, Luqmani RA7, Shea JA13, Tomasson G14, Merkel PA10,11. Patient Relat Outcome Meas. 2018 Jan 4;9:17-34. doi: 10.2147/PROM.S144992. eCollection 2018. |
| 563 | |
Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis |
Wallace ZS1, Miloslavsky EM1, Cascino M1, Unizony SH1, Lu N1, Hoffman GS2, Kallenberg CGM3, Langford CA2, Merkel PA4, Monach PA5, Seo P6, Spiera R7, St Clair EW8, Specks U9, Brunetta P10, Choi HK1, Stone JH1. Arthritis Care Res (Hoboken). 2017 Jul;69(7):1004-1010. doi: 10.1002/acr.23099. |
| 564 | |
Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis |
Cornec D1,2, Kabat BF3, Mills JR4, Cheu M5, Hummel AM1, Schroeder DR3, Cascino MD5, Brunetta P5, Murray DL4, Snyder MR4, Fervenza F6, Hoffman GS7, Kallenberg CGM8, Langford CA7, Merkel PA9, Monach PA10, Seo P11, Spiera RF12, St Clair EW13, Stone JH14, Barnidge DR4, Specks U1. Rheumatology (Oxford). 2018 Jan 10. doi: 10.1093/rheumatology/kex484. [Epub ahead of print] |
| 565 | |
Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis |
Merkel PA1, Xie G2, Monach PA3, Ji X4, Ciavatta DJ5, Byun J4, Pinder BD2, Zhao A2, Zhang J6, Tadesse Y2, Qian D4, Weirauch M7, Nair R8, Tsoi A8, Pagnoux C9, Carette S9, Chung S10, Cuthbertson D11, Davis JC Jr10, Dellaripa PF12, Forbess L13, Gewurz-Singer O8, Hoffman GS14, Khalidi N15, Koening C16, Langford CA14, Mahr AD17, McAlear C1, Moreland L18, Seo EP19, Specks U20, Spiera RF21, Sreih A1, St Clair EW22, Stone JH23, Ytterberg SR20, Elder JT24, Qu J25, Ochi T26, Hirano N26, Edberg JC27, Falk RJ5, Amos CI4, Siminovitch KA6; Vasculitis Clinical Research Consortium. Arthritis Rheumatol. 2017 May;69(5):1054-1066. doi: 10.1002/art.40034. Epub 2017 Apr 6. |
| 566 | |
The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis |
Rhee RL1, Davis JC2, Ding L2, Fervenza FC2, Hoffman GS2, Kallenberg CGM2, Langford CA2, McCune WJ2, Monach PA2, Seo P2, Spiera R2, St Clair EW2, Specks U2, Stone JH2, Merkel PA2. Clin J Am Soc Nephrol. 2018 Feb 7;13(2):251-257. doi: 10.2215/CJN.04160417. Epub 2018 Jan 25. |
| 567 | |
The Pharmacogenomic Association of Fc? Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis |
Cartin-Ceba R1, Indrakanti D2, Specks U1, Stone JH3, Hoffman GS4, Kallenberg CG5, Langford CA4, Merkel PA6, Spiera RF7, Monach PA8, St Clair EW9, Seo P10, Tchao NK11, Ytterberg SR1, Brunetta PG12, Song H2, Birmingham D2, Rovin BH2; RAVE-Immune Tolerance Network Research Group. Arthritis Rheumatol. 2017 Jan;69(1):169-175. doi: 10.1002/art.39822. |
| 568 | |
Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy |
Wei W1, Knapp K2, Wang L3, Chen CI4, Craig GL2, Ferguson K2, Schwartzman S5. Adv Ther. 2017 Aug;34(8):1936-1952. doi: 10.1007/s12325-017-0578-8. Epub 2017 Jul 3. |
| 569 | |
Economic impact of biologic utilization patterns in patients with psoriatic arthritis |
Schwartzman S1, Li Y2, Zhou H3, Palmer JB2. Clin Rheumatol. 2017 Jul;36(7):1579-1588. doi: 10.1007/s10067-017-3636-3. Epub 2017 May 4. |
| 570 | |
Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases |
Kay J1, Schoels MM2, Dörner T3, Emery P4, Kvien TK5, Smolen JS2,6, Breedveld FC7; Task Force on the Use of Biosimilars to Treat Rheumatological Diseases. Ann Rheum Dis. 2018 Feb;77(2):165-174. doi: 10.1136/annrheumdis-2017-211937. Epub 2017 Sep 2. |
| 571 | |
Osteoporosis in Rheumatic Diseases: Anti-rheumatic Drugs and the Skeleton |
Dubrovsky AM1, Lim MJ1,2, Lane NE3,4. Calcif Tissue Int. 2018 Feb 22. doi: 10.1007/s00223-018-0401-9. [Epub ahead of print] |
| 572 | |
Sex dimorphic regulation of osteoprogenitor progesterone in bone stromal cells |
Kot A1, Zhong ZA1,2, Zhang H1,3, Lay YE1, Lane NE1, Yao W4. J Mol Endocrinol. 2017 Nov;59(4):351-363. doi: 10.1530/JME-17-0076. Epub 2017 Sep 4. |
| 573 | |
Comparison of fracture risk assessment tools in older men without prior hip or spine fracture: the MrOS study |
Gourlay ML1, Ritter VS2, Fine JP2, Overman RA3, Schousboe JT4,5, Cawthon PM6, Orwoll ES7, Nguyen TV8,9, Lane NE10, Cummings SR6, Kado DM11,12, Lapidus JA13, Diem SJ14,15, Ensrud KE14,15,16; Osteoporotic Fractures in Men (MrOS) Study Group. Arch Osteoporos. 2017 Oct 20;12(1):91. doi: 10.1007/s11657-017-0389-1. |
| 574 | |
Patterns and Predictors of Frailty Transitions in Older Men: The Osteoporotic Fractures in Men Study |
Pollack LR1, Litwack-Harrison S2,3, Cawthon PM2,3, Ensrud K4, Lane NE5, Barrett-Connor E6, Dam TT1,7. J Am Geriatr Soc. 2017 Nov;65(11):2473-2479. doi: 10.1111/jgs.15003. Epub 2017 Sep 5. |
| 575 | |
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis |
Buckley L1, Guyatt G2, Fink HA3, Cannon M4, Grossman J5, Hansen KE6, Humphrey MB7, Lane NE8, Magrey M9, Miller M10, Morrison L11, Rao M12, Byun Robinson A13, Saha S6, Wolver S14, Bannuru RR12, Vaysbrot E12, Osani M12, Turgunbaev M15, Miller AS15, McAlindon T12. Arthritis Care Res (Hoboken). 2017 Aug;69(8):1095-1110. doi: 10.1002/acr.23279. Epub 2017 Jun 6. |
| 576 | |
Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis |
Wallace ZS1, Miloslavsky EM1, Cascino M1, Unizony SH1, Lu N1, Hoffman GS2, Kallenberg CGM3, Langford CA2, Merkel PA4, Monach PA5, Seo P6, Spiera R7, St Clair EW8, Specks U9, Brunetta P10, Choi HK1, Stone JH1. Arthritis Care Res (Hoboken). 2017 Jul;69(7):1004-1010. doi: 10.1002/acr.23099. |
| 577 | |
Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis |
Cornec D1,2, Kabat BF3, Mills JR4, Cheu M5, Hummel AM1, Schroeder DR3, Cascino MD5, Brunetta P5, Murray DL4, Snyder MR4, Fervenza F6, Hoffman GS7, Kallenberg CGM8, Langford CA7, Merkel PA9, Monach PA10, Seo P11, Spiera RF12, St Clair EW13, Stone JH14, Barnidge DR4, Specks U1. Rheumatology (Oxford). 2018 Jan 10. doi: 10.1093/rheumatology/kex484. [Epub ahead of print] |
| 578 | |
Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis |
Merkel PA1, Xie G2, Monach PA3, Ji X4, Ciavatta DJ5, Byun J4, Pinder BD2, Zhao A2, Zhang J6, Tadesse Y2, Qian D4, Weirauch M7, Nair R8, Tsoi A8, Pagnoux C9, Carette S9, Chung S10, Cuthbertson D11, Davis JC Jr10, Dellaripa PF12, Forbess L13, Gewurz-Singer O8, Hoffman GS14, Khalidi N15, Koening C16, Langford CA14, Mahr AD17, McAlear C1, Moreland L18, Seo EP19, Specks U20, Spiera RF21, Sreih A1, St Clair EW22, Stone JH23, Ytterberg SR20, Elder JT24, Qu J25, Ochi T26, Hirano N26, Edberg JC27, Falk RJ5, Amos CI4, Siminovitch KA6; Vasculitis Clinical Research Consortium. Arthritis Rheumatol. 2017 May;69(5):1054-1066. doi: 10.1002/art.40034. Epub 2017 Apr 6. |
| 579 | |
The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis |
Rhee RL1, Davis JC2, Ding L2, Fervenza FC2, Hoffman GS2, Kallenberg CGM2, Langford CA2, McCune WJ2, Monach PA2, Seo P2, Spiera R2, St Clair EW2, Specks U2, Stone JH2, Merkel PA2. Clin J Am Soc Nephrol. 2018 Feb 7;13(2):251-257. doi: 10.2215/CJN.04160417. Epub 2018 Jan 25. |
| 580 | |
The Pharmacogenomic Association of Fc? Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis |
Cartin-Ceba R1, Indrakanti D2, Specks U1, Stone JH3, Hoffman GS4, Kallenberg CG5, Langford CA4, Merkel PA6, Spiera RF7, Monach PA8, St Clair EW9, Seo P10, Tchao NK11, Ytterberg SR1, Brunetta PG12, Song H2, Birmingham D2, Rovin BH2; RAVE-Immune Tolerance Network Research Group. Arthritis Rheumatol. 2017 Jan;69(1):169-175. doi: 10.1002/art.39822. |
| 581 | |
Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study |
Ferreira I1, Croca S1, Raimondo MG1, Matharu M2, Miller S2, Giles I1, Isenberg D1,3, Ioannou Y1,3, Hanly JG4, Urowitz MB5, Anderson N5, Aranow C6, Askanase A7, Bae SC8, Bernatsky S9, Bruce IN10, Buyon J11, Clarke AE12, Dooley MA13, Fortin P14, Ginzler E15, Gladman D5, Gordon C16, Inanc M17, Jacobsen S18, Kalunian K19, Kamen D20, Khamashta M21, Lim S22, Manzi S23, Merrill J24, Nived O25, Peschken C26, Petri M27, Ramsey-Goldman R28, Ruiz-Irastorza G29, Sanchez-Guerrero J30, Steinson K31, Sturfelt GK25, van Vollenhoven R32, Wallace DJ33, Zoma A34, Rahman A35. Arthritis Res Ther. 2017 Dec 22;19(1):287. doi: 10.1186/s13075-017-1495-6. |
| 582 | |
Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort |
Little J1,2, Parker B2, Lunt M1, Hanly JG3, Urowitz MB4, Clarke AE5, Romero-Diaz J6, Gordon C7,8, Bae SC9, Bernatsky S10, Wallace DJ11, Merrill JT12, Buyon J13, Isenberg DA14, Rahman A14, Ginzler EM15, Petri M16, Dooley MA17, Fortin P18, Gladman DD4, Steinsson K19, Ramsey-Goldman R20, Khamashta MA21, Aranow C22, Mackay M22, Alarcón GS23, Manzi S24, Nived O25, Jönsen A25, Zoma AA26, van Vollenhoven RF27, Ramos-Casals M28, Ruiz-Irastorza G29, Sam Lim S30, Kalunian KC31, Inanc M32, Kamen DL33, Peschken CA34, Jacobsen S35, Askanase A36, Sanchez-Guerrero J37, Bruce IN1,2. Rheumatology (Oxford). 2018 Jan 18. doi: 10.1093/rheumatology/kex444. [Epub ahead of print] |
| 583 | |
Cerebrovascular Events in Systemic Lupus Erythematosus |
Hanly JG1, Li Q2, Su L2, Urowitz MB3, Gordon C4, Bae SC5, Romero-Diaz J6, Sanchez-Guerrero J3, Bernatsky S7, Clarke AE8, Wallace DJ9, Isenberg DA10, Rahman A10, Merrill JT11, Fortin P12, Gladman DD3, Bruce IN13,14, Petri M15, Ginzler EM16, Dooley MA17, Steinsson K18, Ramsey-Goldman R19, Zoma AA20, Manzi S21, Nived O22, Jonsen A22, Khamashta MA23, Alarcón GS24, Chatham W24, van Vollenhoven RF25, Aranow C26, Mackay M26, Ruiz-Irastorza G27, Ramos-Casals M28, Lim SS29, Inanc M30, Kalunian KC31, Jacobsen S32, Peschken CA33, Kamen DL34, Askanase A35, Theriault C36, Farewell V2. Arthritis Care Res (Hoboken). 2018 Jan 5. doi: 10.1002/acr.23509. [Epub ahead of print] |
| 584 | |
Associations of osteoprotegerin with coronary artery calcification among women with systemic lupus erythematosus and healthy controls |
Poornima IG1, Shields K2, Kuller LH3, Manzi SM2, Ramsey-Goldman R4, Richardson C5, Rhew E6, Dunlop DD7, Song J8, Edmundowicz D9, Kondos GT10, Carr JJ11, Langman CB12, Price H13, Chung AH4, Santelices LB2, Mackey RH14. Lupus. 2018 Jan 1:961203317751060. doi: 10.1177/0961203317751060. [Epub ahead of print] |
| 585 | |
Cell-bound complement activation products as lupus biomarkers: diagnosis, monitoring and stratification |
Ahearn JM1, Liu CC1, Manzi S1. Expert Rev Clin Immunol. 2017 Dec;13(12):1133-1142. doi: 10.1080/1744666X.2017.1392238. Epub 2017 Nov 6. |
| 586 | |
A North American perspective of content and quality of websites in the English language on childhood-onset lupus erythematosus |
Cutler C1, Peng T2, Stinson J3, Tucker L4, Boneparth A1, Klein Gitelman M5, Moorthy LN1. Lupus. 2017 Jan 1:961203317746246. doi: 10.1177/0961203317746246. [Epub ahead of print] |
| 587 | |
Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register |
McCarthy EM1, Sutton E2, Nesbit S2, White J2, Parker B1,3, Jayne D4, Griffiths B5, Isenberg DA6, Rahman A6, Gordon C7,8, D'Cruz DP9, Rhodes B10, Lanyon P11, Vital EM12,13, Yee CS14, Edwards CJ15,16, Teh LS17, Akil M18, McHugh NJ19,20, Zoma A21, Bruce IN1,2. Rheumatology (Oxford). 2017 Dec 5. doi: 10.1093/rheumatology/kex395. [Epub ahead of print] |
| 588 | |
Epidemiology of systemic lupus erythematosus: an update |
Stojan G1, Petri M. Curr Opin Rheumatol. 2017 Dec 14. doi: 10.1097/BOR.0000000000000480. [Epub ahead of print] |
| 589 | |
Understanding the role of environmental factors in the development of systemic lupus erythematosus |
Parks CG1, de Souza Espindola Santos A2, Barbhaiya M3, Costenbader KH4. Best Pract Res Clin Rheumatol. 2017 Jun;31(3):306-320. doi: 10.1016/j.berh.2017.09.005. Epub 2017 Oct 21. |
| 590 | |
The initiation of autoimmunity at epithelial surfaces: a focus on rheumatoid arthritis and systemic lupus erythematosus |
Pentony P1, Duquenne L1, Dutton K1, Mankia K1, Gul H1, Vital E1, Emery P1. Discov Med. 2017 Nov;24(133):191-200. |
| 591 | |
Physical activity and sedentary behavior in patients with systemic lupus erythematosus and rheumatoid arthritis |
Legge A1, Blanchard C1, Hanly JG2,3. Open Access Rheumatol. 2017 Nov 8;9:191-200. doi: 10.2147/OARRR.S148376. eCollection 2017. |
| 592 | |
Lupus Nephritis: Current Treatment Paradigm and Unmet Needs |
Menez SP1, El Essawy B2, Atta MG1. Rev Recent Clin Trials. 2017 Nov 22. doi: 10.2174/1574887112666171123113200. [Epub ahead of print] |
| 593 | |
Plasma C4d as marker for lupus nephritis in systemic lupus erythematosus |
Martin M1, Smol?g KI1, Björk A1, Gullstrand B2, Okrój M3, Leffler J4, Jönsen A2, Bengtsson AA2, Blom AM5. Arthritis Res Ther. 2017 Dec 6;19(1):266. doi: 10.1186/s13075-017-1470-2. |
| 594 | |
Epilepsy among Systemic Lupus Erythematosus Patients: Insights from a Large Database Analysis |
Watad A1,2,3, Tiosano S1,3, Bragazzi NL4, Brigo F5, Comaneshter D6, Cohen AD6,7, Amital H1,2,3. Neuroepidemiology. 2017 Dec 1;50(1-2):1-6. doi: 10.1159/000485136. [Epub ahead of print] |
| 595 | |
Economic evaluation of lupus nephritis in the Systemic Lupus International Collaborating Clinics inception cohort using a multistate model approach |
Barber MRW1, Hanly JG2, Su L3, Urowitz MB4, Pierre YS5, Romero-Diaz J6, Gordon C7, Bae SC8, Bernatsky S9, Wallace DJ10, Isenberg DA11, Rahman A11, Ginzler EM12, Petri M13, Bruce IN14,15, Fortin PR16, Gladman DD4, Sanchez-Guerrero J4, Ramsey-Goldman R17, Khamashta MA18, Aranow C19, Mackay M19, Alarcón GS20, Manzi S21, Nived O22, Jönsen A22, Zoma AA23, van Vollenhoven RF24, Ramos-Casals M25, Ruiz-Irastorza G26, Sam Lim S27, Kalunian KC28, Inanc M29, Kamen DL30, Peschken CA31, Jacobsen S32, Askanase A33, Theriault C34, Farewell V3, Clarke AE35. Arthritis Care Res (Hoboken). 2017 Nov 28. doi: 10.1002/acr.23480. [Epub ahead of print] |
| 596 | |
Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial |
van Vollenhoven RF1, Keystone EC2, Strand V3, Pacheco-Tena C4, Vencovský J5, Behrens F6, Racewicz A7, Zipp D8, Rharbaoui F8, Wolter R8, Knierim L8, Schmeidl R8, Zhou X8, Aigner S8, Dälken B8, Wartenberg-Demand A8; TREAT2b study team. Collaborators (99) Aelion J, Arreola JA, Arias MA, Back J, Baranauskaite A, Behrens F, Bennett R, Bookman A, Brzezicki J, Butrimiene I, Churchill M, Djacenko S, Dokoupilova E, Drescher E, Dudek A, Edwards W, Eliseeva L, Ershova O, Fortin I, Galatikova D, De la Torre IG, Garmish O, Gasanov Y, Gnylorybov A, Goldberg M, Golovchenko O, Gordeev I, Hiepe F, Sil GH, Husarova V, Iaremenko O, Jeka S, Kamburova D, Kavanaugh A, Keszthelyi P, Keystone E, Knyazeva L, Krechikova D, Kuzmanova S, Lapcikova A, Levinson D, Lopez Garcia JA, Lymar I, Marinova N, Moiseev S, Musilova L, Nagy M, Najam S, Nedovic J, Nemeth E, Novosad L, Ochoa-Ortega L, Oparanov B, Tena CP, Penev D, Pesant Y, Podrazilova L, Pulka G, Racewicz A, Raskina T, Rekalov D, Reshetko O, Riega Torres JC, Rubbert-Roth A, Rychlewska-Hanczewska A, Savina L, Schulze-Koops H, Bukilica MS, Shevchuk S, Simoncsics E, Simova L, Sitek-Ziolkowska K, Skublova A, Sliwowska B, Smakotina S, Spieler W, Stanislavchuk M, Stefanovic D, Stejfova Z, Stoilov R, Strapkova M, Stryuk R, Sulyok G, Sylwestrzak A, Szombati I, Theander J, Tomkova S, Trapp R, Tseluyko V, Tälli J, Vencovsky J, Vitek P, Vladeva S, Vo J, Vollenhoven RV, Vujasinovic-Stupar N, Wassenberg S, Wollenhaupt J, Zielinska A. Ann Rheum Dis. 2018 Jan 17. pii: annrheumdis-2017-212478. doi: 10.1136/annrheumdis-2017-212478. [Epub ahead of print] |
| 597 | |
Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials |
Strand V1, Michalska M2, Birchwood C2, Pei J2, Tuckwell K3, Finch R4, Gabay C5, Kavanaugh A6, Jones G7. RMD Open. 2017 Sep 14;3(2):e000496. doi: 10.1136/rmdopen-2017-000496. eCollection 2017. |
| 598 | |
Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis |
Kavanaugh A1, van Vollenhoven RF2, Fleischmann R3, Emery P4,5, Sainsbury I6, Florentinus S6, Chen S6, Guérette B6, Kupper H7, Smolen JS8. Ann Rheum Dis. 2018 Feb;77(2):289-292. doi: 10.1136/annrheumdis-2017-211871. Epub 2017 Nov 16. |
| 599 | |
Understanding the determinants of health-related quality of life in rheumatoidarthritis-associated interstitial lung disease |
Natalini JG1, Swigris JJ2, Morisset J1, Elicker BM3, Jones KD4, Fischer A5, Collard HR1, Lee JS6. Respir Med. 2017 Jun;127:1-6. doi: 10.1016/j.rmed.2017.04.002. Epub 2017 Apr 5. |
| 600 | |
Routine Use of Quantitative Disease Activity Measurements among US Rheumatologists: Implications for Treat-to-target Management Strategies in Rheumatoid Arthritis |
Curtis JR1,2, Chen L3,4, Danila MI3,4, Saag KG3,4, Parham KL3,4, Cush JJ3,4. J Rheumatol. 2018 Jan;45(1):40-44. doi: 10.3899/jrheum.170548. Epub 2017 Nov 15. |
| 601 | |
Weight Change During the Early Rheumatoid Arthritis Period and Risk of Subsequent Mortality in Women With Rheumatoid Arthritis and Matched Comparators |
Sparks JA1, Chang SC1, Nguyen US2, Barbhaiya M1, Tedeschi SK1, Lu B1, Kreps DJ1, Costenbader KH1, Zhang Y3, Choi HK3, Karlson EW1. Arthritis Rheumatol. 2018 Jan;70(1):18-29. doi: 10.1002/art.40346. Epub 2017 Dec 7. |
| 602 | |
Overweight and Obesity Reduce the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort Study |
Schulman E1, Bartlett SJ2, Schieir O3, Andersen KM1, Boire G4, Pope JE5, Hitchon C6, Jamal S7, Thorne CJ8, Tin D8, Keystone EC9, Haraoui B10, Goodman SM1, Bykerk VP1,9, Investigators C. Arthritis Care Res (Hoboken). 2017 Nov 30. doi: 10.1002/acr.23457. [Epub ahead of print] |
| 603 | |
Trends in Joint Replacement Surgery in Patients with Rheumatoid Arthritis |
Young BL1, Watson SL1, Perez JL1, McGwin G1, Singh JA1, Ponce BA1. J Rheumatol. 2017 Dec 1. pii: jrheum.170001. doi: 10.3899/jrheum.170001. [Epub ahead of print] |
| 604 | |
Lessons Learned from Imaging on Rheumatoid Arthritis |
Antonietta D'Agostino M1. Isr Med Assoc J. 2017 Nov;19(11):703-707. |
| 605 | |
A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United States |
Spivey CA1, Griffith J2, Kaplan C3, Postlethwaite A3, Ganguli A2, Wang J4. Rheumatol Ther. 2017 Dec 4. doi: 10.1007/s40744-017-0089-8. [Epub ahead of print] |
| 606 | |
Clinical course over two years in patients with early non-radiographic axial spondyloarthritis and ankylosing spondylitis without anti-tumor necrosis factor ? treatment: Results from the GErman SPondyloarthritis Inception Cohort (GESPIC) |
Poddubnyy D1, Haibel H1, Braun J2, Rudwaleit M3, Sieper J1. Arthritis Rheumatol. 2015 May 27. doi: 10.1002/art.39225. [Epub ahead of print] |
| 607 | |
Systemic lupus erythematosus observations of travel burden: A qualitative inquiry |
Williams EM1, Ortiz K2, Flournoy-Floyd M1, Bruner L3, Kamen D4. Int J Rheum Dis. 2015 Jul 14. doi: 10.1111/1756-185X.12614. [Epub ahead of print] |
| 608 | |
Updated systematic review and meta-analysis of randomized controlled trials comparing low- versus high-dose rituximab for rheumatoid arthritis |
Bredemeier M1, Campos GG, de Oliveira FK. Clin Rheumatol. 2015 Jun 12. [Epub ahead of print] |
| 609 | |
Foot problems in people with gout in primary care: baseline findings from a prospective cohort study |
Roddy E1, Muller S1, Rome K2, Chandratre P1, Hider SL1, Richardson J1, Blagojevic-Bucknall M1, Mallen CD1. J Foot Ankle Res. 2015 Jul 23;8:31. doi: 10.1186/s13047-015-0090-9. eCollecARTHROS_RA_Bredemeier07272015-105949 |
| 610 | |
Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy |
Garcia C1, Lyon L2, Conell C2, Littell RD1, Powell CB3. Gynecol Oncol. 2015 Jun 16. pii: S0090-8258(15)30042-1. doi: 10.1016/j.ygyno.2015.06.020. [Epub ahead of print] |
| 611 | |
Impact of obesity on disability, function, and physical activity: data from the Osteoarthritis Initiative |
Shauver MJ1, Zhong L1, Chung KC2. J Hand Surg Eur Vol. 2015 Jun 17. pii: 1753193415589735. [Epub ahead of print |
| 612 | |
Hyponatremia is Associated with Increased Osteoporosis and Bone Fractures in a Large U. S. Health System Population |
Miriam Rachel Usala G1, Fernandez SJ2, Mete M2, Cowen L3, Shara NM2, Barsony J3, Verbalis JG3. J Clin Endocrinol Metab. 2015 Jun 17:jc20151261. [Epub ahead of print] |
| 613 | |
Mortality after distal radial fractures in the Medicare population |
Shauver MJ1, Zhong L1, Chung KC2. J Hand Surg Eur Vol. 2015 Jun 17. pii: 1753193415589735. [Epub ahead of print |
| 614 | |
Oral Bisphosphonate and Risk of Esophageal Cancer: A Nationwide Claim Study |
Seo GH1, Choi HJ2. J Bone Metab. 2015 May;22(2):77-81. doi: 10.11005/jbm.2015.22.2.77. Epub 2015 May 31. |
| 615 | |
Weight changes after total hip or knee arthroplasty: prevalence, predictors, and effects on outcomes |
Ast MP1, Abdel MP1, Lee YY1, Lyman S1, Ruel AV1, Westrich GH1. J Bone Joint Surg Am. 2015 Jun 3;97(11):911-9. doi: 10.2106/JBJS.N.00232. |
| 616 | |
Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty |
Arden N1, Richette P, Cooper C, Bruyère O, Abadie E, Branco J, Brandi ML, Berenbaum F, Clerc C, Dennison E, Devogelaer JP, Hochberg M, D'Hooghe P, Herrero-Beaumont G, Kanis JA, Laslop A, Leblanc V, Maggi S, Mautone G, Pelletier JP, Petit-Dop F, Reiter-Niesert S, Rizzoli R, Rovati L, Tajana Messi E, Tsouderos Y, Martel-Pelletier J, Reginster JY. Drugs Aging. 2015 Jun 18. [Epub ahead of print] |
| 617 | |
ABCs of Evidence-based Anterior Cruciate Ligament Injury Prevention Strategies in Female Athletes |
Sugimoto D1, Myer GD2, Micheli LJ3, Hewett TE4. Curr Phys Med Rehabil Rep. 2015 Mar 1;3(1):43-49. |
| 618 | |
Physical function, hyperuricemia and gout in older adults enrolled in the atherosclerosis risk in communities cohort study |
Burke BT1, Köttgen A1,2, Law A3, Windham BG4, Segev D3, Baer AN5, Coresh J1, McAdams-DeMarco MA1,3. Arthritis Care Res (Hoboken). 2015 Jul 2. doi: 10.1002/acr.22648. [Epub ahead of print] |
| 619 | |
Does a family history of RA influence the clinical presentation and treatment response in RA? |
Frisell T1, Saevarsdottir S2, Askling J3. Author information Ann Rheum Dis. 2015 Jun 19. pii: annrheumdis-2015-207670. doi: 10.1136/annrheumdis-2015-207670. [Epub ahead of print] |
| 620 | |
Medication Adherence in Patients with Rheumatoid Arthritis: The Effect of Patient Education, Health Literacy, and Musculoskeletal Ultrasound |
Joplin S1, van der Zwan R2, Joshua F3, Wong PK4. Biomed Res Int. 2015;2015:150658. Epub 2015 Apr 28. |
| 621 | |
The optimal combination therapy for the treatment of early rheumatoid arthritis |
De Cock D1, Van der Elst K, Meyfroidt S, Verschueren P, Westhovens R. Expert Opin Pharmacother. 2015 Aug;16(11):1615-25. doi: 10.1517/14656566.2015.1056735. Epub 2015 Jun 10. |
| 622 | |
Predictors of arthritis in pediatric patients with lupus |
Sule SD1, Moodalbail DG2, Burnham J3, Fivush B4, Furth SL5,6. Pediatr Rheumatol Online J. 2015 Jul 14;13(1):30. doi: 10.1186/s12969-015-0027-7 |
| 623 | |
Leukopenia, lymphopenia, and neutropenia in systemic lupus erythematosus: Prevalence and clinical impact-A systematic literature review |
Carli L1, Tani C2, Vagnani S2, Signorini V2, Mosca M3. Semin Arthritis Rheum. 2015 May 21. pii: S0049-0172(15)00115-8. doi: 10.1016/j.semarthrit.2015.05.009. [Epub ahead of print] |
| 624 | |
A highlight from the LUPUS 2014 meeting: eight great ideas |
Buyon JP1, Cohen P2, Merrill JT3, Gilkeson G4, Kaplan M5, James J6, McCune WJ7, Bernatsky S8, Elkon K9. Lupus Sci Med. 2015 Jun 30;2(1):e000087. doi: 10.1136/lupus-2015-000087. eCollection 2015. |
| 625 | |
Juvenile spondyloarthritis |
1aDivision of Rheumatology, The Children's Hospital of Philadelphia bDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. |
| 626 | |
Biomarkers in axial spondyloarthritis |
Maksymowych WP1. Curr Opin Rheumatol. 2015 Jul;27(4):343-8. doi: 10.1097/BOR.0000000000000180. |
| 627 | |
A rheumatology perspective on cutaneous vasculitis: assessment and investigation for the non-rheumatologist |
Rawlings CR1, Fremlin GA, Nash J, Harding K. Int Wound J. 2015 Mar 26. doi: 10.1111/iwj.12437. [Epub ahead of print] |
| 628 | |
Impact of certolizumab pegol on patient-reported outcomes in patients with axial spondyloarthritis |
Sieper J1, Kivitz A, van Tubergen A, Deodhar A, Coteur G, Woltering F, Landewé R. Arthritis Care Res (Hoboken). 2015 Apr 1. doi: 10.1002/acr.22594. [Epub ahead of print] |
| 629 | |
Patient Information about Gout: An International Review of Existing Educational Resources |
Johnston ME1, Treharne GJ1, Chapman PT1, Stamp LK1. J Rheumatol. 2015 Apr 1. pii: jrheum.141442. [Epub ahead of print] |
| 630 | |
Association Between Colchicine and Risk of Diabetes Among the Veterans Affairs Population With Gout |
Wang L1, Sawhney M2, Zhao Y3, Carpio GR4, Fonseca V5, Shi L6. Clin Ther. 2015 Apr 6. pii: S0149-2918(15)00147-2. doi: 10.1016/j.clinthera.2015.03.010. [Epub ahead of print] |